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ABSTRACT 
Hanadi Talal Abdullah Ahmedah 
Title: Correlation between the expression of integrins and their role in cancer 
progression. 
Subtitle: Expression pattern of integrins αvβ3, αvβ5 and α5β1 in clinical and 
experimental tumour samples. 
Keywords: Integrins, Protein expression, Migration, Tumour cells survival, 
Immunohistochemistry.  
The integrins play a crucial role in cancer cell proliferation, migration, 
differentiation, survival and angiogenesis. It has been shown that integrin 
expression is positively correlated to cancer dissemination, this suggests 
targeting selected integrins as an anti-metastatic strategy. The aim of this study 
is to investigate the effect of novel antagonists of α5β1, αvβ3 and αvβ5 integrins 
on cancer cell migration, a key process in tumour cell dissemination. 
Immunohistochemistry was used to evaluate the expression of α5, αv, β3 and 
β5 integrin subunits in prostate cancer tissues. Furthermore the expression of 
these integrin subunits in tumour and normal human head and neck tissues was 
compared. The expression profile of these integrin subunits in established 
human cancer cell lines was subsequently evaluated using immunodetection 
methods in cells and xenograft tumour samples. The effect of integrin inhibition 
on cell migration was then assessed using neutralizing antibodies against αvβ3, 
αvβ5, and α5β1 integrins in the scratch-wound healing assay. This assay was 
then used to evaluate the potential of novel small molecule integrin antagonists 
in preventing tumour cell migration. In H & N tissues, αvβ3, αvβ5 and α5β1 
integrins are extensively expressed in tumour tissues but weakly expressed in 
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normal tissue from the same patient. Further, prostate cancer tissues expressed 
variable levels of αvβ3, αvβ5 and α5β1 integrins. αvβ3 and αvβ5 integrins were 
expressed in variable levels in OSC-19, PC-3, DU145, DLD-1, HT-29, HUVEC, 
MCF-7, MCF-7ADR and M14 human tumour cell lines and in OSC-19, PC-3, 
HT-29 and MCF-7 xenografts. α5β1 integrin was expressed in all cell lines and 
xenografts except in MCF-7 cell line and HT-29 cell line and xenograft. Overall, 
the expression was elevated in xenografts compared to the corresponding 
cultured cells. Based on the expression profile and ability of cells to migrate, 
three cell lines (DLD-1 colon, DU145 prostate and OSC-19 HNSCC) were 
selected as models to further evaluate the potential of novel small molecule 
integrin antagonists to inhibit cell migration. The cell lines were characterized by 
using neutralizing antibodies against αvβ3, αvβ5, and α5β1 integrins to 
determine which of these three integrins were primarily involved in tumour cell 
migration. In DLD-1 and DU145, blocking αvβ5 and αvβ3 significantly inhibited 
migration, whilst the migration of OSC-19 was 50% inhibited by a multi-integrin 
inhibitor combination. Among the antagonists, ICT9055 and ICT9072 
significantly decreased DLD-1 cell migration by 70% and 60% respectively while 
ICT9023, ICT9024, and ICT9026 significantly decreased DU145 cell migration 
by 60%, 60% and 50% respectively. The findings suggest that single integrin 
inhibition is not sufficient to prevent cell migration whereas dual or multiple 
inhibition is more effective. Two novel anti-migratory agents were identified in 
colon cancer and three in prostate cancer which would warrant further 
investigation. 
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1 Chapter 1: Introduction 
1.1 Cancer 
Cancer is defined as the process of new growth that exceeds and is unrelated 
to the growth of normal tissues and that continues even when the stimuli 
evoking the change are removed, thus creating an abnormal mass of tissue 
(tumour) (Pecorino, 2012). Cancer can be hereditary or sporadic. When multiple 
members of a family have the same or related cancers, or when there is a 
germline mutation in the tumour suppressor or proto-oncogenes and the cancer 
is transmitted from one generation to another, the tumour is classified as 
inherited. On the other hand, a tumour found in a single, older individual  is 
usually classified as sporadic. 90% of cancer cases are sporadic and the 
tumours develop as a result of the accumulation of multiple somatic mutations 
due to environmental factors, such as chemicals or radiation (Boccia et al., 
2015, Stewart, 2014). 
There are two tumour classifications: behavioural and histogenetic. The 
histogenetic classification identifies the cells or tissue type from which the 
tumour originates, for example epithelial, glandular, lymphoid or haemopoietic 
tissues. This classification is very important when it comes to choosing the best 
treatment option for the patient. Classification is carried out by a histological 
examination of the tumour (Underwood and Cross, 2004). Tumours can be 
classified as benign or malignant, depending on their behaviour. Benign 
tumours grow slowly, remain localised and are not able to invade the 
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surrounding tissue or spread to other sites in the body. Conversely, malignant 
tumours (cancer) grow rapidly and have the ability to invade and destroy 
adjacent tissue, allowing neoplastic cells to penetrate the walls of the blood 
vessels and lymphatic channels and so spread to other sites in the body 
(metastasis) (Pecorino, 2012). 
1.1.1 Epidemiology of cancer 
Cancer is the second most common cause of death worldwide, with one in three 
people likely to suffer from cancer during their lifetime (Siegel et al., 2011). In 
2012, the estimated number of new cancer cases worldwide was about 14 
million and there were 8.2 million cancer-related deaths. The number of new 
cases is expected to rise by about 70% over the next two decades (WHO, 
2015). Carcinoma (malignant epithelial tumours) and lymphoma (malignant 
lymphoid tumours) are the most common human cancers, while sarcomas 
(malignant connective tissue tumours) are rare (Pecorino, 2012). 
1.1.2 Mechanism of tumour development and metastasis 
A complex, multistep process of proliferation, invasion, intravasation, migration, 
extravasation, colonisation and angiogenesis is necessary for the growth of a 
primary tumour and metastasis. 
Excessive and uncontrolled cellular proliferation or loss of the capacity for 
apoptosis are considered the main features of cancer. Certain genes, such as 
proto-oncogenes, are responsible for promoting normal cell growth. Mutant 
alleles of proto-oncogenes are known as oncogenes, and the activation of 
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oncogenes such as Bcl-2  leads to abnormal cell growth (Besbes et al., 2015). 
Moreover, the products of other genes called tumour suppressor genes such as 
P53, suppress the proliferation stimulating activities of cellular oncogenes and 
control the rate of cell loss (apoptosis or programmed cell death) (De Oliveira et 
al., 2015). 
Cancer cells are less attached to one another due to changes in the expression 
of cell adhesion molecules such as cadherin and integrins, which will help the 
cancer cells to easily break free from their molecular constraints and invade the 
surrounding tissue (Sawada et al., 2008, Ganguly et al., 2013). Then, these 
tumour cells adhere to the basement membrane and start to produce, or induce 
surrounding cells to produce, proteolytic enzymes such as serine proteases and 
matrix metalloproteases (MMP) to break up the blood or lymph vessel walls 
(Pecorino, 2012). The tumour cells adhere to the platelets and migrate in the 
direction of blood flow (Figure 1) (Gay and Felding-Habermann, 2011). When a 
tumour cell reaches the metastatic site, it escapes from the blood or lymph 
vessels by adhesion to endothelial cells through various cell adhesion 
molecules and then passes through the endothelial cells and basement 
membrane and migrates to the stroma. At the metastatic site, tumour cells 
interact with the extracellular matrix proteins via cell adhesion molecules such 
as integrins, which in turn mediate the intracellular signalling that promotes cell 
proliferation and differentiation. Finally, the tumour cells secrete growth factors 
and chemokines such as VEGF-A, bFGF, and TNFα, which stimulate quiescent 
vascular endothelium to enter the cell cycle and create new blood vessels to 
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provide the tumour cells with the oxygen and nutrients that are necessary for 
cell proliferation (Avraamides et al., 2008, Hanahan and Weinberg, 2011). The 
project described in this thesis focuses on the role of integrins in head and neck 
cancer as well as prostate cancer progression. 
 
 
Figure 1 Contribution of platelets to tumour metastasis (Gay and Felding-
Habermann, 2011). 
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1.2 The integrins 
Integrins are heterodimeric transmembrane glycoproteins consisting of an α-
subunit and a β subunit (Cox et al., 2010). Eighteen different α subunits and 
eight different β subunits have been reported in vertebrates. These combine to 
create 24 different heterodimers (Campbell and Humphries, 2011, Hohenester, 
2014). There are different types of integrins categorized according to which cell 
surface, extracellular matrix or inflammatory ligands they bind (Shimaoka et al., 
2002). Vertebrates have four receptor subgroups: laminin receptors, leukocyte 
specific integrins, collagen receptors and RGD receptors which recognise the 
triplet sequence arginine-glycine-aspartate (RGD) motif found in many ECM 
proteins such as fibronectin, collagen, and vitronectin, osteoponin and 
thrombospondin (Figure 2) (Hynes, 2002).  
The β1 and αv integrins are the largest subgroups. β1 can be associated with 
all α subunits except αD, αM, αX, αL, αIIb and αE. The integrin αv subunit can 
be associated with at least five distinct beta subunits: β1, β3, β5, β6 and β8, 
whereas the integrin β3 subunit can form heterodimers with only αv and αIIb 
subunits (Rupp and Little, 2001, Wilder, 2002, Barczyk et al., 2010). These 
integrins play an important role in cell-cell adhesion. Cells adhere to 
extracellular matrix proteins and integrins connect the extracellular matrix 
proteins to the cytoskeleton and active internal signal pathways. Now the 
integrins have become the target for therapeutic studies aiming to develop 
drugs to combat thrombosis, inflammation and cancer (Hynes, 2002). This 
6 
 
thesis discusses in detail the structure and function of αvβ5 and α5β1 integrins 
as well as their roles in normal and diseased states, especially in cancer cells. 
 
 
 
 
Figure 2 Diagram showing the integrins families.  
Half of the α-subunits contain I domains (asterisks) (Shimaoka et al., 2002, Hynes, 
2002, Campbell and Humphries, 2011, Liddington, 2014). 
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1.2.1 Integrin structure  
Both α and β subunits are type 1 membrane proteins which have long 
extracellular domains of >940 and >640 residues respectively, and short 
intracellular domains (except β4) (Bennett, 2005, Shimaoka et al., 2002). Each 
α and β integrin subunit has a large extracellular N-terminal globular domain 
where the ligand binding site is located, a membrane spanning region and a 
short C-terminal cytoplasmic domain (Figure 3) (Liddington, 2014).  
 
Figure 3 Structure of a non-I-domain Integrin (Lau et al., 2009). 
 
8 
 
 
 
Figure 4 Domains within the primary integrin subunit structures (Luo et al., 
2007).  
The α chain consists of a seven-bladed β-propeller, followed by one thigh, two 
calf domains, a transmembrane domain and a short cytoplasmic domain. The 
region between the thigh and first calf domain is the knee or genu where the 
head region bends (Figure 4). In nine of the integrins (the collagen receptors 
and leukocyte specific receptors), there is an inserted domain located between 
blades 2 and 3 in the β-propeller. This inserted domain is known as the I 
domain or A domain. The β chain consists of a PSI (plexin, semaphorins and 
integrin) domain, a hybrid domain, a βI domain, four integrin epidermal growth 
factor-like domain repeats, β-tail domain (βTD), transmembrane domain and 
long cytoplasmic domain. The α-subunit β-propeller meets the βI domain at the 
site where the α head interacts with the β head (Barczyk et al., 2010, Lee et al., 
1995a, Shimaoka et al., 2002). 
Some integrins (e.g. αLβ2) have two I domains (αI domain and βI domain), 
whereas other (e.g. αvβ3) have only the βI domain. Both these domains contain 
9 
 
metal ions that interact with ligand, known as the metal-ion dependent adhesion 
site (MIDAS).  The αI domains are the major ligand-binding sites in integrins 
that contain I domains whereas the βI domain binds ligand in integrins that lack 
I domains and regulate ligand binding by integrins that contain I domains (Cox 
et al., 2010, Liddington, 2014, Lee et al., 1995b). 
 
Figure 5 Conformational changes of integrins lacking an I domain.  
α subunit shown in blue and β subunit in red (Xiong et al., 2001). 
Xiong et al. found that the crystal structure of a head region of the αvβ3 
extracellular region was severely bent over two almost parallel tails. This form is 
called the bent conformation (Figure 5). The flexed or bent conformation 
represents the inactive form, whereas the extended conformation of the integrin, 
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which appeared to be similar to rotary shadowed EM images of αIIbβ3, 
represents the active form (Xiong et al., 2001),(Xiao et al., 2004). The cell 
surface normally expresses the integrins in the inactive conformation; however, 
integrins can be activated by both outside-in (regulating the cell function) and 
inside-out signalling (regulating cell adhesion) (Millard et al., 2011),(Han et al., 
2006). 
When the integrins’ extracellular domains bind to one of the different ligands 
that are usually found in the subendothelial matrix, such as fibronectin, 
vitronectin and collagen, this leads to the creation of outside-in signalling and 
conformational changes, such as separation of the α and β legs to allow the 
cytoplasmic tail to interact with intracellular molecules like talin, FAK/c-SRC, 
small GTPases Ras and Rho, and adaptors like cas/crk and paxillin (Figure 6: A) 
(Schwartz and Ginsberg, 2002),(Legate et al., 2009), (Cox et al., 2010). 
Whereas when external stimuli such as selectin ligation or cytokine binding to 
G-protein coupled receptors stimulates intracellular signalling, this allows 
cytosolic proteins to bind to the cytoplasmic tail of the integrin. The changes in 
the tail induce changes in the extracelluar domain, thus regulating the affinity of 
the integrin for its ECM ligand (inside-out signalling) (Figure 6: B) (Vinogradova 
et al., 2002),(Takagi et al., 2001),(Xiao et al., 2004),(Cox et al., 2010). 
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Figure 6 Integrin signalling.  
A) Integrin outside-in signalling governs cellular processes. B) Integrin inside-out 
signalling promotes integrin activation and heightens ligand affinity (Millard et al., 
2011). 
A 
B 
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1.2.2 Integrin functions: 
Integrins play an important role in a large number of signalling pathways, 
controlling various cellular functions such as cell adhesion, tissue integrity 
maintenance and the promotion of cellular migration, proliferation, survival, 
division, differentiation and apoptosis. These functions are important in many 
physiological and pathological processes, such as inflammation, angiogenesis, 
wound healing, embryonic development, neoplastic transformation and 
thrombosis (Brooks et al., 1994a, Weis and Cheresh, 2011, Jacobsen et al., 
2010, Bloor et al., 2002, Stachurska et al., 2012, Bellucci and Caen, 2002, 
Seguin et al., 2015). In addition, integrin binding has been recognized as a 
means of viral entry into cells (Jackson et al., 2002).  
1.2.2.1 Function of α5β1, αvβ5 and αvβ3 integrins  
There are 11 integrins which contain β1 (αvβ1, α1β1, α2β1, α3β1, α4β1, α5β1, 
α6β1, α7β1, α8β1, α9β1, α10β1 and α11β1). β1 integrins promote cell 
proliferation, migration, invasion and survival by activating several signalling 
pathways such as FAK, PI3 kinase and Akt (Hanks et al., 1992),(Meng and 
Lowell, 1998). The β1 integrins have been characterized in all three 
developmental layers of the organism (endodermal, ectodermal, and 
mesenchymal). They are critical in the development and function of the kidney 
glomerulus (Kanasaki et al., 2008), organogenesis (Potocnik et al., 2000), skin 
and hair formation (Raghavan et al., 2000), bone and cartilage formation 
(Aszodi et al., 2003), skeletal muscle and cerebral cortex development 
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(Schwander et al., 2003),(Belvindrah et al., 2007) and angiogenesis (Mettouchi 
and Meneguzzi, 2006). 
Integrin α5β1 is a major cellular receptor for the extracellular matrix protein 
fibronectin. It participates in many cell functions including cell adhesion, 
migration and proliferation (Akiyama et al., 1989). Fibronectin and its receptor 
α5β1 have an essential role in vascular development during embryogenesis, as 
early embryonic lethality occurs due to yolk sac and other mesodermal tissue 
defects in mice in which fibronectin has been deleted (George et al., 1993). 
Similarly, α5-null embryos display lethal vasculature and cardiac defects 
(Francis et al., 2002),(Beauvais-Jouneau and Thiery, 1997). It has been shown 
that α5β1 plays an important role in wound healing; its deficiencies interfere 
with the migration of epidermal keratinocytes to close the wound (Ongenae et 
al., 2000, Widgerow, 2013).  
The αv subfamily integrins consist of five integrins (αvβ1, αvβ3, αvβ5, αvβ8, 
αvβ6). All these integrins recognize the arginine-glycine-aspartic acid (RGD) 
sequence present in certain matrix proteins such as vitronectin, fibronectin, 
osteopontin, collagens, thrombospondin, fibrinogen and von Willebrand factor 
(Pytela et al., 1985a, Pytela et al., 1985b). The β5 subunit is present in 
blastocyst stage embryos and in all embryonic organs such as ependymal layer 
of the central nervous system, glomeruli of the kidney, epicardial region of the 
heart, and in the tooth germs suggesting specific functions for this molecule 
during morphogenetic events in these organs (Bloor et al., 2002),(Yamada et al., 
1995). αvβ5 is involved in epithelial-mesenchymal interaction during tooth 
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development (Salmivirta et al., 1996), regulates lung vascular permeability and 
pulmonary endothelial barrier function (Su et al., 2007a), and mediates smooth 
muscle cell migration and neointimal formation in response to injury (Su et al., 
2007b), (Dufourcq et al., 2002).  
αvβ3 is found on the surface of platelets (expression is low compared to αIIbβ3), 
active endothelial cells, such as the ductal epithelium of the parotid glands, 
intestinal epithelium, glomeruli, Bowman's capsules and smooth muscle cells. It 
is expressed at a high level on osteoclasts, the mid-menstrual cycle 
endometrium, the placenta, inflammatory sites and invasive tumours (Natali et 
al., 1997). The cell types that express high levels of αvβ3 include mature bone 
resorbing osteoclasts and activated macrophages, a small fraction of 
neutrophils, angiogenic endothelial cells and migrating smooth muscle cells 
(Wilder, 2002). αvβ3 mediates the adhesion of osteoclast to the osteopontin of 
bone matrix proteins (Ross et al., 1993). When the integrin interacts with bone 
matrix protein, this keeps the osteoclast on the bone surface and allows a 
resorptive cavity to form under the osteoclast. This interaction also promotes 
osteoclast survival by producing anti-apoptotic signals (Tofteng et al., 2007). 
αvβ3 antagonism prevents bone resorption in vitro by inhibiting osteoclast 
migration (Nakamura et al., 1999). The role of αvβ3, αvβ5 and α5β1 integrins in 
angiogenesis and cancer will be discussed in more details later in this report. 
Some of the integrins’ functions are summarized in Table 1.
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Integrin Function Ligand References 
α1β1  Binding the osteoclast to collagen. 
 Angiogenesis. 
 Lymphangiogenesis. 
CO, LN (Lee et al., 2007),(Hong et al., 
2004) 
α2β1  Angiogenesis. 
 Lymphangiogenesis. 
CO, LN, TSP (Hong et al., 2004) 
α3β1  Neuronal migration. 
 Controls the expression of MMP2. 
 Participates in the development of lung and kidney glomeruli. 
 Keratinocyte migration. 
CO, LN-5, FN, TSP (Anton et al., 1999),(Kubota et 
al., 1997),(Kreidberg et al., 
1996),(Wen et al., 2010) 
α4β1  Promotes angiogenesis. 
 Regulates embryonic development. 
 Lymphangiogenesis and tumour metastasis. 
 
VCAM-1, TSP , FN (Garmy-Susini et al., 
2005),(Garmy-Susini et al., 
2007),(Sengbusch et al., 
2002),(Slack-Davis et al., 2009) 
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Integrin Function Ligand References 
α5β1  Angiogenesis. 
 Lymphatic growth. 
 Cancer metastasis. 
 Wound healing.  
 Controls mesodermal formation and function during 
embryogenesis. 
FN, Opn (Boudreau and Varner, 
2004),(Kim et al., 2002),(Francis 
et al., 2002),(Okazaki et al., 
2009),(Strobel and Cannistra, 
1999),(Ongenae et al., 
2000),(Widgerow, 2013),(Yang 
et al., 1993) 
α6β1  Skin homeostasis. 
 Regulates endothelial tube formation.  
LN (Chabut et al., 2003),(Georges-
Labouesse et al., 1996) 
α7β1  Cerebral vascularisation. 
 Muscle development and structural integrity. 
LN 1,2,4 (Flintoff-Dye et al., 
2005),(Hodges et al., 1997) 
α8β1  Regulates kidney development and other morphogenetic 
processes. 
 Regulates spreading, adhesion, growth and survival in 
neuronal and mesenchymal-derived cell types. 
 
FN, VN and TN (Denda et al., 1998),(Farias et 
al., 2005),(Bieritz et al., 
2003),(Muller et al., 1995) 
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Integrin Function Ligand References 
α9β1  Lymphangiogenesis. 
 Angiogenesis. 
TN, Opn, VCAM, 
FN, CO, LN 
(Huang et al., 2000), (Taooka et 
al., 1999),(Bazigou et al., 2009) 
α10β1   Growth plate morphogenesis and function. CO-II (Bengtsson et al., 2005) 
α11β1  Migration/reorganization of fibroblasts throughout the ligament 
in order to help in tooth eruption. 
CO-I (Popova et al., 2007) 
αvβ1  Cancer cell migration on fibronectin. 
 Migration of oligodendrocyte precursors. 
VN, FG (Koivisto et al., 2000) ,(Milner et 
al., 1996) 
αvβ3  Angiogenesis. 
 Osteoclast function. 
 Tumour metastasis. 
 Activation and localisation of MMPs. 
 Tumour growth and aggressiveness of the tumour cells. 
FN, FG, vWF, VN, 
CO and LN. 
(Silva et al., 2008),(Kim et al., 
2002),(Sloan et al., 
2006),(Hosotani et al., 2002), 
(Chatterjee et al., 2000) 
αvβ5  Angiogenesis. 
 Enhances cell migration and liver metastasis of colon 
carcinoma. 
VN, FG, FN. 
 
(Boudreau and Varner, 2004, 
Kim et al., 2002), (Yoshioka et 
al., 2010) 
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Integrin Function Ligand References 
αvβ6  Mediates colon cancer cells proliferation and invasion. 
 Promotes invasion of squamous carcinoma cells through up-
regulation of matrix metalloproteinase-9. 
 Regulates epithelial remodelling during development, tissue 
repair and neoplasia. . 
 Required for wound healing. 
FN. (Cantor et al., 2013),(Thomas et 
al., 2001),(Breuss et al., 
1995),(Jacobsen et al., 2010) 
αvβ8  Brain vessel homeostasis. 
 Vascularisation in embryo development. 
VN, CO and LN. (Silva et al., 2008),(Zhu et al., 
2002)  
αIIbβ3  Platelet aggregation and thrombus formation. 
 Invasion and metastasis progression of melanoma and 
prostate cancer. 
VN, FG, vWF, TSP, 
FN. 
(Millard et al., 2011),(Cox et al., 
2010),(Coller and Shattil, 
2008),(Chen et al., 
1992),(Trikha et al., 1998a) 
αLβ2  Leukocyte adhesion and migration. ICAM-1,2,3 (Kinashi, 2007),(Ding et al., 
1999) 
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Integrin Function Ligand References 
αMβ2  Contributes in the maintenance of hematopoietic progenitor 
cells in the bone marrow. 
 Participates in the movement of leucocytes from the capillaries 
to the endothelium. 
ICAM, iC3b, FG (Katayama et al., 2004),(Ding et 
al., 1999) 
αXβ2  Participates   in the adhesion of monocytes to endothelial cells. FG, ICAM-1, iC3b, (Keizer et al., 1987) 
α4β7  Recruitment of leukocytes to sites of inflammation Specifically 
to intestine – Peyer’s patches. 
 Angiogenesis. 
FN, VCAM-1 (Kummer and Ginsberg, 
2006),(Qin et al., 2006) 
Table 1 Integrins functions and their ligands 
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1.2.3 Integrins and cancer 
1.2.3.1 Expression 
Studies have shown that integrins on tumour cells are altered quantitatively and 
qualitatively. Some integrins are expressed at high levels due to continued 
expression of growth factors and some are absent, while others become 
phosphorylated or have changes in glycosylation, disturbing the properties of 
their cytoskeletal and extracellular ligand binding (Fawcett and Harris, 
1992) ,(Switala-Jelen et al., 2004),(Mizejewski, 1999). These alterations may 
help both transformation and tumour progression. Tumour cell expression of 
integrins is correlated with disease progression in various tumour types as 
shown in Table 2. 
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Table 2 The correlation between integrin expression and tumour progression 
Tumour Integrins 
expressed 
Correlation with disease References 
Colon αvβ6 Significantly associated with T 
stage and TNM stage 
(Niu et al., 2014) 
Colon αvβ3 Correlated with poor 
differentiation and lymph node 
invasion 
(Ibrahim et al., 
2013) 
Melanoma αvβ3 Expression restricted to cells 
within vertical growth phase and 
metastatic melanomas 
(Albelda et al., 
1990) 
HNSCC αvβ5 
Promotes lymphatic metastasis 
and angiogenesis. 
(Li et al., 2013) 
Prostate αvβ5 Correlated significantly with the 
Gleason pattern 
(Hess et al., 
2014) 
Prostate αvβ3 Increased bone metastasis. (McCabe et al., 
2007) 
Breast αvβ5 Increased invasiveness of 
breast cancer cells. 
(Bianchi et al., 
2010a) 
Breast αvβ6 
Associated with very poor 
survival and increased 
metastases to distant sites 
(Moore et al., 
2014) 
Glioblastoma αvβ3 Associated with a poor 
prognosis/decreased survival.  
(Schittenhelm et 
al., 2013) 
Non-small 
cell lung 
carcinoma 
α5β1 Associated with decreased 
survival rates in patients with 
lymph node-negative tumours. 
(Adachi et al., 
2000) 
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1.2.3.2 Integrins mediate survival and apoptotic pathways. 
The microenvironment stimulates the integrins to initiate either a pro-survival 
pathway or apoptosis. Integrin ligation can initiate a pro-survival pathway by 
increasing nuclear factor-κB (NF-κB) (Scatena et al., 1998) or PI3K–AKT 
activity (Aoudjit and Vuori, 2001a), decreasing p53 activation (Bao and 
Stromblad, 2004) and increasing the expression of the pro-survival molecules 
BCL-2 and FLIP (Matter and Ruoslahti, 2001, Aoudjit and Vuori, 2001b). 
Cooperative signalling between growth factor receptors and integrins also 
protects cells from the intrinsic and extrinsic pathways of apoptosis by activating 
the Raf pathway (Desgrosellier and Cheresh, 2010). For example, the crosstalk 
between αvβ3 and fibroblast growth factor receptor (FGFR) and αvβ5 integrin 
and vascular endothelial growth factor receptor 2 (VEGFR2) prevents 
endothelial cells  from undergoing apoptosis (Hood et al., 2003, Alavi et al., 
2003). Unligated integrins can induce apoptosis by activating caspase 8, 
resulting in apoptotic cell death (Figure 7) (Stupack et al., 2001). 
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Figure 7  Integrin regulation of cell survival and apoptosis. (Desgrosellier and 
Cheresh, 2010). 
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1.2.3.3 Integrins in metastasis 
Many reviews have covered detailed of integrins roles in cancer progression for 
example (Desgrosellier and Cheresh, 2010, Sheldrake and Patterson, 2009, Jin 
and Varner, 2004, Seguin et al., 2015, Ganguly et al., 2013). The role of 
integrins in each step of the metastatic process will be discussed below. 
  Invasion from primary tumor site  1.2.3.3.1
The initial step in metastasis is the separation of some cancer cells from the 
primary tumour mass, which then invade the surrounding tissues as cohesive 
multicellular units (collective invasion) or individual tumour cells (single cell 
invasion). There are two proposed methods of single cell invasion: the integrin-
dependent mesenchymal invasion program or the integrin-independent 
Rho/ROCK-dependent amoeboid invasion program (Ganguly et al., 2013, Friedl 
and Wolf, 2003). In the integrin-dependent mesenchymal invasion program, the 
cells change shape and convert to a metastatic phenotype during epithelial-
mesenchymal transition (EMT), they lose polarity and cell-cell adhesion, and 
gain migratory and invasive properties (Lamouille et al., 2014).  It has been 
shown that there is crosstalk between TGFβ and integrins such as αvβ3 
(Galliher and Schiemann, 2006), αvβ5 (Bianchi et al., 2010b), αvβ6 (Ramos et 
al., 2009) and α5β1(Maschler et al., 2005) to mediate the EMT process. 
Furthermore, the ligation of integrins activates a battery of downstream 
molecules such as focal adhesion kinase (FAK)-Src family kinase (SFK) that 
mediate cell motility and migration (Wu et al., 2008). 
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  Intravasation 1.2.3.3.2
Integrins enable tumour cells to invade surrounding tissue and break up the the 
blood or lymph vessels wall (Pecorino, 2012) by regulating the localization and 
activity of matrix-degrading proteases such as matrix metalloproteases  (MMPs) 
and urokinase-type plasminogen activator (uPA) (Brooks et al., 1996). Many 
integrins such as α5β1, αvβ3 and αvβ6 induce expression and activation of 
MMP-2, MMP-9 and MMP-3 respectively (Morozevich et al., 2009, Rolli et al., 
2003, Ramos et al., 2002, Thomas et al., 2001). Within blood vessels or lymph 
vessels, platelet integrin αIIbβ3 and tumour receptors such as integrin αvβ3, 
mediate tumour cell-platelet cohesion which guards tumour cells from immune 
elimination within the circulatory system. Tumour cells are then passively 
transferred in the direction of blood flow to distant sites in the body (metastatic 
sites) (Gay and Felding-Habermann, 2011). 
  Extravasation 1.2.3.3.3
The tumour cells escape from the blood or lymph vessels by adhesion to 
endothelial cells through various cell adhesion molecules, and then an adhesive 
bond to endothelial cells is created by integrins. The cells pass through the 
endothelial cells and basement membrane and migrate to the stroma (Ganguly 
et al., 2013). 
  Micrometastases 1.2.3.3.4
In the metastatic site, integrins regulate tumour cell proliferation by mediating 
the expression of key cell cycle proteins and the cyclin-dependent kinase 
 26 
 
inhibitor family which control entry into S phase of cell cycle (Fournier et al., 
2008).  
  Angiogenesis 1.2.3.3.5
In the metastatic site, new blood vessels must be created to provide the tumour 
cells with oxygen and nutrients that are necessary for cell proliferation and this 
process is known as angiogenesis (Pecorino, 2008). When tumour cells 
proliferate, the local blood supply becomes inadequate, leading to a hypoxic, 
nutrient-deprived tumour environment. The local hypoxic condition activates 
hypoxia-inducible factor-1 (HIF-1), resulting in the release of vascular 
endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF2) and tumour 
necrosis factor alpha (TNF-α) from proliferating tumour cells and thus leads to 
activation of integrins which in turn mediate endothelial cell proliferation, 
differentiation and migration (Figure 8). Many integrins participate in 
angiogenesis such as α4β1, αvβ3, αvβ5,  α4β1, α5β1, and α9β1 (Avraamides et 
al., 2008). This section will focus primarily on αvβ3, αvβ5 and α5β1 integrins in 
angiogenesis. 
αvβ5 is required for vascular endothelial growth factor (VEGF) or transforming 
growth factor α (TGF-α) to induce angiogenesis (Friedlander et al., 1995). αvβ5 
integrin activates the FAK/Src signalling pathway to stimulate endothelial cell 
proliferation, differentiation and migration (Hood et al., 2003). Also αvβ5 integrin 
protects the endothelial cells from intrinsic-mediated apoptosis through 
activation of Raf and MEK1-dependent pathways (Alavi et al., 2003).  
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αvβ3 integrin is present on blood vessels in human tumour tissues but not on 
vessels in normal tissue apart from during growth, wound healing and normal 
turnover of endometrium (Fabricius et al., 2011, Goodman et al., 2012). 
Angiogenic growth factors such as basic fibroblast growth factor (bFGF) or 
tumour necrosis factor α (TNF-α) stimulate the expression of αvβ3 integrin on 
endothelial cells (Brooks et al., 1994b). In normoxic conditions, cells expressing 
activated αvβ3 are able to mediate angiogenesis by up-regulating VEGF protein 
(Lorger et al., 2009).  
αvβ3 integrin uses the FAK/Src signalling pathway to stimulate endothelial cell 
proliferation, differentiation and migration (Eliceiri et al., 1998). Antagonists of 
αvβ3 induce caspase 8-dependent cell death, so suppressing angiogenesis by 
inducing endothelial cell apoptosis (Stupack et al., 2001). Antagonists of αvβ3 
inhibit angiogenesis and tumour growth in several animal models of cancer 
(Brooks et al., 1995).  
α5β1 integrin mediates endothelial cell migration and survival in vivo and in vitro 
by suppressing the activity of protein kinase A (PKA) (Kim et al., 2002). α5β1 is 
poorly expressed on quiescent endothelium but it is highly expressed in the 
vasculature of both mouse and human tumours (Kim et al., 2000a). Varner et al. 
found that α5β1 integrin and its ligand fibronectin are up regulated during 
angiogenesis (Varner et al., 1995). The expression of α5β1 integrin is controlled 
by many angiogenic factors such as bFGF, IL-8 and TNF-α (Kim et al., 2000a). 
Ligation of α5β1 has been shown to promote cell proliferation through ERK, Akt 
and FAK-dependent mechanisms (Lee and Ruoslahti, 2005). α5β1 antagonists,
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 such as SJ749 and ATN-161 inhibit angiogenesis and thus reduce tumour 
growth in vivo (Kim et al., 2002),(Stoeltzing et al., 2003).  
 
Figure 8  Angiogenesis and lymphangiogenesis mechanisms 
Tumour cells stimulate the secretion of growth factors and chemokines which in turn 
stimulate the expression of α1β1, α2β1, α4β1, α5β1 and αvβ3 integrins on the blood 
vessels, and α4β1, α9β1, and α1β1 on lymphatic vessels. The integrins mediate 
endothelial cell migration and survival, leading to creation of new blood vessels which 
in turn provide nutrients to tumour cells. These new blood and lymphatic vessels 
promote tumour metastasis to lymph nodes or distant tissues such as lung 
(Avraamides et al., 2008). 
1.2.3.4 Integrins and treatment resistance 
Acquired radiation or chemotherapy resistance is a major problem in cancer 
treatment and it can be developed by many factors such as alteration in the 
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drug target, initiation of prosurvival pathways or loss of the capacity for 
apoptosis. Integrin ligation has the ability to initiate a pro-survival pathway and 
protect the tumour cells from apoptosis, therefore, inhibition of integrin-ligand 
interaction has become an attractive target for cancer therapy  (Seguin et al., 
2015, Goswami, 2013). The role of integrins in resistance to radiation or 
chemotherapy has been identified occurs in multiple types of solid cancers; for 
example α3β1 integrin is involved in head and neck squamous cell carcinoma 
cell radioresistance (Steglich et al., 2015, Eke et al., 2012), β1 integrins 
contribute to breast cancer resistance to trastuzumab and lapatinib (Huang et 
al., 2011), and αv integrins mediate multicellular radioresistance in human 
nasopharyngeal carcinoma by activating the SAPK/JNK pathway (Ou et al., 
2012). αvβ3 integrin and its ligand osteopontin induce resistance of oral 
squamous cell carcinoma (OSCC) tissues to 5-FU-based chemoradiotherapy 
(Nakamura et al., 2015). Interaction between vitronectin and αvβ3 and αvβ5 
integrins protects glioma cells from apoptosis induced by chemotherapy (Uhm 
et al., 1999). Unligated αvβ3 can also mediate resistance; recruiting KRAS and 
RaIB to the tumour plasma membrane and causing activation of TBK1 and NF-
kB pathways that mediate erlotinib resistance (Seguin et al., 2014).    
Cancer treatment can also alter the expression of integrins; for example in lung 
cancer, cisplatin induced a significant alteration in the integrin expression 
pattern by leading to overexpression of integrin α4, αv, β1, and β5, which led to 
increased cell motility, while it had no effect on integrin α5, and β3 (Maiuthed 
and Chanvorachote, 2014). It has been shown that using integrin antagonists in 
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combination with radiation or chemotherapy increases the treatment sensitivity. 
Heiduschka et al. showed that cilengitide (see section 1.2.4.2.5), in combination 
with cisplatin, synergistically inhibited cell growth and increased apoptosis due 
to a decrease in the antiapoptotic protein Bcl-2. They also found that cilengitide 
in combination with irradiation significantly inhibited colony formation 
(Heiduschka et al., 2014).  
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1.2.3.5 Role of RGD-binding integrins in solid tumours 
In this section, the role of RGD-binding integrins in cancer progression will be 
discussed, focusing on two types of cancer; head and neck and prostate 
cancers because they are the models selected for experimental work in this 
thesis. 
  Head and neck cancer 1.2.3.5.1
Head and neck cancer is the term used for any malignancies that originate in 
the oral cavity, oesophagus, pharynx, larynx, paranasal sinuses and nasal 
cavity (Argiris et al., 2008).. In 2012, about 1,142,000 people were diagnosed 
with head and neck cancer, while about 776,000 died as a result of the cancer 
(Ferlay et al., 2015). The most common types of head and neck cancers are 
oesophageal cancer and oral cancer, which are the 13th and 16th most 
common cancers in the UK, causing over 7,701 and 2,119 deaths in 2012 
respectively (Cancer Research UK, 2012). Squamous cell carcinoma of the 
mucosal surfaces of the head and neck (SCCHN) is the most common cause 
and it accounts for about 90% of all such cancers (Walden and Aygun, 2013). 
Despite the improvement in surgical, radiation and chemotherapy treatments, 
the five-year survival rate for oral cancers has not improved significantly over 
the past 30 years, with two-thirds of all patients diagnosed with the advanced 
stage disease that is characterised by lymph node metastasis (Neville and Day, 
2002). Radiation treatment concurrent with chemotherapy has been recognised 
to improve survival (Adelstein et al., 2003, Bourhis et al., 2012). However, 
chemoradiotherapy treatment causes severe, long-term side effects and it is 
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therefore very important to identify targeted therapies and predictive biomarkers 
in order to improve disease management and minimise the treatment toxicity. 
Studies have shown that the expression of epidermal growth factor receptor 
(EGFR) in head and neck squamous cell carcinoma is associated with 
advanced stage lymph node metastasis and a poor chance of survival (Mak and 
William, 2014). It has been found that the targeting of EGFR by antibodies or 
small molecules improved the treatment of HNSCC patients. Cetuximab which 
is an antibody targets the cells that express EGFR with either radiation or 
chemotherapy therapy showed improve in overall survival for patients with 
HNSCC (Bonner et al., 2006, Vermorken et al., 2008). 
Preventing angiogenesis is one of the most rapidly evolving new approaches to 
cancer therapy. Head and neck cancer is a highly vascularised cancer, which 
could thus be an ideal candidate for such antiangiogenic strategies. As 
previously described, integrins play an important role in angiogenesis, 
particularly the αvβ3, αvβ5 and α5β1 integrins (Avraamides et al., 2008). 
Targeting these integrins could therefore inhibit angiogenesis and tumour 
growth.   
1.2.3.5.1.1 The αv subfamily integrins (αvβ3, αvβ5, αvβ6, αvβ1, and αvβ8) 
The overexpression of the αv integrin subunit in oesophageal, orbital, eyelid, 
and periorbital squamous cell carcinomas (SCCs) has been shown to be 
associated with tumour invasion and metastasis (Miller and Veale, 2001). 
Furthermore, the expression of αv is correlated with the lymphatic metastasis of 
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laryngeal and hypopharyngeal carcinoma. However, the associated β subunit 
that plays a major role in SCC aggressiveness has not been identified (Lu et al., 
2011). In in vitro studies, the expression of αv integrin subunits was evaluated in 
human nasopharyngeal CNE-2 cells grown as multi-cellular spheroids (MCSs) 
or as monolayers. MCSs expressed higher levels of the αv integrin subunit than 
monolayers, and were more resistant to x-ray irradiation. Blocking the αv 
integrin with an inhibitory peptide was found to increase the radiosensitivity of 
MCSs in vitro and in vivo (Ou et al., 2012). Down-regulation of αv-containing 
integrins by antisense oligonucleotide sequences against the αv subunit 
inhibited the proliferation of the laryngeal carcinoma cell line (Hep-2 cells) and 
enhances apoptosis (Lu et al., 2009).  
Fabricius et al. compared the expression of αvβ3, αvβ5, and α5β1 integrins 
between human oral, head, and neck tumour tissues and normal control tissues 
within the same patients by immunohistochemistry. αvβ3 was extensively 
expressed in endothelia, and αvβ5 expression was significantly higher in tumour 
cells and tumour stroma than in normal epithelium (Fabricius et al., 2011). 
However, the role of the αvβ5 integrin in head and neck cancer is controversial. 
Certain clinical studies have shown αvβ5 integrin expression to be significantly 
higher in larynx and tongue SCC cells than in the epithelium cells of normal 
tissues, and this to be associated with lymphatic metastasis and angiogenesis 
(Li et al., 2013, Kurokawa et al., 2008). However, Jones et al. demonstrated the 
αvβ5 integrin to be expressed in both normal and tumour cells of oral squamous 
cell carcinoma, with expression being weak or absent in poorly differentiated 
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lesions (Jones et al., 1997). The expression of RGD-binding integrins in clinical 
tissue samples is summarized in Table 3.  
RGD-
binding 
integrin 
SE  SCC E S Reference 
αvβ3 -/+ -/+ +++ + (Fabricius et al., 2011) 
  -   (Jones et al., 1997) 
 + -/+   (Li et al., 2013) 
 -/+   +++ (Li et al., 2011) 
αvβ5 + ++ ++ +++ (Fabricius et al., 2011) 
 + +++   (Li et al., 2013) 
 + ++  ++ (Jones et al., 1997) 
αvβ1 +++ +++   (Li et al., 2013) 
αvβ6 - ++ n/a  (Jones et al., 1997) 
 ++ +++   (Li et al., 2013) 
αvβ8 +++ +++   (Li et al., 2013) 
αIIbβ3      
α5β1 + ++ + ++ (Fabricius et al., 2011) 
 - +++   (Vitolo et al., 2000) 
 -/+ ++   (Shinohara et al., 1999) 
 
Table 3  The expression of RGD-binding integrins in squamous cell carcinoma 
tissues from the head and neck site. 
  
SE; squamous epithelium: SCC squamous cell carcinoma: E; endothelial cells: S; 
stroma: - negative;-/+ weak; + moderate; ++ strong; +++ very strong; blank not tested. 
 35 
 
 
 
Moreover, an in vitro study showed αvβ5 integrin to be implicated in cancer 
regression. αvβ5 integrin-deficient cell lines lose the ability of terminal 
differentiation and grow in an anchorage-independent manner. When an αvβ5 
deficient cell line was transfected with the αv subunit, the cells expressed αvβ5 
integrins and reversed the in vitro malignant phenotype (Jones et al., 1996). In 
addtion, the transduction of an αv-negative human SCC line (H357 cells) with 
retroviral vectors encoding αv integrins showed αvβ5 expression to enhance 
apoptosis (anoikis) by activating caspases 8 and 9 and suppressing AKT 
activity, (Janes and Watt, 2004). 
The strong expression of integrin αvβ3 on endothelial cells in head and neck 
cancer tissues indicates its role in angiogenesis and this is supported by a 
recent study conducted by Chuang et al. who showed that interaction of αvβ3 
with the extracellular matrix-related protein WISP-1 promotes VEGF-A 
expression which in turn regulates the angiogenesis within the OSCC 
microenvironment (Chuang et al., 2015). Moreover, it has been shown that 
activation of αvβ3 to enhance cell migration and invasion (Li et al., 2011). 
Chuang et al. showed that αvβ3 integrin increased the migration of oral 
squamous cell carcinoma by increasing MMP-3 expression (Chuang et al., 
2012).    
 
Several studies have shown oral squamous carcinoma cells express αvβ6, 
whereas normal oral epithelium does not (Jones et al., 1997, Ramos et al., 
1997). Peptide immunolabelling has shown 94.7% of HNSCCs express αvβ6 
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(Hsiao et al., 2010). Eriksen et al. has demonstrated β1, β4, and β6 integrins to 
be upregulated in carcinomas compared to adjacent mucosa within formalin-
fixed, paraffin-embedded pre-irradiation biopsies from 85 patients with HNSCC 
but the expression was not correlated with tumour or histopathological 
parameters (Eriksen et al., 2004). αvβ6 expression in primary laryngeal 
squamous cell carcinoma (LSCC) has also been shown to be higher than in 
normal epithelium cells, but no significant relationship existed between αvβ6 
expression and any clinicopathological features of LSCC (Li et al., 2013). 
In vitro studies have suggested αvβ6 is important for cell proliferation and 
migration. β6 expression has been shown to increase tumour growth in vitro 
and in vivo (Ramos et al., 2002), and αvβ6 targeting by an inhibitory peptide 
significantly inhibited the proliferation of oral squamous cell carcinoma cells 
(Hsiao et al., 2010). Additionally, it has been shown that the αvβ6 integrin 
protects SCCs from anoikis by activating an AKT survival signal (Janes and 
Watt, 2004). 
In normal tissues, αvβ6 is expressed at the tips of migrating epithelial sheets 
during oral mucosal wound healing (Larjava et al., 1996). Forcing the 
expression of β6 subunits into poorly-invasive human oral SCC9 cell lines by 
retroviral transduction with full-length β6 cDNA increased SCC-cell migration on 
fibronectin and invasion through the basement membrane. Blocking of the αvβ6 
integrin with an antibody inhibited cell adhesion, migration and growth in a 
three-dimensional collagen gel, as well as retarding tumour growth in vivo (Xue 
et al., 2001).  
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αvβ6 has been shown to promote tumour migration by modulating epithelial to 
mesenchymal transition (EMT). Romes et al. found that poorly invasive 
squamous cell carcinoma SCC9 cells expressing full-length β6 subunits are 
able to modulate EMT whereas, cells expressing a truncated form of the β6 
subunit lacking the C-terminal 11 amino acids are not (Ramos et al., 2009).  
Koivisto et al. showed that αvβ6 was expressed on 73% of a panel of SCC cell 
lines screened by flow cytometry. Among these cell lines they selected UT-
SCC-14, UT-SCC-7 and UT-SCC-11 cells that have high, moderate and low 
expression of αvβ6 integrin respectively to evaluate the expression of other 
integrins and they found that αvβ1 integrin was expressed on the three cell lines 
but α5β1 integrin expression was higher in UT-SCC-14 than in the other 2 cell 
lines. These three cell lines were used to study the role of αvβ6, αvβ1 and α5β1 
on cell spreading and migration on fibronectin; SCC cells cooperatively used 
αvβ1, αvβ6, and α5β1 integrins to adhere and migrate on fibronectin (Koivisto et 
al., 2000). 
Recently, Li et al. demonstrated the expression of β8 and β1 integrin subunits in 
primary LSCC cancer to be slightly higher than in normal epithelium, although 
no significant relationship existed between the expression of these subunits and 
any clinicopathological features of LSCC (Li et al., 2013).  
1.2.3.5.1.2 α5β1 integrin 
The role of the β1 integrin subunit in head and neck cancer was studied by 
Wang et al., who used three HNSCC cell lines (M4E, 212LN and PCI-37B), a 
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xenograft animal model, and tissue samples obtained from patients with 
HNSCC to demonstrate that β1 expression was significantly higher in metastatic 
primary tumours than in non-metastatic tumours, and that expression was 
inversely correlated with overall survival rate of patients. The absence of the β1 
integrin reduced lymph node and lung metastasis in vivo and matrigel invasion 
in vitro by reducing the levels of active MMP-2 (Wang et al., 2012). Moreover, it 
has been shown that targeting the β1 integrin with antibodies increases the 
sensitivity to ionizing radiation and delays the growth of HNSCC cell lines in 3D 
and xenograft mice (Eke et al., 2012). However, studies looking at β1 without 
identifying the α subunit bound do not provide definitive evidence for α5β1 as a 
target. 
α5 has been shown to be extensively expressed in biopsy specimens of primary 
oral squamous cell carcinoma from invasive or metastatic cases. This 
expression was statistically correlated with tumour invasion and nodal 
involvement (Shinohara et al., 1999). Oral SCC has been shown to express 
higher levels of the α5β1 integrin than normal cells (Fabricius et al., 2011) 
(Vitolo et al., 2000). Also it has been shown that α5β1 integrin is overexpressed 
in many HNSCC cell lines grown under physiological three-dimensional 
conditions (Steglich et al., 2014). 
1.2.3.5.1.3 αIIbβ3 integrin 
αIIbβ3 is primarily expressed by platelets, although expression has also been 
observed in some tumour types and cell lines, including HSC-3 (Parikka et al., 
2006). The clinically used αIIbβ3 antagonist Tirofiban inhibits HSC-3 
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transmigration. It has also been shown that platelet αIIbβ3 integrin promotes the 
metastasis of nasopharyngeal carcinoma cells, suggesting interventions 
affecting platelet activation and tumour-platelet interactions may improve patient 
survival (Chen et al., 2009).  
 Prostate cancer 1.2.3.5.2
Prostate cancer was the most common cancer in men in the UK in 2011 
(Cancer research UK, 2014). In the UK, the estimated number of new prostate 
cancer cases was about 41,736 in 2011, while there were 10,837 deaths from 
the cancer in 2012 (Cancer research UK, 2014). Despite the improvement in 
prostate cancer detection and treatment, treating advanced prostate cancer still 
a challenge due to the tumour becoming castration resistant and no longer 
responding to hormone therapy (Amaral et al., 2012). Bone metastasis is 
common in castration-resistant prostate cancer and it significantly reduces the 
patient’s quality of life due to the severe pain and pathological fractures 
(Weinfurt et al., 2005). Docetaxel is the most common therapeutic agent for 
advanced prostate cancer. However, this agent is poorly tolerated (Amaral et al., 
2012). Therefore, it is very important to identify molecular target agents that can 
prevent tumour metastasis to the bone and so improve quality of life. It has 
been demonstrated that integrins play an important role in the metastasis of 
prostate cancer cells to bone, as well as in promoting tumour survival, invasion, 
migration and adhesion to bone vitronectin and osteopontin (Sutherland et al., 
2012, Suyin et al., 2013). These factors suggest a potential role for integrin 
antagonists in this area. 
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1.2.3.5.2.1 The αv subfamily of integrins (αvβ3, αvβ5, αvβ6, αvβ1, and 
αvβ8) 
The expression and implications of RGD-binding integrins in prostate cancer 
progression has been previously reviewed in an excellent review by Sutherland 
(Sutherland et al., 2012). Since then, Hess et al. evaluated the expression of a 
panel of integrins by immunohistochemistry (αvβ3, αvβ5, αvβ6, αvβ8, β3, and 
αv-pan) in formalin-fixed and paraffin-embedded (FFPE) tissue samples from 
prostate cancer patients and found that the αvβ6 and αvβ8 integrins were not 
expressed in tumour cells, and that αvβ3 was expressed in blood vessels only. 
αvβ5 was almost always expressed in prostate cancer cells in correlation with 
the Gleason pattern (GP) (Hess et al., 2014). Moreover, Goodman et al. 
confirmed the expression of αvβ3 on vasculature, αvβ5 on tumour cells and the 
absence of both αvβ6 and αvβ8 integrins from human prostate tissues 
(Goodman et al., 2012). Lastly, Gorlov et al. identified genes that were 
differentially expressed at different stages of prostate tumourigenesis and found 
the expression of αv and β5 subunits to be high in prostatic intraepithelial 
neoplasia compared to normal prostate tissues, although expression of β5 
integrins to be negatively correlated with Gleason scores. The α5, β1, β3, and 
β6 integrins subunits were decreased, and the αIIb, αv, and β5 subunits were 
increased in the transition from normal prostate tissues to non-metastatic 
cancer  (Gorlov et al., 2009). 
 41 
 
The majority of prior studies have focussed on αvβ3, and few studies have 
examined the role of αvβ5 in prostate cancer. It has been shown that αvβ3 
integrin is implicated in the metastasis of prostate cancer cells by mediating 
cancer cell adhesion to, and migration on, osteopontin and vitronectin in the 
bone microenvironment (Cooper et al., 2002). Further studies indicate that 
inactive or constitutively active mutants of αvβ3 integrin prevent tumour growth 
in bone (McCabe et al., 2007). Moreover, Putz et al. evaluated the expression 
of integrins in nine tumour cell lines established from bone marrow 
micrometastases of patients with cancer of the prostate (four cell lines), breast 
(two cell lines), lung (two cell lines), and colon (one cell line) using flow 
cytometry and they found that α5, αv, β1 and β3 integrin subunits are common 
characteristics of micrometastatic cells (Putz et al., 1999). In addition, De et al. 
demonstrated the expression of activated αvβ3 and αvβ5 in the tissue sections 
of metastatic prostate cancer by immunohistochemistry and they reported that 
the interaction of αvβ3 and αvβ5 integrins with SPARC (secreted protein, acidic 
and rich in cysteine) which is a component of bone matrix enhances VEGF 
production, which in turn activate αvβ3 and αvβ5 integrins (De et al., 2003).  
Zheng et al. report that αvβ3 integrin expressed in primary human prostate 
cancer cells, yet not in normal prostate epithelial cells. The expression of αvβ3 
mediates the adhesion to and migration of PC-3 cells and primary human 
prostate cancer cells on vitronectin (VN). Transfection of LNCaP with an αvβ3 
expression plasmid allowed the previously non-invasive cells to migrate on VN 
by mediating the FAK- signalling pathway (Zheng et al., 1999). Edlund et al. 
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have shown that LNCaP cells do not express αvβ3, which reduces their 
migration ability on VN and OPN, whereas these cells’ more metastatic sublines 
(C4, C4-2, and C4-2B) express αvβ3.  Blocking αvβ3 by antibodies inhibited 
migration of the more metastatic cells on VN, and OPN (Edlund et al., 2001). 
Increased αvβ3 expression in response to CCl2 or 12-LOX has also been 
shown to promote prostate cancer cell growth, migration and survival (Lin et al., 
2013) (Pidgeon et al., 2003). 
Bisanz et al. demonstrated that knocking-down αv integrin expression in 
PC-3 cells by liposome-encapsulated human αv-siRNAs inhibited the growth of 
PC-3 tumours in the skeleton due to enhanced tumour-cell apoptosis in bones 
(Bisanz et al., 2005). Furthermore, Gordon et al. showed the transfection of PC-
3 cells with bone sialoprotein (BSP) to result in the increased expression of the 
αv, β3, and β5 subunits and FAK and ERK phosphorylation, which in turn 
increased cancer cell invasion and survival (Gordon et al., 2009).  
In vitro studies have shown highly invasive human prostate cancer (PC3) 
and non-invasive (LNCaP) prostate cancer cell lines to not express the β6 
integrin (Zheng et al., 1999). Azare et al. evaluated by immunohistochemistry 
the expression of αvβ6 in 40 primary prostate tumours and found that αvβ6 was 
detected in 9 samples, and its expression was not significantly correlated with 
clinical stages, Gleason scores, or prostate-specific antigen levels. However, 
blocking of αvβ6 inhibited tumour cell migration in vitro (Azare et al., 2007). 
Dutta et al. found αvβ6 was overexpressed in bone metastases from prostate 
cancer, indicating it may support dissemination rather than primary tumour 
 43 
 
growth (Dutta et al., 2014). Recently, Dutta et al. showed that αvβ6 interacts 
with TGFβ receptor II (TβRII) and consequently activates Smad3 which in turn 
upregulates MMP2 and enhances cell migration (Dutta et al., 2015). In addition 
αvβ6 promotes osteolysis by increasing the expression of MMP2 in many 
prostate cancer cell lines (Dutta et al., 2014). Fedele et al. demonstrated that 
horizontal transfer of αvβ6 via exosomes from αvβ6-expressing (PC-3 and 
RWPE cell lines) to αvβ6-negative recipient cell lines (DU145 and C4-2B) 
enhanced cell adhesion and migration on LAP-TGFβ (Fedele et al., 2015).  
1.2.3.5.2.2 αIIbβ3 
Junior et al. evaluated the expression of integrins in clinically localized 
prostate cancer in a tissue microarray to evaluate the association between 
integrin expression and tumour recurrence following radical prostatectomy in a 
case-control study. α3β1 and αIIbβ3 expressions were more strongly expressed 
in recurrent tumours (Pontes-Junior et al., 2010). αIIbβ3 integrin had previously 
been shown to be expressed in PC-3 and DU145 prostate tumour cells by 
Western, dot-blotting, and flow cytometry, and in prostate carcinoma tissues by 
using an in situ hybridisation (ISH) technique. Blocking αIIbβ3 inhibited DU-145 
cell invasion (Trikha et al., 1996). DU145 cells were found to be more invasive 
than PC-3 cells due to the expression of αIIbβ3 in focal contact sites allowing it 
to participate in metastatic progression, whereas PC-3 cells express αIIbβ3 
intracellularly (Trikha et al., 1998b). DU145 cell xenografts developed tumours 
that invaded the surrounding tissue and metastasised to lymph nodes; PC-3 
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xenografts remained localised to the prostate. Blocking αIIbβ3 prevented lung 
colonization by DU145 cells in a tail vein injection model (Trikha et al., 1998b). 
1.2.3.5.2.3 α5β1 
The expression of α5β1 integrin in clinical tissue samples was studied by 
Nagle et al. who reported one case expressed α5β1 integrin from 20 cases of 
primary prostate cancer (Nagle et al., 1995).  Moreover, Chen et al. showed that 
the expression of α5β1 in normal prostate tissues was higher than in prostate 
cancer tissues. α5β1 expression is positively correlated with tumour’s Gleason 
grade (Chen et al., 2006). Zimmermann et al. demonstrated α5β1 to be the 
primary integrin receptor for fibronectin on human bone marrow stroma, as 
antibodies against α5, β1, and FN inhibit tumour cell adhesion processes in the 
bone, (Van der Velde-Zimmermann et al., 1997). Blocking α5β1 significantly 
inhibited PC-3 cell adhesion to fibronectin and partially inhibited PC-3 cell 
migration (Stachurska et al., 2012). Lastly, studies have shown in 3D cultures 
that the α5β1 integrin is the primary integrin that regulates the proliferation of 
prostate cancer cells by regulating the expression of the sonic hedgehog 
effector protein, GLI1 (Goel et al., 2010).  PHSCN-polylysine dendrimer that 
targets α5β1 inhibits prostate cancer cells invasion and induction of matrix 
metalloproteinase 1 (MMP-1) in vitro, and inhibits extravasation and lung colony 
formation in vivo (Yao et al., 2010).  
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1.2.4 Integrin antagonism   
All the reported anti-integrin drugs are designed to block integrin-extracellular 
matrix interaction. Some of the integrin-targeted drugs have made it to the 
market and some are still in clinical trials. Some integrin antagonists which are 
in clinical trial are summarised in Table 4. Considerable details regarding 
integrin antagonism have been reviewed (Goodman and Picard, 2012, 
Goswami, 2013, Millard et al., 2011, Cox et al., 2010). This section will focus on 
α5β1, αvβ3 and αvβ5 integrin-targeted drugs. 
1.2.4.1 α5β1 integrin antagonists 
Due to the role of α5β1 integrin in angiogenesis, a great deal of effort has gone 
into the development of α5β1 integrin antagonists as treatments for cancer and 
retinal neovascularisation in age-related macular degeneration. As a result of 
this effort, there are now several α5β1 integrin antagonists being investigated in 
pre-clinical and clinical trials, such as:  
  Volociximab (M200) 1.2.4.1.1
Volociximab (M200) is a high-affinity humanized monoclonal antibody against 
α5β1. It has been developed as an anti-angiogenic agent for the treatment of 
solid tumours and age-related macular degeneration (Tucker, 2006).  
Sawada et al. demonstrated that the murine parent antibody of volociximab, 
IIA1, inhibited the invasion of ovarian tumour cells into matrigel and adhesion to 
mesothelial cells in vitro (Sawada et al., 2008). Volociximab itself inhibited 
fibronectin binding, HUVEC proliferation, tube formation induced by VEGF 
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and/or bFGF and induced apoptosis of actively proliferating endothelial cells 
(Ramakrishnan et al., 2006). In vivo, IIA1 decreased metastases and total 
tumour burden while survivability increased in a mouse SKOV-3ip1 ovarian 
cancer xenograft model (Sawada et al., 2008). Furthermore, in multiple 
xenograft models, 339.1 antibody which recapitulates the properties of 
volociximab inhibited the growth of established tumours by 40-60% and 
decreased vessel density (Bhaskar et al., 2007).    
In a phase I clinical trial, Volociximab could be safely administered at a dosage 
of 15 mg/kg intravenously weekly. The most common toxicities noted included 
nausea, fatigue, headache, and arthralgia. One patient with renal cell carcinoma 
achieved a minor response and 5 patients were confirmed with stable disease 
(Ricart et al., 2008).   
In a phase II clinical trial, weekly infusions of single agent volociximab was well 
tolerated but without efficacy on patients with platinum-resistant, advanced 
epithelial ovarian or primary peritoneal cancer (Bell-McGuinn et al., 2011). 
Volociximab combined with carboplatin and paclitaxel was well-tolerated and 
led to stable disease in 52% of patients with advanced non-small-cell lung 
cancer (Besse et al., 2013). 
 ATN-161 1.2.4.1.2
The fibronectin domain containing the sequence PHSRN increases the affinity 
and specificity of fibronectin binding to α5β1. This PHSRN synergy sequence 
promotes tumour invasion and angiogenesis. Therefore it has become a target 
for cancer therapy (Livant et al., 2000),(Stoeltzing et al., 2003),(Wang et al., 
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2011),(Cianfrocca et al., 2006). ATN-161 (Ac-PHSCN-NH2) is a five amino acid 
peptide targeting αvβ3, αvβ5 and α5β1, derived from PHSRN sequence but 
replacing the arginine residue with cysteine and derivatising the termini of the 
peptide (Donate et al., 2008).  
ATN-161 inhibited the invasion of DU 145 human and metastatic MATLyLu 
(MLL) rat prostate carcinoma cells in vitro (Livant et al., 2000). ATN-161 in 
combination with fluorouracil reduced metastasis of colon cancer to the liver 
(Stoeltzing et al., 2003).  Breast cancer cells  treated with ATN-161 post 
radiotherapy showed a significant increase in apoptosis, which in turn led to a 
reduction in growth of cancer cells in three dimensional culture (Nam et al., 
2010). ATN-161 combined with radiotherapy has also been shown to prevent 
breast cancer metastasis in vivo (Khalili et al., 2006). A recent study in ovarian 
cancer cell line OV-MZ-6 xenograft models showed that targeting α5β1 integrin 
with ATN-161 in combination with paclitaxel reduced tumour growth by 37.8% 
compared to controls, while ATN-161 alone had no effect on tumour growth 
(Kaemmerer et al., 2014).  
ATN-161 also possesses anti-angiogenic activity, inhibiting VEGF-induced 
migration of choroidal endothelial cells and capillary tube formation in vitro 
(Wang et al., 2011). In phase I, ATN-161 was well tolerated at all dose levels. 
About 1/3 of the patients achieved prolonged stable disease (Cianfrocca et al., 
2006). These findings led to preparation of a phase II trial in head and neck 
cancer in which ATN-161 will be used in combination with radiation and 
chemotherapy.  
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A derivative of ATN-161, the PHSCN-polylysine dendrimer (Ac-PHSCNGGK-
MAP), has been shown to be more effective in inhibiting prostate cancer cell 
invasion and induction of matrix metalloproteinase 1 (MMP-1) in vitro, and 
inhibiting extravasation and lung colony formation in vivo (Yao et al., 2010). The 
same results were demonstrated in breast cancer (Yao et al., 2011). 
1.2.4.2 αvβ3 and αvβ5 integrin antagonists 
  LM609  1.2.4.2.1
LM609 is a mouse monoclonal antibody that binds αvβ3 integrin. This antibody 
blocks αvβ3 and inhibits the attachment of endothelial cells to vitronectin, von 
Willebrand factor (vWF), and fibrinogen (Cheresh and Spiro, 1987). Brook et al. 
demonstrated that LM609 could block angiogenesis in a murine model (Brooks 
et al., 1995). Subsequently, Mitjans et al. showed that LM609 inhibited tumour 
formation and metastasis in a nude mouse model of human melanoma (Mitjans 
et al., 1995). 
  Etaracizumab (Abegrin) 1.2.4.2.2
Abegrin is an IgG humanized monoclonal antibody engineered from LM609. In 
preclinical examination, Abegrin inhibited the adhesion of M21 melanoma cells 
to fibrinogen (Wu et al., 1998). Moreover, that Abegrin decreased ovarian 
cancer proliferation and invasion in vitro and inhibited the growth of ovarian 
cancer in vivo (Landen et al., 2008). 
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In phase I studies, stable disease was observed in several patients with renal 
cell carcinoma. In addition, no serious adverse events and no immune response 
were observed at the dosages tested (McNeel et al., 2005).  
In phase II studies, Hersey et al. evaluated the safety and anti-tumour efficacy 
of Abegrin alone or in combination with dacarbazine in patients with stage IV 
metastatic melanoma. Etaracizumab with dacarbazine did not appear to be 
more effective for treatment of metastatic melanoma than single-agent 
dacarbazine. Consequently, Abegrin is no longer being tested (Hersey et al., 
2010). 
  CNTO 95 (Intetumumab) 1.2.4.2.3
CNTO 95 is a fully humanized antibody that recognises αvβ1, αvβ3, αvβ5 and 
αvβ6. This antibody has anti-tumour and anti-angiogenic properties. In 
preclinical investigation, CNTO 95 inhibited cell adhesion, migration, 
proliferation, and invasion of both tumour and endothelial cells in vitro.  Also, it 
inhibited human tumour growth in a xenograft model (Trikha et al., 2004). In 
phase I, no adverse events were observed except infusion reaction which could 
be controlled with paracetamol. In total 4 of 24 patients achieved stable disease 
and one patient achieved partial response (Mullamitha et al., 2007). CNTO 95 in 
combination with standard drugs docetaxel and prednisone was well tolerated in 
hormone refractory prostate cancer patients (Chu et al. 2007) (Chu et al., 2011). 
However, CNTO 95 in combination with bevacizumab showed limited clinical 
activity in patients with refractory solid tumours and the combination had some 
toxicities (Uronis et al., 2014).  
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In a phase II trial in metastatic castrate-resistant prostate cancer, intetumumab 
in combination with docetaxel failed to reach the primary end point of increased 
progression-free survival (PFS). Median PFS was 7.6 and 11 months for the 
combination and docetaxel alone respectively; the combination of intetumumab 
with docetaxel resulted in shorter PFS without additional toxicity among 
castrate-resistant prostate cancer patients (Heidenreich et al., 2013).  
  S247 1.2.4.2.4
S247 is a small molecule that binds to αvβ3 but also with similar potency to 
other αv integrins (Shannon et al., 2004). In vitro, S247 inhibited cell 
proliferation, adhesion and migration and also mediated apoptosis (Reinmuth et 
al., 2003). S247 inhibited endothelial and tumour cell migration and reduced 
proliferation of endothelial cells but not tumour cells in two highly aggressive 
orthotopic models of breast cancer metastasis. Continuous infusion of S247 did 
not reduce the growth of 435/HAL primary tumours and slightly reduced the 
tumour cells detected in circulating blood but it reduced metastatic tumour 
burden in the lungs of mice. Administration of the agent for only the first 18 h 
after tumour cell inoculation into the tail vein resulted in a 68% decrease in the 
final tumour burden measured by flow cytometry, and an 86% decrease in the 
tumour-associated gain in lung weight relative to the vehicle-treated group. 
These results indicate that S247 has potential to prevent both early and late 
steps of metastasis (Shannon et al., 2004). Further, S247 inhibited the 
development of colon cancer liver metastasis in vivo but did not inhibit the 
growth of the primary tumour.   
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Radiation increases the expression of αvβ3 in endothelial cells and resulted in 
phosphorylated Akt, which increases the pro-survival signaling but in 
combination with S247, the radiation-induced Akt phosphorylation is inhibited 
and the radiosensitivity of endothelial cells is enhanced.  In vivo, combination of 
radiation with S247 resulted in a significantly greater delay in tumour growth, 
reduced tumour cellular proliferation and decreased tumour vessel growth than 
that produced by monotherapy (Abdollahi et al., 2005).   
  Cilengitide (EMD 121974) 1.2.4.2.5
Cilengitide is a cyclic pentapeptide containing the RGD sequence. It recognises 
αvβ3 and αvβ5. Cilengitide is proposed to inhibit tumour growth by two 
mechanisms of action: first, cilengitide inhibits angiogenesis by preventing the 
interaction between endothelial cell integrins and their ligands, thereby 
promoting apoptosis of tumour associated endothelial cells; second, it may 
reduce tumour growth by inhibiting the interaction between tumour cells 
expressing αvβ3 or αvβ5 and the extracellular matrix, which then promotes 
apoptosis of these cells (Reardon and Cheresh, 2011). 
Initial preclinical studies showed that cilengitide inhibited the adhesion, growth, 
and proliferation of tumour cells in xenografts. Xenograft studies have 
demonstrated the activity of cilengitide as a single agent against brain tumours, 
in combination with radiation in breast cancer, and with temozolomide in 
malignant melanoma (Reardon and Cheresh, 2011),(Burke et al., 2002),(Tentori 
et al., 2008). MacDonald et al. implanted human brain tumour cell lines DAOY 
(medulloblastoma) and U87 MG (glioblastoma) into either the forebrain 
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(orthotopic) or the subcutis (heterotopic) of nude mice, and systemically treated 
these animals with cilengitide to observe the difference in microenvironment in 
the growth of tumours and response to the drug. In the brain, cilengitide showed 
good activity, blocking the growth of tumour cells completely, whereas in skin, 
the drug had no effect (MacDonald et al., 2001). Recently, Ruffini et al. showed 
that cilengitide inhibits melanoma cells invasion, vasculogenic mimicry and 
secretion of VEGF-A and metalloproteinase 9 (Ruffini et al., 2014). 
Huber et al. demonstrated cilengitide with cetuximab to have a synergistic 
antitumor activity effect on A431 epidermoid carcinoma and U87MG 
glioblastoma cell xenografts (Vermorken et al., 2014). Heiduschka et al. 
evaluated the effect of cilengitide as a single agent or in combination with 
chemotherapy (cisplatin) or irradiation on the proliferation and colony formation 
of three HNSCC cell lines (SCC25, CAL27 and FaDu) and found that cilengitide, 
in combination with cisplatin, synergistically inhibited cell growth and increased 
apoptosis due to a decrease in the antiapoptotic protein Bcl-2, which is 
associated with chemo-resistance in various malignancies. They also found that 
cilengitide in combination with irradiation significantly inhibited colony formation 
(Heiduschka et al., 2014).  
In a single patient case study, cilengitide with gemcitabine inhibited the growth 
of a highly vascularized head and neck tumour and prolonged life for more than 
one year encouraging further investigation in HNSCC (Raguse et al., 2004). In 
the first phase I study the safety and toxicity of cilengitide in dosages between 
30-1600 mg/m2 twice weekly among adult patients with recurrent solid tumours 
 53 
 
were evaluated and no dose limiting toxicities observed (Eskens et al., 2003).  
Cilengitide was subsequently evaluated in phase I trials in adults with recurrent 
malignant glioma in dosages of 120-2400 mg/m2 twice weekly. Several dose 
limiting toxicities were observed (in 6/51 patients), thrombosis, joint and bone 
pain, thrombocytopenia, anorexia, hypoglycaemia, and hyponatraemia, but no 
MTD was found. Two patients demonstrated a complete response, three 
patients had partial responses, and four patients exhibited stable disease 
(Nabors et al., 2007). 
In phase II, Reardon et al. assessed the activity and safety of cilengitide in 
glioblastoma multiforme (GBM) patients at first recurrence, who received dosing 
of either 500 or 2000 mg infusion of cilengitide twice weekly for up to 48 weeks. 
Greater antitumour response was observed at the 2000 mg dosage (Reardon et 
al., 2008).  
Several studies have evaluated the effects of cilengitide when combined with 
treatment regimens for pancreatic cancer and GBM. Treatment of advanced 
stage pancreatic cancer patients with a combination of cilengitide with 
gemcitibine failed to demonstrate a difference in outcome compared to 
treatment with gemcitabine alone (Friess et al., 2006). Cilengitide has been 
evaluated on newly diagnosed GBM patients in combination with radiation and 
chemotherapy. The one year overall survival was 67% for patients on cilengitide 
combined with radiation and chemotherapy and 62% for patients on radiation 
and chemotherapy alone (Stupp et al., 2010). A Phase II trial in patients with 
head and neck squamous cell carcinoma showed that cilengitide in combination 
with cisplatin, 5-fluorouracil, and cetuximab did not improve progression-free 
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survival (Vermorken et al., 2014). Moreover, in a phase III trial of cilengitide 
combined with standard treatment in MGMT-promoter methylated glioblastoma, 
cilengitide did not improve the overall survival of patients with glioblastoma; 
median overall survival was 26.3 months in the cilengitide group and in the 
control group (Stupp et al., 2014). Consequently, the clinical development of 
cilengitide has been discontinued. 
The trial investigators suggested that the failure of cilengitide in head and neck 
cancer is because HNSCC cells (in contrast to tumour endothelium) tend to 
express low levels of αvβ3, the integrin most tightly bound by cilengitide 
(Fabricius et al., 2011).  Tumour expression of related integrins not targeted by 
cilengitide may also provide a mechanism for drug resistance and therapeutic 
failure. Moreover, Becker et al. showed that cilengitide was not distributed from 
the plasma to other compartments, and was mainly just excreted by the kidney. 
Its short half-life means tumours are not exposed to therapeutic concentrations 
for much of the time and may promote tumour growth; poor pharmacokinetics 
has ultimately led to its development being discontinued (Becker et al., 2015, 
Stupp et al., 2014). 
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Drug name Target Type of 
drug 
Disease 
indication 
Status References 
Volociximab α5β1 Antibody Untreated non-
small-cell lung 
cancer 
Phase II 
 
 
(Besse et 
al., 2013) 
ATN-161 α5β1, 
αvβ3 
and 
αvβ5 
Non-
RGD-
based 
peptide 
Recurrent 
intracranial 
malignant glioma 
Phase II (Cianfrocca 
et al., 2006). 
 
JSM6427 α5β1 Small 
molecule 
Age-related 
macular 
degeneration 
Phase I (ClinicalTrial
s.gov) 
Etaracizumab αvβ3 Antibody Melanoma 
 
Cancer 
Rheumatoid 
arthritis 
Plaque psoriasis 
Phase II (Hersey et 
al., 2010). 
(Wu et al., 
1998),(McN
eel et al., 
2005),(Hers
ey et al., 
2010),(Broo
ks et al., 
1995) 
CNTO 95 αv Antibody Metastatic 
castration 
resistant prostate 
cancer 
Phase II (Heidenreic
h et al., 
2013) 
Cilengitide αvβ3 
and 
αvβ5 
Cyclic 
RGD 
pentapep
tide 
Glioblastoma 
Melanoma 
Phase III (Stupp et 
al., 2014) 
 
 
DI17E6 αv Antibody Castration 
resistant prostate 
cancer and bone 
metastases 
Phase II (Wirth et al., 
2012) 
MK-0429 αvβ3 Small 
molecule. 
Metastatic bone 
disease in 
patients with 
hormone-
refractory 
Phase I (Rosenthal 
et al., 2010) 
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prostate cancer. 
Natalizumab α4β1 
and 
α4β7 
Antibody Multiple sclerosis 
and Crohn’s 
disease 
Approved (Miller et al., 
2003) 
Abciximab αIIbβ3 
αvβ3 
αmβ2 
Antibody Percutaneous 
coronary 
intervention. 
Acute Coronary 
Syndromes. 
Myocardial 
Infarction. 
Approved (Tam et al., 
1998),(Mag
er et al., 
2003),(Mazz
aferri and 
Young, 
2008),(Yeun
g and 
Holinstat, 
2012) 
Eptifibatide αIIbβ3 
 
A 
synthetic 
cyclic 
heptapep
tide 
Thrombosis Approved (Dennis et 
al., 
1990),(Yeun
g and 
Holinstat, 
2012) 
Tirofiban αIIbβ3 
 
Small 
molecule 
Thrombosis Approved (Hartman et 
al., 
1992),(Cann
on et al., 
2001) 
Table 4 Integrin antagonists in clinical use and clinical trials 
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1.3 Overall aims  and objectives 
The aim of this study was to evaluate the effect of potential novel small 
molecule RGD integrins antagonists on the inhibition of human tumour cell 
migration using 2D wound healing assays (scratch assays). This was achieved 
by: 
 Evaluating the targets (αvβ3, αvβ5 and α5β1 integrins) in clinical tumour 
samples.  
 Detecting the expression of αvβ3, αvβ5 and α5β1 integrins in human 
xenograft tissue as well as in human tumour cell lines. 
 Developing models that can be used for both the in vitro and in vivo 
evaluation of novel small molecule integrin antagonists 
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2 Chapter 2: Characterisation of integrin expression in clinical 
head and neck and prostate tumour samples and 
investigation of correlation between integrin expression and 
cancer aggressiveness 
 
2.1 INTRODUCTION 
Extracellular matrix (ECM) proteins have been shown to play a very important 
role in cancer progression; these proteins keep the cells linked to matrix 
elements and to the basal membrane, and also contribute to the matrix-cell 
signalling cascades that transmit from the ECM to the cells through integrin 
molecules. Changes in the interaction between ECM proteins and integrins lead 
to the activation of cytokines, growth factors and intracellular adaptor molecules, 
which have an effect on tumour behaviour, especially with respect to 
proliferation, survival, signal transduction and migration (Hu and Luo, 2013, 
Pecorino, 2012, Hehlgans et al., 2007, Rathinam and Alahari, 2010). In order to 
understand the mechanisms involved in these processes and identify molecular 
targets for therapy, the altered integrins and their correlations with clinical and 
pathological stages must first be demonstrated to be relevant to the tumour. 
Determining the integrin distribution in human samples is crucial because the 
benefit of drugs that target integrins is correlated with integrin expression 
(Sheldrake and Patterson, 2014). The previous studies detected the expression 
of integrins in cell lines and only on fresh frozen tissues originating from human 
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or human tumour cell xenografts. This limitation is due to the lack of monoclonal 
antibodies that label integrins in formalin-fixed, paraffin-embedded tissues 
(FFPE) which are the routine diagnostic samples in surgical pathology. This 
problem obstructs the progress of drugs that target αv integrins, by confounding 
the identification of tumour types and patient subgroups which would benefit 
from treatment. More recently, matched rabbit monoclonal antibodies against 
integrins that are useable with native and FFPE human tissues have been 
produced but unfortunately these are not commercially available (Goodman et 
al., 2012). These novel antibodies have led to numerous studies to evaluate the 
expression of integrins in (FFPE) human tissue, such as colorectal (Denadai et 
al., 2013, Ha et al., 2014), prostate (Hess et al., 2014), lung (Boger et al., 2014), 
brain (Schittenhelm et al., 2013) and head and neck (Fabricius et al., 2011).  
The current therapies in head and neck cancer and prostate cancer are not 
totally successful; therefore new therapeutic strategies are required. Head and 
neck cancer is a highly vascularised cancer that expresses integrins. Studies 
have shown that antiangiogenic drugs prevent cancer progression and integrin 
antagonists have good potential in this area (Avraamides et al., 2008, Weis and 
Cheresh, 2011). In prostate cancer, integrins have been implicated in growth, 
spread and tumour growth in bone. Many reviews have heavily emphasized the 
importance of RGD integrins as major pharmaceutical targets in prostate cancer 
(Sutherland et al., 2012, Goswami, 2013). Therefore, this study investigated the 
expression of αvβ3, αvβ5 and α5β1 integrins on normal and head and neck 
cancer, and prostate cancer tissues obtained in Bradford. 
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2.2 AIMS AND OBJECTIVES 
The aim of the research described in this chapter was to characterise integrin 
expression and investigate any a correlation between expression and tumour 
progression. This was achieved through the following objectives: 
 Characterise the expression of αv, β5, αvβ3 and α5β1 integrins in head 
and neck tumours and normal tissues from the same patient 
 Characterise the expression of αv, β5, αvβ3 and α5β1 integrins in 
prostate cancer tissues 
 Use statistical analysis to investigate if there is a relationship between 
expression and tumour aggressiveness. 
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2.3 MATERIALS AND METHODS 
2.3.1 Patients and tissue samples 
This project was approved by Ethical Tissue Licensed Research Tissue Bank 
(ISAC Reference: Application/13/050) University of Bradford in Bradford, UK, 
which is authorised to provide ethical approval from the NHS Leeds (East) 
Research Ethics Committee (07/H1306/98). The clinical characteristics of the 
patients are summarized in Table 5 and Table 6. Paired samples, consisting of 
tumour tissues and control non-cancerous tissues obtained from the same 
patients with head and neck cancer [the control normal tissues were collected 
from the area beyond the cut edge or the surgical margin] (n = 10) or prostate 
cancer (n = 9) were obtained via surgery and were snap frozen in liquid nitrogen 
and stored at −80°C until sectioning. The samples of head and neck tissue were 
collected from patients whose ages ranged between 57 and 90 years; samples 
of prostate cancer tissue were collected from patients whose ages ranged 
between 48 and 65 years. For head and neck cancers, the tumour stage was 
classified according to TNM classification, in which T indicates the size of the 
primary tumour and any tissues of the oral cavity or oropharynx to which it has 
spread, N describes the extent of the spread to nearby (regional) lymph nodes, 
and M indicates whether the cancer has spread (metastasized) to other organs 
of the body (Table 5 and Table 6)(Medscape Drugs & Diseases 2013). Prostate 
cancers were classified by TNM classification and Gleason score (Cancer 
research UK, 2014), although full data was not available on all patients. 
Before cutting sections, tissue blocks were equilibrated to the cryostat 
temperature of −20 ºC for 24 hours. Sections (5-μm thickness sections) were 
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cut from the tissue blocks using a microtome cryostat (Leica CM18604v, Leica 
Microsystems, Nussloch, Germany). Sections were placed on slides coated with 
3-aminopropyltriethoxysilane (APES) and left at room temperature 
(approximately 22 °C) until the sections adhered to the slides. Slides were 
stored at −80 °C until stained. 
No Localization Gender Age TNM stage stage 
2673 SCC of floor of mouth Male 57 pT2, pN2c, pMx 4 
3085 SCC of left tongue Female  pT2 pN2b pMx 4 
3091 SCC buccal mucosa Female 83 pT1 pN2b (both) 4 
3092 SCC tongue Female 90 pT4a, pN2b, 
pMx 
4 
3554 SCC of mouth (left) Male 58 pT4a, pN1 4 
3555 Verrucous carcinoma of 
maxilla 
Male 72 pT4a, pN0 4 
3824 SCC right tonsil Male 68 pT4a/4b, pN1, 
pMx 
4 
3545 Invasive SCC of mouth Male 59 pT3, pN1, pMx 3 
3340 SCC maxillary sinus Male 59 pT3, pN0, pMx 3 
3325 SCC left retromolar 
region 
Female 80 pT4, pN0 4 
 
Table 5 Clinical characteristics of patients with head and neck cancer 
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No Localization Gender Age TNM stage 
3064 Adeocarcinoma M 49 Gleason 6 (3+4). pT2, Nx, Mx 
3586 Acinar type 
adenocarcinoma 
M 57 Gleason sum 7 pT2C N0 Mx 
2759 Adenocarcinoma M 51 Gleason 6 (3+3). pT2, Nx, Mx 
3515 Adenocarcinoma M 65 Gleason sum 6 (3+3) pT3a No Mx 
3592 Microacinar 
adenocarcinoma 
M 48 Gleason 7 (3+4) pT2a No Mx 
6200 Prostatic adenocarcinoma M 65 pT2c 
6201 Prostatic adenocarcinoma M 60 Gleason 7 (4+3), pT3b 
6197 Adenocarcinoma M  Gleason 6 (3+3) pT3a 
2758 Adenocarcinoma n/a n/a n/a 
 
Table 6 Clinical characteristics of patients with prostate cancer 
 
 
2.3.2 Haematoxylin and eosin staining of frozen tissue 
Frozen tissue sections were fixed for 10 minutes with acetone at room 
temperature and then rehydrated for 10 minutes in phosphate buffered saline 
(PBS). Fixed tissues were immersed in Harris’s haematoxylin solution for 10 
minutes before they were washed with running tap water. The tissues were 
soaked in an alcohol/acid solution (0.25% HCl in 70% ethanol) for 10 seconds 
and then blued in Scott’s Tap Water (20 g sodium bicarbonate and 3.5 g 
magnesium sulphate in 1 L of distilled water) for 2 minutes. Tissues were 
counterstained with 1% aqueous eosin for 1 minute and rinsed with running tap 
water. Sections were then dehydrated for 2 minutes in 100% ethanol, cleared 
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for 2 minutes with 50% xylene/ethanol and 100% xylene and coverslip-mounted 
with a distyrene-plasticiser-xylene (DPX) medium (VWR International Ltd). 
Slides were stored at room temperature until stained. 
2.3.3 Immunohistochemistry of frozen sections 
Frozen tissue sections were fixed 10 minutes in acetone at room temperature 
and then rehydrated for 10 minutes in PBS (Sigma-Aldrich). The sections on the 
slides were circled with a wax pen and then blocked by adding 300 µl blocking 
agents 5% BSA (Sigma-Aldrich), 10% goat serum (for PIF6 and Q-20) or horse 
serum (Millipore) (for LM609 and JBS5) for 1 hour at room temperature. Excess 
blocking was removed and 100 µl of diluted primary antibody was added and 
incubated 1 hour at room temperature. Primary antibodies were withheld from 
negative controls. The tissues were washed three times for 10 minutes in PBS 
and then incubated in 100 µl of diluted secondary antibody (1:200) for 30 
minutes at room temperature. Tissues were washed three times for 10 minutes 
in PBS. Tissues were incubated with ABC peroxidase labelled streptavidin 
solution for 30 minutes at room temperature. The ABC reagent was washed off, 
and the tissues were washed three times for 10 min in PBS and then incubated 
5 minutes in 3,3’-diaminobenzidine (DAB Peroxidase (HRP) Substrate Kit, 
Vector laboratories), counterstained with haematoxylin for 20 seconds and 
blued in Scott’s Tap Water for 2 minutes. Finally, tissue sections were 
dehydrated, cleared and mounted as described above (Section 2.3.2). The 
steps that were followed to optimize the antibodies are shown in Figure 9. The 
primary and secondary antibodies used in immunohistochemistry are 
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summarized in Table 7. To identify the squamous epithelium cells in the frozen 
sections, mouse monoclonal anti-pan cytokeratin were used, without scoring the 
expression. 
2.3.3.1 Evaluation of integrin expression 
The immunohistochemical labelling was scored semi-quantitatively in a blinded 
process by a senior clinical pathologist (Dr Philip Batman). 
Immunohistochemical staining intensity was scored as (0) for negative staining, 
as (1) for weak staining, as (2) for moderate staining, as (3) for strong staining 
and as (4) for very strong staining (Figure 10). 
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2.3.3.2  Statistical analysis 
The analysis was carried out by Dr Andrew Scally using Stata v13.1. The 
correlations between integrin expression and clinical characteristics were 
examined using Fisher’s exact t-test. Due to the limitations of the small sample 
size (head and neck sample = 10; prostate sample = 9), a very large observable 
effect would be required to show statistical significance. For these preliminary 
investigations, a P value of < 0.2-0.4 was used as an indicator of potential 
trends which could be further investigated. A qualitative inspection of the data 
was performed to tentatively confirm the existence of trends. Additional studies 
with a larger sample size should, however, be performed to verify the 
significance of any trend. Differences in integrin expression between paired 
tissue types from individual patients were examined using the Wilcoxon signed-
rank test. 
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Immunohistochemistry 
Frozen tissue 
                                  Fixation 
                4% PFA 
            Acetone  
      No labelling               Blocking 
               5% PSA             5% PSA + Serum  
                                Not specific labelling                       Good  
                                                  Primary antibody dilution  
             1:50 
                 Over stained 
1:100 
Good 
1:200 
Weak 
   Different conditions  
 Overnight at 
4 ºC 
One hour at room 
temperature 
Good 
One hour at 
37 ºC 
   Secondary antibody dilution  
  1:50 1:100 
Good  
1:200 
   Incubation with DAB for variable time  
 2 minutes 
Weak 
5 minutes 
     Good 
10 minutes 
Over stained 
Figure 9 The steps which were followed to optimize the antibodies in 
immunohistochemistry. 
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Primary antibody Commercial 
source 
Secondary antibody Commercial 
source 
PIF6: rabbit polyclonal 
antibody (anti-β5 integrin 
subunit). 
Abcam Biotinylated goat anti-rabbit 
IgG antibody 
Vector labs 
Q-20: rabbit polyclonal 
antibody (anti-αv integrin 
subunit). 
Santa Cruz Biotinylated goat anti-rabbit 
IgG antibody 
Vector labs 
LM609: mouse 
monoclonal antibody 
(anti-αvβ3 integrin) 
Chemicon 
(Millipore) 
Biotinylated horse anti-
mouse IgG antibody 
Vector labs 
JBS5: mouse 
monoclonal antibody 
(anti- α5β1 integrin). 
Chemicon 
(Millipore) 
Biotinylated horse anti-
mouse IgG antibody 
Vector labs 
C-11: mouse monoclonal 
antibody (anti-pan 
cytokeratin) 
Abcam Biotinylated horse anti-
mouse IgG antibody 
Vector labs 
 
Table 7 Primary and secondary antibodies used in immunohistochemistry 
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Head and neck 
   
  
 
Prostate 
   
  
 
Figure 10 Representative images of different intensities of integrin expression 
A: (0) no integrin expression; B: (1) weak expression; C: (2) moderate expression; D: (3) strong 
expression; E: (4) very strong expression. Scale bar = 100 µm. 
 
 
A B C 
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2.4 RESULTS 
2.4.1 The expression of integrins in fresh frozen human head and neck 
tissues 
The distribution of αv, β5, αvβ3 and α5β1 integrins was assessed in normal 
epithelium, squamous cells carcinoma, endothelial cells and stroma Figure 12, 
Figure 13 and Figure 14 and Table 8. 
The overall mean of the immunolabelling scores shows that αv, β5, αvβ3 and 
α5β1 integrin expression was higher in squamous cells carcinoma than in the 
control normal epithelium. Integrin αv was expressed in squamous cells 
carcinoma in almost all tumour samples (80% scored 4) and in the normal 
epithelium in normal tissues (80% scored 3). The difference between the 
expression of αv integrin subunits on normal and tumour samples was 
statistically significant (P = 0.01). Moreover, most of the normal epithelium in 
normal tissues lacked integrin αvβ3 (70% scored 0, and 30% scored 1). The 
increase in αvβ3 integrin expression from the normal epithelium in normal 
tissues to squamous cells carcinoma in tumour tissues (50% scored 2) was 
statistically significant (P = 0.02). A similar difference was observed for β5 and 
α5β1 integrins, with an increase in staining from the normal epithelium in normal 
tissues (50% scored 2, and 40% scored 0) and (60% scored 0) to squamous 
cells carcinoma in tumour tissue (40% scored 3 and 50 % scored 2) and (60% 
scored 3), respectively. The difference between the expression of β5 integrin 
subunits on normal and tumour samples was statistically significant (P = 0.05). 
The expression of α5β1 integrin was higher in squamous cells carcinoma than 
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the normal epithelium in control tissues; the difference in expression was 
statistically significant (P = 0.07) Table 9.  
The expression of αvβ3, α5β1 and β5 integrins was very strong, moderate and 
weak respectively in both the tumour and control endothelial cells. The 
expression of these integrins was higher in tumour endothelial cells than normal 
endothelial cells except the expression of αv integrins was higher in the normal 
endothelial cells. The difference between the expression of αv and α5β1 in 
normal and tumour endothelial cells was statistically significant (P = 0.07 and 
0.2). 
The expression of αv, αvβ3, β5 and α5β1 integrins in tumour stroma was higher 
than in stroma of the control sample and the difference was statistically 
significant (P = 0.02, 0.08, 0.02 and 0.05 respectively).  
The expression of αv in tumour stroma, αvβ3 and α5β1 in squamous cells 
carcinoma and α5β1 normal stroma in the group with lymphatic metastasis (N+) 
was significantly higher than in the group without metastasis (N0) (P = 0.13, 
0.03, 0.13 and 0.13 respectively). The data did not show a statically significant 
trend but there was increase in metastasis correlated to the expression of αv in 
squamous cells carcinoma and αvβ3 and β5 in tumour stroma; this may reach 
significance in a larger study Table 9. 
The expression of β5 in tumour endothelial cells and α5β1 in tumour stroma 
was correlated positively with the tumour size (P = 0.2 and 0.04 respectively). 
The data did not show a statically significant trend but there was increase in 
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tumour size correlated to the expression of αv in squamous cells carcinoma, 
αvβ3 in tumour endothelial cells and α5β1 in squamous cells carcinoma and 
tumour endothelial cells; this may reach significance in a larger study  (see 
Table 10).  
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Figure 11 H & E Staining of fresh frozen head and neck tissues. 
Representative images of H & E staining of normal and tumour tissue (First row). Negative control without primary antibody (second row). Immunolabeling 
with C-11 antibody showed strong cytoplasmic expression of cytokeratin in normal and tumour tissues. E, epithelium; SCC, squamous cell carcinoma. Bar 
length = 100 μm. 
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Figure 12 Representative images of immunohistochemical expression patterns of αv and αvβ3 integrins in head and neck samples. 
Q-20 and LM609 antibodies were used to detect αv and αvβ3 integrins in fresh frozen tissues.  E, epithelium; SCC, squamous cell carcinoma; V, blood 
vessels; S,  stroma. Bar length = 100 μm 
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Figure 13 Representative images of immunohistochemical expression patterns of β5 and α5β1 integrins in head and neck samples 
PIF6 and JBS5 antibodies were used to detect β5 and α5β1 integrins in fresh frozen tissues. E, epithelium; SCC, squamous cell carcinoma; V, blood vessels; 
S, stroma. Bar length = 100 μm. 
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 Squamous cells 
carcinoma 
Normal epithelium Endothelial cells 
 
Stroma 
 
  αv   
Normal 0 2.6 ± 0.9 
 
2.6 ± 0.9 
 
0.4 ± 0.8 
 
Tumour 3.7 ± 0.64 
 
0 1.4 ± 1.4 
 
1.8 ± 1.5 
 
  αvβ3   
Normal 0 0.3 ± 0.5 
 
3.7 ± 0.5 
 
0.2 ± 0.6 
 
Tumour 1.1 ± 0.9 
 
0 3.8 ± 0.6 
 
0.8 ± 1 
 
  β5   
Normal 0 1.3 ± 1 
 
1.5 ± 1 
 
0.2 ± 0.6 
 
Tumour 2.2 ± 0.9 
 
0 1.3 ± 1 
 
1.2 ± 1 
 
  α5β1   
Normal 0 0.9 ± 1 
 
1.8 ± 1 
 
1.5 ± 1 
 
Tumour 2.1 ± 1 
 
0 2.2 ± 1 
 
2.4 ± 0.9 
 
Table 8 Integrin expression in head and neck tissues. 
 20 samples from head and neck were used: 10 tumour tissues and 10 non-cancerous 
tissues originating from the same patient. Results are shown as the means ± SD for integrin 
expression levels on the specified tissue. 
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A  B  
IHC in the squamous cells 
carcinoma vs normal 
epithelium in control 
P value HIS in the tumour cells in 
group with (N+) vs (N0) 
p value 
αv 0.01 
 
αv 0.5 
αvβ3 0.02 
 
αvβ3 0.03 
 
β5 0.05 
 
β5 0.4 
 
α5β1 0.07 
 
α5β1 0.1 
 
HIS in the tumour endothelial 
cells vs endothelial cells in 
control 
P value HIS in tumour endothelial 
cells in group with (N+) 
vs (N0) 
P value 
αv 0.07 
 
αv 0.7 
 
αvβ3 0.6 
 
αvβ3 0.7 
 
β5 0.7 
 
β5 1 
 
α5β1 0.2 
 
α5β1 1 
 
HIS in the tumour stroma vs 
stroma in control 
P value HIS in the tumour stroma 
in group with (N+) vs 
(N0) 
P value 
αv 0.02 
 
αv 0.1 
 
αvβ3 0.08 
 
αvβ3 0.7 
 
β5 0.02 
 
β5 0.3 
 
α5β1 0.05 
 
α5β1 1 
 
Table 9 Statistical analysis of the immunohistochemistry scores of integrin 
expression in HNSCC. 
 Comparison of integrin expression (A)  between normal tissues and tumour tissues in 
paired samples from the same patient, and (B) patients with lymph node metastasis (N+) 
versus no lymph node metastasis (N0). 
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Integrin expression in squamous cell carcinoma and 
correlation with tumour size 
P value 
αv 0.8 
αvβ3 0.8 
β5 1 
α5β1 0.7 
Integrin expression in tumour endothelial cells and 
correlation with tumour size 
P value 
αv 0.7 
αvβ3 1 
β5 0.2 
α5β1 0.7 
Integrin expression in tumour stoma and correlation with 
tumour size 
P value 
αv 0.9 
αvβ3 1 
β5 0.3 
α5β1 0.04 
 
Table 10 Statistical analysis for correlation between the immunohistochemistry 
score of integrin expression in tumour tissues with tumour size (T) 
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Figure 14  Integrin expression (% immunolabelled cells) in normal and tumour 
head and neck tissues. 
Ten head and neck samples were used, comprising 10 non-cancerous tissues and 10 
tumour tissues originating from the same patient. The percentage of immunolabelled 
cells in A, normal epithelium and squamous cells carcinoma; B, endothelial cells; C, 
stroma, are shown as the means ± SD. The asterisk * indicates P < 0.2, ** indicates P 
< 0.05. 
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2.4.2 The expression of integrins in prostate tissues 
αvβ3 and α5β1 integrins were often expressed on the cell membrane, whereas 
αv and β5 integrin subunits were cytoplasmic (Figure 15 and Figure 17). The αv 
integrin subunit was strongly expressed in tumour cells (66% score 3), 
moderately in stroma (77.7% score 2) and very weakly expressed in endothelial 
cells. Integrin αvβ3 was rarely expressed in tumour cells and endothelial cells 
(44% and 77% score 0, respectively) and highly expressed in stromal cells 
(100% score 3). The β5 integrin subunit expression was high in tumour cells 
(22% score 4, 33% score 3 and 44% score 2) and very low in stroma and 
endothelial cells (77% and 44% score 0, respectively). Integrin α5β1 was 
strongly expressed in stromal cells (100% score 3) and moderate in tumour 
cells (66% score 2) but was not expressed in endothelial cells (100% score 0) 
(Figure 15, Figure 16 and Figure 17). Expression levels of αv, β5 and α5β1 
integrins in the tumour cells were significantly higher than in normal cells (P = 
0.008, P = 0.0102 and P = 0.0102) respectively. These data did not show any 
correlation between integrin expression and Gleason scores (Table 11). 
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Figure 15 Staining of fresh frozen prostate tissues. 
First row:  Representative images of H & E staining where nucleus stains blue and the 
cytoplasm red. Second row: Negative control without primary antibody. Third row: 
Immunolabelling with Q-2 antibody shows cytoplasmic expression of αv in tumour cells 
and stroma. T, tumour; S, stroma.  Bar length = 100 μm. 
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Figure 16 Representative images of immunohistochemical expression patterns of 
αvβ5, αvβ3 and α5β1 integrins in head and neck samples 
αvβ3 (LM906) and α5β1 (JBS5) antibodies gave membranous staining whereas αvβ5 
(PIF6) antibody gave cytoplasmic staining.  T, tumour; S, stroma. Bar length = 100 μm. 
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Expression 
on tumour 
cells 
 
Expression 
on normal 
cells 
IHC in the 
tumour cells 
vs normal 
cells (P 
value) 
Expression 
on 
endothelium 
 
Expression 
on stroma 
 
αv 2.75 ± 0.5 0 ± 0 
 
0.008 
 
0.3 ± 1 2.125 ± 0.6 
 
 
αvβ3 0.85 ± 1 
 
 
0 ± 0 
 
0.08 
 
0.7 ± 1.3 
 
 
3 ± 0.9 
 β5 3 ±  0.8 
 
0.3 ± 1 0.01 
 
0.5 ± 1.1 
 
 
1 ± 0.9 
 α5β1 2 ± 0.8 
 
 
0 ± 0 
 
0.01 
 
0 ± 0 
 
3 ± 1.2 
 
 
 
Figure 17 Integrin expression in prostate tissues  
Eight samples from the prostate were used. Results are shown as the means ± SD for 
integrin expression levels in the specified tissue. The asterisk * indicates P < 0.4, ** 
indicates P< 0.05. 
 
IHC in the tumour cells in group with Gleason score 6 and 7 p value 
αv 0.2 
αvβ3 0.7 
 β5 1 
 α5β1 0.5 
 IHC in the endothelial cells in group Gleason score 6 and 7 P value 
αv 0.6 
 αvβ3 n/a 
 β5 0.6 
 α5β1 n/a 
 IHC in stromal cells in group with Gleason score 6 and 7 P value 
αv n/a 
αvβ3 n/a 
 β5 0.37 
 α5β1 n/a 
  
Table 11 Statistical difference between the immunohistochemistry score of 
integrin expression with Gleason score 6 vs 7. 
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2.5 Discussion 
In this study, the expression of αv, β5, αvβ3 and α5β1 integrins in head and 
neck fresh frozen tissues, comprising 10 tumour tissues and 10 normal tissues 
originating from the same patient, and in fresh frozen prostate tissues from nine 
patients, were evaluated by immunohistochemistry. This allowed analysis of the 
distribution of these integrins in tumour cells, squamous epithelial cells, 
endothelial cells and stroma.  
Previous studies of integrin distribution in tissue have generally used fresh 
frozen tissues (Max et al., 1997, Fabricius et al., 2011, Denadai et al., 2013) 
because antibodies that react with FFPE tumour tissue were not available. 
Recently, a set of antibodies, which allow the labelling of integrin complexes in 
FFPE tissue have been produced and validated at the molecular, cellular and 
tissue levels but are not yet available for research use (Goodman et al., 2012). 
Inability to obtain these antibodies for this study limits the sample number that 
can be analysed because retrospective analysis of FFPE sections that are 
accessible from stored samples is not possible with the antibodies that label 
integrin complexes in fresh frozen tissues.  
2.5.1 Head and neck tissues 
This study demonstrated frequent expression of β5, αvβ3 and α5β1 integrins in 
tumour cells; importantly, normal squamous epithelium cells weakly express β5, 
αvβ3 and α5β1 integrins. The difference between the expression of αv, β5, 
αvβ3 and α5β1 on normal and tumour samples was statistically significant 
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suggesting up-regulation of these integrins in tumourigenesis. Strong αvβ5 
integrin expression in tumour cells was reported for tongue (Kurokawa et al., 
2008), oral squamous cell carcinoma (Jones et al., 1997) and laryngeal 
squamous cell carcinoma, and its expression is associated with lymphatic 
metastasis and angiogenesis (Li et al., 2013). In addition, strong expression of 
αvβ5 integrins in tumour cells was also reported in other cancers, such as 
colorectal cancer and melanomas (Goodman et al., 2012). Fabricius et al., 
previously found that the expression of αvβ5 and α5β1 integrins in squamous 
cell carcinoma in oral cancer tissues was significantly higher than that of 
squamous epithelium in normal tissues (Fabricius et al., 2011). The expression 
of α5β1 integrins in head and neck tissues was associated with invasion and 
metastasis, and with a poor prognosis (Shinohara et al., 1999, Vitolo et al., 
2000, Charalabopoulos et al., 2005). 
I found that although αvβ3 integrin was weakly expressed in tumour cells, the 
expression was significantly higher than  in noncancerous squamous epithelium 
(P = 0.02). These results are consistent with studies in malignant glioma and 
melanoma, which indicated that tumour cells express higher levels of αvβ3 than 
normal tissues (Albelda et al., 1990). In contrast, Fabricius et al. reported a low 
expression of αvβ3 integrin in head and neck tumour tissues (Fabricius et al., 
2011) and failure of a clinical trial of Cilengitide was suggested to be due to lack 
of expression of the target integrins in this tumour type (Vermorken et al., 2014). 
Our results showed that αvβ3, α5β1 and β5 expression in tumour cells and β5 
in tumour stroma was significantly higher in the group with lymph node 
metastasis (N+) than in tumour cells and stroma in the group without lymph 
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node metastasis (N0) (P = 0.03, 0.4, 0.1 and 0.3 respectively). This finding 
supports preclinical studies that have demonstrated the implications of αvβ5 
integrin in metastasis of head and neck cancer (Li et al., 2011, Li et al., 2013, 
Lu et al., 2009, Koivisto et al., 2000). 
Integrins αvβ3, αvβ5 and α5β1 are implicated in vascular development and the 
blocking of these integrins inhibits angiogenesis and tumour growth (Kim et al., 
2002, Brooks et al., 1995, Reardon et al., 2008, Kumar et al., 2001). The 
present work identifies that the expression of αvβ3 and α5β1 integrins was 
slightly higher in endothelial cells within tumour than normal tissues and 
difference in the expression of α5β1 was statistically significant (P = 0.2 in this 
small study). This finding is in agreement with Fabricius et al. who showed high 
αvβ3 and α5β1 integrin expression in tumour endothelia cells compared to 
endothelial cells in control normal tissues (Fabricius et al., 2011).  Similarly a 
study by Max et al. reported strong αvβ3 integrin expression in tumour blood 
vessels in fresh frozen human tissue from different epithelial tumours (Max et al., 
1997). The expression of αvβ3 and α5β1 integrins indicates their role in 
angiogenesis as other studies showed the involvement of these integrins in 
endothelial cell proliferation, differentiation and migration (Eliceiri et al., 1998) 
(Lee and Ruoslahti, 2005) (Kim et al., 2002).     
Surprisingly, I found the expression of the αv and β5 integrin subunits to be low 
in the endothelial cells of tumour tissues. This contrasts with the results of Li et 
al. (2013), who found that the αvβ5 integrin is upregulated in the tumour blood 
vessels.(Li et al., 2013). 
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In the present study, α5β1 integrin was expressed more frequently than αv, β5 
and αvβ3 integrins in the normal stroma of the control samples. However, in 
tumour stroma, an increased expression of αv, β5, αvβ3 and α5β1 integrins was 
observed, and the expression of these integrins in tumour stroma was 
significantly higher than in the normal stroma. Fabricius et al. reported also that 
the expression of αvβ3, αvβ5 and α5β1 integrins was higher in tumour stroma 
than in normal stroma in control tissue, and found that αvβ5 integrins were 
markedly expressed in tumour stroma rather than in normal stroma in control 
tissues (Fabricius et al., 2011). The present study suggests head and neck 
cancer would be a suitable clinical problem to address by multi-integrin 
targeting. 
It is important to note that the small number of samples in this pilot study 
seriously limits the extent of statistical analysis. As discussed, a larger sample 
size would be required to show statistically significant observable trends. 
Analysis of a larger dataset may reveal further associations between integrin 
expression, tumour size, and metastasis. Scoring integrin expression on a 
continuous scale would also be more useful for statistical analysis. 
2.5.2 Prostate tissues 
This study showed that in prostate tissues, αvβ3 integrin was prevalent in 
stroma, and occasionally on tumour cells and endothelial cells, and was not 
detected in squamous epithelium cells. Zheng et al., previously observed a 
similar expression profile for αvβ3 integrin in prostate cancer cells but not in 
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normal prostate epithelial cells (Zheng et al., 1999) whereas Hess et al. (2014) 
and Goodman et al. (2012) reported the expression of αvβ3 integrins on blood 
vessels only. Differences between the results could be due to experimental 
procedures, the patient demographic investigated, type of prostate tumour and 
invasiveness of the tumour.   
These data showed that αv and β5 integrin subunits was extensively expressed 
in tumour cells, occasionally in stroma and rarely in endothelial cells. These 
results are in agreement with those of Goodman et al., who found that prostate 
cancer samples expressed essentially only αvβ5 integrins in tumour cells and 
stroma (Goodman et al., 2012). Hess et al. reported a high expression of αvβ5 
integrin in prostate cancer cells which was correlated significantly with the 
Gleason pattern (Hess et al., 2014). I found that β5 integrin expression in 
tumour stroma was significantly higher in the group with a Gleason score of 7 
than in the group with a score of 6. 
In the present study, α5β1 integrin was strongly expressed in stroma and 
moderately in tumour cells, but it was not detected in endothelial cells or 
squamous epithelial cells. This is in contrast to observations noted by Chen et 
al. (2006) and Nagle et al. (1994), who found that squamous epithelium cells 
expressed higher levels of α5β1 integrins than tumour cells (Chen et al., 2006, 
Nagle et al., 1994). 
Again, this analysis was limited by the very small number of patient samples 
available. Some samples did not allow for the scoring of integrin expression on 
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all tissue types, and some patient data was incomplete. As a result, it was 
difficult to observe any trends between integrin expression and tumour 
progression. 
2.6 Conclusion 
Despite the very small number of samples available for use in this pilot study, 
αv, β5, αvβ3 and α5β1 have been identified as significantly overexpressed in 
tumour tissues, and there are trends suggesting a correlation with metastasis 
and tumour size in head and neck cancer. Further analysis of a larger number 
of samples, preferably scoring by percentage integrin expression, will be 
required to unambiguously state that αvβ5, αvβ3 and α5β1 are a promising 
target for cancer therapy. In order to further investigate the effect of integrin 
expression on tumour cell function, and to provide models for use in drug 
development, it will be necessary to identify cell line models which match the 
integrin expression of clinical tissues. 
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3 CHAPTER 3: Characterisation of integrin expression in in 
vitro and in vivo cell line models 
 
3.1 Introduction 
Cell-cell adhesion and interaction of cell integrins with extracellular matrix 
proteins play crucial roles in each step of tumour progression: integrins are 
implicated in tumour cell proliferation, migration, survival and angiogenesis.  
For this reason, the distribution and expression of integrins has been 
extensively studied in clinical samples, and in in vitro and in vivo models 
(Goodman et al., 2012, Terry et al., 2014, Seguin et al., 2012, Stachurska et al., 
2012, Roman et al., 2010). The expression and role of integrins, specifically the 
RGD-binding integrin subfamily in cancer progression, are described in Chapter 
1. In this chapter, the expression of α5, αv, β5 and β3 integrin subunits was 
evaluated in vitro and in vivo to select appropriate in vitro and in vivo models to 
evaluate the efficacy of novel integrin antagonists as drug targets. 
3.2 Aim of this study 
Interaction of cell integrins with ECM proteins is associated with cell migration, 
invasion and tumour metastases. Moreover, cancer cell survival depends on an  
ability to bind with the ECM proteins. Therefore, this study investigated the 
involvement of αvβ5, αvβ3 and α5β1 integrins in cancer progression. In 
particular: 
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 the expression of αv, β3, β5 and α5 integrin subunits in a panel of tumour 
cell lines: tongue squamous carcinoma cells OSC-19; prostate cancer 
cells PC-3 and DU-145; human breast carcinoma cells MCF-7; MCF-
7ADR/NCRI ADR-RES cells as a drug-resistant model; colorectal 
adenocarcinoma cells DLD-1 and HT-29; melanoma cells M14 and 
human umbilical vein endothelial cells HUVEC using 
immunofluorescence and Western blot in order to select cell line models 
with high or low expression of αv, β5 and α5 integrin subunits to use in 
functional studies. 
 The expression of αv, β3, β5 and α5 integrin subunits in a panel of FFPE 
and fresh frozen human xenograft tumours grown in mice using 
immunohistochemistry and Western blot. Expression of these integrin 
subunits in fresh frozen xenograft tissues was compared with in vitro 2D 
cell cultures to investigate the effect of the tumour microenvironment on 
the expression of integrins. Confirmation of the expression profile in vivo 
will allow the selection of models to be used once novel antagonists 
eventually progress to in vivo screening.  
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3.3 MATERIALS AND METHODS 
3.3.1 Reagents 
All cell culture materials were purchased from Sigma-Aldrich unless indicated. 
For immunofluorescence and Western blot, reagents were purchased from 
several sources, as described in the relevant section below. 
3.3.2 Cell lines and Cell culture 
A panel of cell lines reported in the literature to have high or low expression of 
αv, β5 and α5 integrin subunits were selected: human breast carcinoma cells 
MCF-7; MCF-7ADR/NCRI ADR-RES cells as a drug-resistant model (Taherian 
et al., 2011, Nista et al., 1997); prostate cancer cells PC-3 and DU-145 
(Stachurska et al., 2012, Witkowski et al., 1993); colorectal adenocarcinoma 
cells DLD-1 and HT-29 (Haier et al., 1999, Petersen et al., 2013); tongue 
squamous carcinoma cells OSC-19 (Kawahara et al., 1995); melanoma cells 
M14 and human umbilical vein endothelial cells HUVEC (Goodman et al., 2012). 
All cell lines were purchased from NCI, except for DU-145 and DLD-1 which 
were obtained from ATCC. Cells were regularly grown in 75 cm2 cell culture 
flasks (T-75) flasks (Corning) at 37 °C, 5% CO2 and 95% air as monolayer 
cultures in RPMI-1640 culture medium containing 10% foetal bovine serum 
(FBS), sodium pyruvate (1 mM) and L-glutamine (2 mM). 
When the cells had become 70-80% confluent, they were passaged by 
trypsinisation. The old medium was aspirated using a pipette, cells were 
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washed 2 times with 10-15 ml of HBSS prior to the addition of 3 ml of trypsin-
EDTA and the mixture was incubated for 5-15 minutes at 37 °C until the cells 
were completely detached and separated into single cells. 10 ml of complete 
media was added and the cell suspension was centrifuged at room temperature 
for 5 minutes at a speed of 1000 RPM. The supernatant was discarded and the 
cell pellets were re-suspended in 10 ml of fresh RPMI medium. The required 
amount of cell suspension was aliquoted into a sterile non-vented T-75 flask. 
Cells were discarded after 10 passages and replaced with fresh stocks because 
cell lines at high passage numbers experience alterations in cell morphology, 
response to stimuli, growth rates, and protein expression, compared to lower 
passage cells. 
To determine the cell density in a cell suspension, a Neubauer’s modified 
haemocytometer was used. A cell suspension (10 µl) was transferred with a 
pipette to the edge of both chambers of the haemocytometer. Due to capillary 
action, the mixture was drawn underneath the cover slip. The cell count was 
performed in 10 chambers (8 corner squares and 2 middle squares) by using a 
low-power (x10) objective microscope. The number of cells per ml was 
calculated as the following: 
Number of cells per ml = average number of cells counted × dilution factor ×104 
3.3.3 In vivo xenograft modelling 
Animal procedures were performed according to a protocol approved by the UK 
Home Office and in accordance with the UK National Cancer Research Institute 
Guidelines for the Welfare of Animals (Workman et al. 2010). Immunodeficient 
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Balb/C Nu/Nu mice aged 6 to 8 weeks obtained from Harlan (Loughborough, 
UK) were injected subcutaneously with human tumour cells and when the 
tumour reached 500 mm3 in volume, the mice were sacrificed and the tumour 
extracted. Some tumours were snap-frozen and stored in liquid nitrogen and 
some were embedded in paraffin. Four cell lines were used in this study: OSC-
19, PC-3, HT-29 and MCF-7. In vivo xenograft modelling was done by Patricia 
Cooper. 
3.3.4 Immunofluorescence 
3.3.4.1 General protocol 
A cell suspension was prepared and 3 × 105 cells/ml seeded on cover slips in 6 
well plates because this concentration was sufficient to give 70% confluency 
after overnight incubation at 37 °C. The culture medium was aspirated from 
each well. Cells were washed twice with 1 ml of HBSS at room temperature. 
The cells were then fixed by adding 1 ml of one of the fixative agents: acetone 
(1 second at room temperature), methanol (15 minutes at −20 °C) or 4% 
paraformaldehyde (15 minutes at room temperature) and the plate were left to 
dry. The plate was left in –20 °C overnight. The cells were rehydrated in PBS 
(Sigma-Aldrich) and blocked by adding 300 µl of one of the blocking agents: 
BSA (Sigma-Aldrich), goat serum or donkey serum (Millipore) for 1 hour at room 
temperature (approx. 22 °C). The blocking was removed and 100 µl of diluted 
primary antibody was added and incubated at overnight at 4 °C or 1 hour at 
room temperature or one hour at 37 °C. Primary antibody was withheld from 
 95 
 
negative controls. The cells were washed three times for 10 minutes with 
blocking agent and then incubated with 100 µl of diluted secondary antibody for 
1 hour in dark at room temperature. Cells were washed three times for 10 
minutes with PBS. The cover slips were mounted with Mounting Medium with 
DAPI (Vector Laboratories) and left in the freezer in the dark until dry. The 
primary and secondary antibodies which were used are summarized in Table 12. 
Also the steps which were followed to optimize the antibodies are shown in 
Figure 18.  
Antibody Company  Secondary antibody Company 
[ab15459]: Rabbit 
polyclonal anti- β5. 
Abcam Alexa Fluor 546 donkey anti 
rabbit IgG 
Millipore 
[Q-20]: Rabbit 
polyclonal anti-αv. 
Santa Cruz Alexa Fluor 546 donkey anti 
rabbit IgG 
Millipore 
[C-9]: Mouse 
monoclonal anti-α5. 
Santa Cruz Alexa Fluor 488 F(ab)2 
fragment of goat anti mouse 
Millipore 
(B-7): Mouse 
monoclonal anti-β3. 
Santa Cruz Polyclonal rabbit anti-mouse 
immunoglobulins conjugated 
with tetramethylrhodamine 
isothiocyanate (TRITC) 
Dako 
 
Table 12 Primary and secondary antibodies used in immunofluorescence studies for 
detection of αv, β5, α5 and β3 integin subunits. 
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 Different fixation  
4% PFA Acetone Ice cold methanol 
 Different blocking  
5% BSA + 10% 
serum 
5% BSA 10% serum 
 Different conditions  
1 hour at 37 °C 1 hour at room 
temperature 
Overnight at 4°C 
 Different dilution of the 
primary antibody 
 
1:100 1:200 1:500 
 Different dilution of the 
secondary  antibody 
 
1:100 1:200 1:500 
Figure 18 The steps which were followed to optimise the 
immunofluorescence staining technique  
PFA; Paraformaldehyde, BSA; Bovine serum albumin.  
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3.3.5 Western blot 
3.3.5.1 Protein extraction from cells 
Three 75% confluent T-75 flasks were used to collect the cells from each cell 
line. Each flask was washed once with 10 ml of HBSS. After washing, a further 
5 ml of HBSS was added and the cells were gently scraped by cell scraper and 
collected in an Eppendorf tube. The cell suspension was centrifuged at a speed 
of 13,000 rcf for 5 minutes at 22 ºC. The liquid phase was discarded and the 
pellet was resuspended in 2 X pellet volume of protein extraction buffer.  Two 
lysis buffers were used to extract the protein: urea lysis buffer [71.5 µl of PIC 
with EDTA (Roche), 7 M urea, 2 M thiourea, 4% CHAPS, 0.1 % SDS and 0.05% 
sodium deoxycholate (Sigma-Aldrich) in PBS] and Triton lysis buffer [100 mM 
tris buffer, 300 mM NaCl, 5 mM EDTA and 2% Triton (Sigma-Aldrich)]. 
3.3.5.2 Protein extraction from xenograft tissues: 
Human xenograft frozen tissue samples were placed on ice to prevent 
degradation by proteases and cut by a clean blade into approximately 2 mm3 
pieces. One piece was placed in Eppendorf tubes with 100 µl of RIPA lysis 
buffer [10 µl 10% SDS, 25 µl 10% sodium deoxycholate (Sigma-Aldrich), 71.5 µl 
of PIC with EDTA (Roche) in 893.5 µl PBS] for 30 minutes at room temperature 
with constant vortexing. The samples were sonicated 9 times for 3 cycles of 3 
seconds with cooling on ice between each time to avoid overheating. The 
homogenate was centrifuged at a speed of 13,000 rcf for 20 minutes at 4 ºC. 
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The liquid phase was extracted to a new tube whereas the pellet was incubated 
with 100 µl of urea lysis buffer [71.5 µl of PIC  with EDTA (Roche), 7 M urea, 2 
M thiourea, 4% CHAPS, 50 mM DTT (Sigma-Aldrich) in PBS] for 30 minutes at 
room temperature with constant vortexing. The mixture was then treated with 
RIPA lysis buffer as described above until the tissue was totally homogenised. 
The proteins were aliquoted and stored at −80 °C for later use. 
3.3.5.3 Determination of protein concentration 
The Bradford assay was used to determine the concentration of the protein in 
each sample by comparison to a standard curve. 1 mg of BSA was dissolved in 
1 ml of water. 6 series of protein standards (1 ml each) were prepared as 1 
mg/ml, 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml and 0.0625 mg/ml BSA and blank 
by serial dilution. 45 µl of water and 5 µl of sample were added to the sample 
tube and mixed by vortex. 1.5 ml of Bradford reagent (Sigma-Aldrich) was 
mixed with 50 µl of standards, blank, and sample and incubated at room 
temperature for 15 minutes. The optical density of each standard and unknown 
sample was measured by spectrophotometer (Cary 50 BIO UV-Visible) at 595 
nm. The protein concentration for the test sample was obtained from the 
standard curve. 
3.3.5.4 SDS-Polyacrylamide Gel Electrophoresis 
Equivalent amounts of protein determined by the Bradford assay were mixed 
with 1 volume of sample buffer [3.55 ml of water, 1.25 ml of 0.5 M Tris-HCl, 2.0 
ml of 10% SDS, 0.2 ml of 0.5% W/V bromophenol blue, 50 μl of β-
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mercaptoethanol and 2.5 µl of glycerol (Sigma-Aldrich)]. The mixture was mixed 
by vortex then centrifuged at a speed of 13,000 rcf for 1 minute at room 
temperature. The samples were heated in a water bath for 10 minutes at 60 °C. 
The samples were centrifuged again before loading in the gel. The 
electrophoresis tank was filled with electrophoresis buffer (1.5 g of Tris, 7.2 g of 
glycine and 0.5 g of SDS (Sigma-Aldrich) into 500 ml of distilled water). 5 µl of 
PageRuler™ Plus Prestained Protein Ladder (Thermo Scientific) and the 
desired concentration of each sample were loaded on a 12% polyacrylamide gel. 
The electrophoresis tank was run for 20 min at 80 V and then 1 hour at 160 V. 
Once bromophenol blue reached the bottom of the gel, the power was turned 
off. 
3.3.5.5 Blotting 
An electrical current was used to transfer the protein from the polyacrylamide 
gel to ECL nitrocellulose membrane (GE Healthcare Life Sciences). The 
transfer method involves placing a membrane on top of the gel, and a stack of 
blotting papers on top of that. The entire stack was placed vertically in transfer 
buffer [200 ml of methanol into 750 ml of distilled water and 100 ml of stock 
transfer buffer which consists of: 144 g of glycine, 30 g of Tris and 2 g of SDS 
(Sigma-Aldrich), and 250 ml of distilled water (pH adjusted to 8.3)]. The transfer 
tank was connected to the power supply and electrophoresed at 58 mA for 2 
hours on ice. 
The membranes were then blocked with blocking agents (Marvel skimmed milk 
or BSA) for 1 hour at room temperature and incubated overnight at 4 °C with 
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suitably diluted primary antibodies. Membranes were washed three times with 
0.5 % Tween PBS for 15 minutes. Membranes were incubated for 1 hour at 
room temperature with diluted horseradish peroxidise conjugated secondary 
antibody. Proteins were detected using an enhanced chemiluminescence (ECL) 
detection reagent (GE Healthcare Life Sciences). Each membrane was 
exposed to Amersham Hyper-film ECL (GE Healthcare Life Sciences) for an 
appropriate time (between 30 seconds and 10 minutes). Film was developed in 
Multigrade Paper Developer solution (Ilford), rinsed with water and fixed in 
Rapid Film and Paper Fixer solution (Ilford) for 2 minutes. The film was left to 
dry. The primary and secondary antibodies which were used are summarized in 
Table 13. 
For accurate quantitative measurements for the protein, single-protein loading 
controls, such as β-actin, that should not change between samples were used 
in every run to show any technical error such as overloading or mis-loading of 
the protein. To obtained semi-quantitative analysis from three independent 
experiments, ImageJ software (National Institutes of Health) was used to 
quantify each blot by dividing the signal intensity of the protein of interest by the 
signal intensity of the internal control β-actin. Expression was classified as: 0; 
no expression, <0.5; low, 0.5-1; moderate, >1 high. 
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Primary antibody Company Secondary antibody Company 
[ab15459]: Rabbit 
polyclonal anti-β5.  
Abcam Polyclonal goat anti rabbit linked 
to horseradish peroxidise 
Dako 
[Q-20]: Rabbit 
polyclonal anti-αv.  
Santa Cruz Polyclonal goat anti rabbit linked 
to horseradish peroxidise 
Dako 
[B-7]: Mouse 
monoclonal anti-β3. 
Santa Cruz Polyclonal rabbit anti mouse 
linked to horseradish peroxidise 
Dako 
Mouse monoclonal 
antibody anti-β-actin.  
Sigma 
Aldrich 
Polyclonal rabbit anti mouse 
linked to horseradish peroxidise 
Dako 
[C-9]: Mouse 
monoclonal anti-α5. 
Santa Cruz Polyclonal rabbit anti mouse 
linked to horseradish peroxidise 
Dako 
 
Table 13 Primary and secondary antibodies used in Western blot studies for detection of 
αv, β5, α5 and β3 integin subunits. 
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3.3.6 Immunohistochemistry 
3.3.6.1 Frozen tissues 
 Before cutting sections, blocks were equilibrated to the cryostat temperature 
(−20 °C) for 24 hours. The blocks were sectioned to 5 μm thickness using 
cryostat (Leica CM1100, Leica Microsystems, Nussloch Germany). Sections 
were picked up onto 3-aminopropyltriethoxysilane (APES) coated slides and left 
at room temperature till the sections were adhered to the slides. Slides were 
stored at −80 °C until staining.  
 Haematoxylin and eosin staining of frozen tissue 3.3.6.1.1
Tissue sections were stained as described in section 2.3.2. 
 Immunohistochemical labelling of frozen sections 3.3.6.1.2
Immunohistochemical labelling of frozen sections was carried out as described 
in section 2.3.3. The primary and secondary antibodies which were used are 
summarized in  Table 14.  
 Mouse on mouse (M.O.M.) kit  3.3.6.1.3
For antibodies raised from mouse, an M.O.M kit (Vector Laboratories) was used 
to localise mouse primary antibodies on mouse tissues which should eliminate 
background staining in mouse tissue. The 5 μm thick frozen tissues were fixed 
in acetone for 10 minutes and then washed with PBS for 10 minutes. The 
endogenous enzyme activity was blocked with bloxall endogenous peroxidase 
and alkaline phosphatase blocking solution (Vector Laboratories) for 10 
minutes.  After washing 10 minutes with PBS, sections were blocked for one 
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hour with M.O.M. mouse Ig blocking reagent (90 μl of stock solution with 2.5 ml 
of PBS) and incubated for 5 minutes with working solution of M.O.M diluent 
(600 μl of protein concentrate stock solution to 7.5 ml of PBS). Sections were 
incubated for 30 minutes with diluted primary antibody and then washed three 
times with PBS and incubated for 10 minutes with M.O.M. biotinylated anti-
mouse IgG (10 μl of stock solution to 2.5 ml of prepared M.O.M. diluent). Tissue 
sections were then processed as described in section 2.3.3. 
3.3.6.2 Paraffin embedded tissues 
Tumours were immersed in 10% neutral buffered formalin (VWR International 
Ltd. Poole, UK) for 24 to 48 hours and then placed in plastic cassettes 
(Raymond A. Lamb Ltd, UK). The sample was then placed in an automatic 
tissue processor (Leica TP 1020, Leica Microsystems, Nussloch, Germany) 
where the samples transferred through baths of progressively more 
concentrated ethanol (70 %, 80 %, 95 % and 100%) and xylene to clear any 
remaining ethanol. Fixed tissues were then embedded in the wax and allowed 
to harden overnight. After that the blocks were sectioned to 5 μm thickness 
using a Leitz rotary microtome (Leica RM2155, Leica Microsystems, Nussloch, 
Germany). Sections were attached onto 3-aminopropyltriethoxysilane (APES) 
coated slides and stored at room temperature. 
  Haematoxylin and eosin staining of paraffin embedded 3.3.6.2.1
tissues 
Tissue sections were de-waxed and rehydrated by immersing twice in different 
tank of 100% xylene for 10 minutes, once in 50% xylene/ethanol for 5 minutes, 
 104 
 
twice in absolute ethanol for 10 minutes, once in 90% ethanol for 5 minutes, 
once in 70% ethanol for 5 minutes and finally in distilled water for 5 minutes. 
Sections were then stained as described section 2.3.2.  
   Immunohistochemical staining of paraffin embedded tissues 3.3.6.2.2
Tissue sections were de-waxed and rehydrated as described in section 
3.3.6.2.1. To block the endogenous peroxidase activity, tissues were treated 
with 1% hydrogen peroxide (Vector Laboratories) for 30 minutes and then 
rinsed 10 minutes in PBS. For antigen retrieval, slides were placed in a plastic 
container of citrate buffer (2.1 g citric acid monohydrate in 950 ml of distilled 
water) and heated by the microwave at 600 W for 20 minutes or tissues were 
covered by pre-warmed trypsin (400 mg trypsin + 8 ml of 5% CaCl2 in 400 ml of 
distilled water) for 15 minutes at 37 °C. Following another PBS wash, the 
sections were circled with a wax pen and stained as described in section  2.3.3. 
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Primary antibody Company Secondary antibody Company 
[ab15459]: Rabbit 
polyclonal anti-β5.  
Abcam Biotinylated goat anti-
rabbit IgG antibody 
Vector labs 
[Q-20]: Rabbit 
polyclonal anti-αv.  
Santa Cruz Biotinylated goat anti-
rabbit IgG antibody 
Vector labs 
[B-7]: Mouse 
monoclonal anti-β3. 
Santa Cruz Biotinylated horse anti-
mouse IgG antibody 
Vector labs 
[C-9]: Mouse 
monoclonal anti-α5. 
Santa Cruz Biotinylated horse anti-
mouse IgG antibody 
Vector labs 
 
Table 14 Primary and secondary antibodies used in immunohistochemistry studies for 
detection of αv, β5, α5 and β3 integin subunits in xenograft tissues. 
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3.4 Results 
3.4.1 Protein expression in cell lines 
3.4.1.1 Immunofluorescence 
 αv integrin subunit 3.4.1.1.1
The optimal conditions for using each antibody for immunofluorescence are 
summarized in Table 15. The Q-20 antibody was used to determine the 
expression and the localization of αv integrin subunit on a panel of cell lines 
comprising: MCF-7, MCF-7ADR, DLD-1, PC-3, DU-145, HT-29, HUVEC and 
OSC-19. The MCF-7 cell line was used to optimize the Q-20 antibody because 
literature suggested it expresses a high level of αv integrin subunits (Taherian et 
al., 2011). The steps followed to optimize the αv antibody (Q-20) are 
summarized in Figure 19.  The optimized conditions were: fixation with 4% 
paraformaldehyde, blocked with 5% BSA with 0.3 M glycine, overnight 
incubation  at 4 °C with (1:50) primary antibody (Q-20) and 1 hour incubation at 
room temperature with (1:200) diluted secondary antibody (Alexa Fluor 546 
donkey anti rabbit IgG).   
The immunofluorescence images suggest localisation of the αv integrin subunit 
on the cell membrane. The αv integrin subunit screening results showed that all 
these cell lines express the αv integrin subunit, but with variable levels. PC-3 
has very weak expression, whereas the OSC-19, DLD-1, HT-29 and HUVEC 
cells have the highest expression. The DU145, MCF-7 and MCF-7ADR cell 
lines demonstrated low expression (see Figure 20).  
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 Anti αv Anti β5 Anti α5 (c-9) 
Fixation 4% PFA Acetone Acetone 
Blocking 5% BSA/PBS 5% BSA/PBS 5% BSA and 10 goat 
serum 
Primary antibody 
dilution 
1:50 1:200 1:100 
Incubation condition Overnight at 4 °C One hour at room 
temperature 
Overnight at 4 °C 
Secondary antibody 
dilution 
1:200 for 1 hour in 
dark. 
1:200 for 1 hour in 
dark. 
1:200 for 1 hour in 
dark. 
 
Table 15 Summary of optimal conditions for each antibody in immunofluorescence 
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     Fixation  
 4% PFA  
     Different blocking  
5% BSA  5% BSA with 0.3 M glycine 
         High background     Incubated overnight at 4 °C with diluted primary 
antibody 1:50 
 Different dilutions for secondary antibody 
 1:50                                 1:100                             1:200 
 High background    High background       Clean background 
Figure 19 The steps followed to optimize the αv antibody (Q-20). 
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Figure 20 Immunofluorescence images of αv expression in cancer cell lines. 
DAPI stained the nuclei (blue) and the Q-20 antibody labelled αv integrin subunit, which may have been localised on the cell membrane (red). Scale bar = 50 
µm. 
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 β5 integrin subunit 3.4.1.1.2
The ab15459 antibody was used to determine the expression of the β5 integrin 
subunit. The MCF-7 cell line was used to optimize this antibody because 
literature suggested it expresses a high level of β5 integrin subunits (Taherian 
et al., 2011). The steps followed to optimize the β5 antibody (ab15459) are 
shown in Figure 21. 
MCF-7 Cells were fixed with acetone and blocked with 5% BSA/PBS. The cells 
were incubated 1 hour at room temperature with primary antibody (ab15459) 
(1:200) and 1 hour at room temperature with diluted secondary antibody (Alexa 
Fluor 546 donkey anti rabbit IgG) (1:200). The immunofluorescence images 
suggest the localisation of the β5 integrin subunit in the cytoplasm and cell 
membrane. The β5 integrin subunit screening results showed that all cell lines 
express β5, but at variable levels. As shown in Figure 22, DU-145 has the 
lowest expression, while OSC-19, MCF-7ADR, PC-3, DLD-1 and MCF-7 have 
the highest. HT-29 and HUVEC have moderate levels of the β5 integrin subunit.  
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Figure 21 The steps followed to optimize the β5 antibody (ab15459). 
 Fixation  
4% PFD Acetone Ice-cold methanol 
Bad Very good Good 
 Different blocking  
5% BSA + 10% donkey 
serum 
5% BSA 10% donkey serum 
Very good Very good Good 
 Different condition  
1 hour at 37 °C 1 hour at room 
temperature 
Overnight at 4 ° C  
Good Very good Bad 
Different dilutions for the primary antibody (rabbit polyclonal to 
integrin β5 [ab15459]) 
 
1:100 1:200 1:500 
Very good Very good Bad 
Different dilutions for the secondary antibody (Alexa Fluor 546 donkey 
anti rabbit IgG) 
 
1:100 1:200 1:500 
Very good Very good Bad 
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Figure 22 Immunofluorescence images of β5 expression in cancer cell lines. 
DAPI stained the nuclei (blue) and ab15459 antibody labelled β5 integrin subunit, which may have been localised on the cell membrane and in the cytoplasm 
(red). Scale bar = 50 µm. 
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 α5 integrin subunit 3.4.1.1.3
The C-9 antibody was used to determine the expression of the α5 integrin 
subunit. The MCF-7ADR cell line was used to optimize this antibody because 
literature suggested it expresses a high level of α5 integrin subunits (Nista et al., 
1997). The steps followed to optimize the α5 antibody are shown in Figure 23. 
MCF-7ADR cells were fixed with acetone and blocked with mixture containing 5% 
BSA and 10% goat serum. The cells were incubated overnight at 4 °C with 
diluted primary antibody (1:100) and 1 hour at room temperature with diluted 
secondary antibody (Alexa Fluor 488 F(ab)2 fragment of goat anti mouse) 
(1:200). The immunofluorescence images show that the expression of the α5 
integrin subunit is potentially localised to the cell membrane and cytoplasm in 
the MCF-7ADR, DLD-1, PC-3, DU-145, HUVEC and OSC-19 cell lines. The HT-
29 and MCF-7 cell lines do not express the α5 integrin subunit (Figure 24).  
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 Fixation  
4% PFD Acetone Methanol 
 Very good  
 Blocking  
5% BSA/PBS 5% BSA+ 10% goat 
serum/PBS 
10% goat serum/PBS 
 Very good  
 Different conditions  
1 hour at room temperature Overnight at 4 °C 1 hour at 37 °C 
 Very good  
 Different dilution for the primary 
antibody 
 
1:50 1:100 1:200 
 Very good  
 Different dilution for the secondary  
antibody 
 
1:50 1:200 1:100 
 Very good  
Figure 23 The steps followed to optimize the α5 antibody (C-9). 
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Figure 24 Immunofluorescence images of α5 expression in cancer cell lines. 
DAPI stained the nuclei (blue) and C-9 antibody labelled α5 integrin subunit, which may have been localised on the cell membrane and in the cytoplasm 
(green). Scale bar = 50 µm. 
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3.4.1.2 Western blot on cell line 
Whilst immunofluorescence provided evidence of spatial localisation of the 
integrin proteins, the results were not quantitiative i.e they did not demonstrate 
relative amounts of protein present or specificity of the antibody for a specific 
integrin; for this purpose Western blotting was used. The optimum conditions for 
each antibody are summarised in Table 16. 
 
 
 αv integrin subunit 3.4.1.2.1
All cell lines (MCF-7, MCF-7ADR, DLD-1, PC-3, DU-145, HT-29, HUVEC and 
OSC-19) expressed αv but the relative expression profile differed between cell 
lines. HUVEC, OSC-19, M14, DLD-1 and HT-29, expressed a moderate αv level 
of the integrin subunit, whereas others, such as MCF-7ADR, MCF-7 and DU-
145, expressed low αv levels and PC-3 cells did not express αv (Figure 27).  
 β5 integrin subunit  3.4.1.2.2
The process used to optimize β5 antibody is explained in Figure 25. β5 integrin 
was expressed at high levels by DU145, M14, OSC-19, DLD-1 and MCF-7 and 
at moderate level by HT-29, HUVEC and MCF-7ADR.  PC-3 cells expressed 
low level of β5 integrin subunit (Figure 27).  
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 α5 integrin subunit 3.4.1.2.3
The optimisation of the α5 antibody is detailed in Figure 26. DLD-1, DU145, 
MCF-7ADR, HUVEC, OSC-19 and M14 expressed a high level and PC-3 
expressed moderate level of the α5 integrin subunit. HT-29 and MCF-7 cells did 
not express α5 integrin subunit (Figure 27). 
 Anti αv Anti β5 Anti α5 Anti-β actin 
Lysis buffer to extract protein 
from cells 
Triton Urea Urea Triton or Urea 
Lysis buffer to extract protein 
from xenograft tissues 
Riba + Urea Riba + Urea Riba + Urea Riba + Urea 
Blocking 5% 
BSA/PBS 
5% milk 5% milk 5% BSA/PBS 
Primary antibody dilution 1:2000 1:2000 1:300 1:2000 
Incubation condition Overnight at 
4 °C 
Overnight at 
4 °C 
Overnight at 
4 °C 
Overnight at 
4 °C 
Secondary antibody 1:3000 1:2500 1:3000 1:3000 
Exposure time 10 min 10 min 10 min 30 sec 
Expected result Single band 
size 130 
KDa 
Single band 
size 85 KDa 
Single band 
size 150 KDa 
Single band 
size 44 KDa 
 
Table 16 Summary of optimal conditions for each antibody in Western blot 
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 Extract the protein with different lysis buffer   
  (Urea)                        (Triton)   
Loading different protein concentration  Loading different protein concentration  
   20 µg                        80 µg                    100 µg 50 µg      20 µg                 80 µg 
Different blocking  Different blocking  
5% BSA 5% Milk 5% BSA          5% Milk 
                 Good                  Good Overnight incubation at 4 ºC with (1:500) 
diluted primary anti β5 (ab15459) 
 
Different antibody dilutions  Incubation with 1:3000 secondary antibody for 
1 hour at room temperature 
 
1:2000 1:3000 No bands  
Good result    
Overnight incubation at 4 ºC    
Incubation with 1:2500 secondary antibody for 1 hour 
Single band at 85 KDa 
   
    
Figure 25 The steps followed to optimize the β5 antibody (ab15459). 
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 Extract the protein with different lysis 
buffer 
  
  (Urea)                      (with Triton)  
 
 
Loading different protein concentration  Loading different protein concentration  
   20 µg                     80 µg              100 µg 50 µg 20 µg                 80 µg 
Different blocking  Different blocking  
5% BSA 5% Milk 5% BSA 5% Milk 
             Good               Good Overnight incubation at 4 ºC with (1:500) 
diluted primary anti α5 (C-9) 
 
          Different antibody dilutions  Incubation with 1:3000 secondary 
antibody for 1 hour at room temperature 
 
1:300 1:200 No bands  
Good result    
Overnight incubation at 4 ºC    
Incubation with 1:3000 secondary antibody for 1 
hour 
Single band at 150 KDa 
   
    
Figure 26 The steps followed to optimize the α5 antibody (C-9). 
 
 
 
 120 
 
α
V
 
   
β
5
 
    
α
5
 
  
A
n
a
ly
s
is
 b
y
 I
m
a
g
e
 J
 
  
 
Figure 27 Expression of αv, β5 and α5 integrin subunits in a panel of human tumour cell lines 
by Western blot. 
Membranes were blotted with anti αv (B-Q), anti β5 (ab15459), anti α5 (C-9) and anti β-actin 
antibodies, which recognize proteins with band size 130, 85, 150 and 42 kDa respectively. Results 
shown are the average of three independent experiments. 
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3.4.2 Protein expression in xenograft tissues 
3.4.2.1 IHC on xenograft tissues 
The steps which were followed to optimize the antibodies are shown in Figure 
28. The optimal conditions for each antibody used in immunohistochemistry are 
summarized in Table 17. To evaluate the expression of αv, β3 α5 and β5 
integrin subunits on xenograft tissues, two rabbit polyclonal antibodies, Q20 
(anti-αv) and ab15459 (anti-β5) and two mouse monoclonal antibodies, B7 
(anti-β3) and C-9 (anti-α5) were used. On formalin fixed paraffin embedded 
(FFPE) tissue, the four antibodies did not label the protein, most likely because 
the FFPE process involves cross-linking, dehydration, hydrophobic 
environments, and heat, all of which can destroy or conceal epitopes (Figure 
29). On fresh frozen xenograft tissues, strong cytoplasmic immunolabelling 
without non-specific background was observed with rabbit antibodies against αv 
(Q-20) and β5 (ab15459). Non-specific labelling of mouse tissues with mouse 
antibodies made it difficult to identify α5 and β3 integrin subunit distribution on 
mouse xenografts. A M.O.M kit was used to prevent non-specific binding but 
unfortunately all methods proved unsuccessful (Figure 30). Therefore, the 
expression of α5 and β3 integrin subunits was evaluated by Western blot 
(Figure 32). 
On HT-29 and MCF-7 xenografts, αv integrin subunit was intensely expressed 
only on tumour cells whereas the β5 integrin subunit was moderately expressed 
(Figure 31). On the OSC-19 xenograft, αv and β5 integrin subunits were highly 
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expressed on tumour cells and stroma respectively (Figure 31). On the PC-3 
xenograft, both tumour cells and stroma expressed moderate level of αv and β5 
integrin subunits (Figure 31).  
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Immunohistochemistry 
  
 
Frozen tissue 
 
Paraffin tissue 
 
 Fixation  
Antigen retrieval 
 
4% PFA  
Acetone           Citric acid 
 
Trypsin 
No labelling  Blocking No labelling  
 5% PSA 5% PSA + Serum M.O.M. kit  
 Not specific labelling Good for αv and β5 antibodies Not specific labelling  
  Primary antibody dilution   
 1:50 
Over stained 
1:100 
Good 
1:200 
Weak 
 
  Different conditions   
 Overnight at 4 ºC One hour at room temperature 
Good 
One hour at 37 ºC 
  Secondary antibody dilution   
 1:50 1:100 
Good 
1:200  
  Incubation with DAB for variable time   
 2 minutes 
Weak 
5 minutes 
Good 
10 minutes 
Over stained 
 
Figure 28 The steps which were followed to optimize the antibodies in 
immunohistochemistry 
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Antibody Q-20 and ab15459    
Type of tissue Frozen 
Fixation Acetone (10 minutes) 
Blocking 5% BSA/PBS + 10 serum 
Primary antibody dilution 1:100 
Incubation condition One hour at room temperature 
Secondary antibody 1:200 
DAB 5 min 
 
Table 17 Summary of optimal conditions for rabbit antibodies in 
immunohistochemistry 
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Figure 29 αv, β5, α5 and β3 integrin subunit detection in FFPE MCF-7, HT-29 
and PC-3 xenografts.  
IHC was unsuccessful for immunodetection of αv, β5, α5 and β3 integrin subunits in 
FFPE tissue using Q20 (anti-αv), ab15459 (anti-β5), B7 (anti-β3) and C-9 (anti-α5). 
No labelleling was observed.  Scale bar = 100 µm. 
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Figure 30 Immunohistochemistry with mouse antibodies on fresh-
frozen xenograft material. 
A M.O.M kit was used to detect the expression of α5 and β3 integrin 
subunits in fresh frozen MCF-7 and PC-3 xenografts by using mouse 
antibodies B7 (anti-β3) and C-9 (anti-α5). Unspecific labelling of mouse 
tissues with mouse antibodies was observed in the negative control. Scale 
bar = 100 µm. Scale bar = 100 µm. 
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Figure 31 Expression of αv and β5 subunits in fresh frozen xenografts using rabbit 
antibodies.  
Q-20 and ab15459 antibodies gave cytoplasmic staining. -ve control which was stained 
with secondary antibody only was clean. T; tumour cells, S; stroma. Scale bar = 100 µm. 
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3.4.2.2 Western blot of xenograft tissues 
Western blot results showed that Q-20 anti-αv antibody bound to a protein of 
weight circa 130 KDa in all xenograft tissues. OSC-19 and HT-29 xenografts 
expressed the αv integrin subunit strongly, whereas PC-3 and MCF-7 
xenografts expressed αv moderately. The anti-β5 antibody (Ab15459) gave a 
single band on 85 KDa in all xenografts. The β5 integrin subunit was highly 
expressed on PC-3, MCF-7 and HT-29 xenografts and weakly on OSC-19 
xenograft. The anti-β3 antibody (B7) gave two bands; one band at 120 kDa 
consistent with the β3 integrin, and another band, at circa 60 kDa. The lower 
molecular weight bands resulted from using secondary anti-mouse antibody on 
mouse tissues since it was also obtained when the secondary antibody was 
added to membrane without primary antibody (Figure 32). The β3 integrin 
subunit was moderately expressed on MCF-7 and OSC-19 xenografts whereas 
its expression was low in HT-29 xenografts. PC-3 xenografts expressed the 
highest amount of β3 integrin subunit.  The anti-α5 antibody (C-9) recognised 
two protein bands; one at the molecular weight, 150 kDa consistent with α5 
integrin and one band at about 60 kDa. The lower molecular weight bands 
resulted from using secondary anti-mouse antibody on mouse tissues since it 
was also obtained when the secondary antibody was added to membrane 
without primary antibody. The MCF-7 xenograft had the highest expression of 
α5 integrin subunit; whereas PC-3 and OSC-19 xenografts had a moderate 
level of α5 integrin subunit. Normal mouse tissue showed no protein bands that 
were detected by the human integrin antibodies but a faint signal in the normal 
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lane on β5 blot, this mean that ab15459 antibody binds with mouse integrin as 
well (Figure 32 and Figure 33).  
The expression of αv, β3, β5 and α5 integrin subunits was increased in most 
xenograft tissue compared with the corresponding cultured cells except the 
expression of β5 and α5 integrin subunits was elevated in OSC-19 cultured 
cells. The difference between the expression of αv integrin subunit in HT-29, 
PC-3 and MCF-7 xenograft tissue and corresponding cultured cells and β5 
integrin subunit in OSC-19 cultured cells and corresponding xenograft tissue  
was statistically significant (P= 0.04, 0.03, 0.01 and 0.03 respectively) (Figure 
34 and Table 18).  
 130 
 
 
α
V
 
  
β
5
 
 
 
 
α
5
 
 
 
 
 
 
 
β
3
 
 
 
 
 
 131 
 
C
o
n
tr
o
l 
w
it
h
o
u
t 
p
ri
m
a
ry
 a
n
ti
b
o
d
ie
s
 
 
 
 
Figure 32 Integrin subunit expression on xenograft tissues by Western blot. 
Mouse antibodies C-9 (α5) and B-7 (β3) gave two bands; one band at 120 kDa and 
another band, at circa 60 kDa whereas rabbit antibodies Q-20 (αv) and ab15459 (β5) 
antibodies gave specific single band at 130 kDa and 80 kDa respectively, in the control, 
the membrane was incubated with secondary antibody only and it  gave single band at 
about 60 kDa.  
 
Figure 33 The expression of αv, β5, β3 and α5 integrin subunits in a panel of 
xenografts.  
Results shown are the average of three independent experiments. * indicates P < 0.05, ** 
indicates P < 0.01. 
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Figure 34 Comparison of the expression of αv, α5 and β5 integrin subunits in 
tumour cells by Western blot in tumour xenografts and in cell lines in vitro. 
Results shown are the average of three independent experiments. * indicates P < 0.05. 
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MCF-7  Expression of 
integrin subunits in 
tumour xenografts 
Expression of 
integrin subunits in 
cell lines in vitro 
Expression of integrin 
subunits in tumour 
xenografts vs in cell lines 
in vitro (P value) 
αv ++ + 0.01 
β5 +++ +++ 1 
α5 +++ - 0.1 
β3 ++ n/a  
OSC-19    
αv +++ ++ 0.1 
β5 + +++ 0.03 
α5 ++ +++ 0.1 
β3 ++ n/a  
PC-3    
αv ++ +/- 0.03 
β5 +++ + 0.1 
α5 ++ ++ 0.2 
β3 +++ n/a  
HT29    
αv +++ ++ 0.04 
β5 +++ ++ 0.4 
α5 - - 0.3 
β3 + n/a  
Table 18 Comparison of the expression of αv, α5 and β5 integrin subunits in 
tumour cells by Western blot in tumour xenografts and in cell lines in vitro. 
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3.5 Discussion 
The integrin expression in clinical tumour samples described in Chapter 2 
suggests head and neck and prostate cancer would be suitable clinical 
problems to address by multi-integrin targeting. Therefore, this chapter 
assessed the expression of αv, β5, and α5 subunits in head and neck (OSC-19) 
and prostate (PC-3 and DU145) cell lines by immunofluorescence and Western 
blot. The expression of αv, β5, and α5 subunits in other cell lines reported in the 
literature to have high or low expression of αv, β5 and α5 integrin subunits was 
also investigated: human breast carcinoma cells MCF-7; MCF-7ADR/NCRI 
ADR-RES cells as a drug-resistant model (Taherian et al., 2011, Nista et al., 
1997); colorectal adenocarcinoma cells DLD-1 and HT-29 (Haier et al., 1999, 
Petersen et al., 2013); melanoma cells M14 and human umbilical vein 
endothelial cells HUVEC (Goodman et al., 2012) were evaluated by 
immunofluorescence and Western blot. 
Furthermore, this chapter investigates the expression of αv, β3, β5, and α5 
subunits in human tumour xenografts in order to identify in vivo models that can 
be used to test the efficacy of novel integrin antagonists as drug targets in 
cancer therapy. 
3.5.1 Integrin expression in cell lines 
Using immunofluorescence, the antibody recognizes the target protein in its 
native state, but with Western blotting, the antibody recognizes a denatured 
form of the protein caused by SDS/detergents, reducing agents and heat. 
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Furthermore, with immunofluorescence, some antibodies react with target and 
non-target proteins giving false-positive results. Therefore, Western blotting was 
used to determine the specificity and selectivity of the antibodies. It must be 
noted that, unfortunately, the expression of the integrins might be 
underestimated due to the overexposure of the western blots. The expression of 
the αv, β5, and α5 integrin subunits by immunofluorescence and western blot is 
summarised in Table 19.  
3.5.1.1 The expression of αv and β5 integrin subunits  
In this study, Q20 (anti-αv) and ab15459 (anti-β5) antibodies were used to 
evaluate the expression of αv and β5 integrin subunits on a panel of cell lines. 
With the breast cancer cells, the immunofluorescence results demonstrated that 
MCF-7 and MCF-7ADR cells express low levels of αv and high levels of the β5 
integrin subunit on their surface. The western blot results confirmed the 
immunofluorescence results, but moderate expression of the β5 integrin subunit 
was observed in MCF-7 ADR. Meyer et al.  detected that the αvβ5 integrin is 
expressed in many cell lines, such as ZR75-1, MDA-MB-231, MDA-MB-468, 
T47D, BT474, SKBR3, MCF-7, and BT20 and showed that αvβ5 integrin is the 
dominant vitronectin receptor in these cells (Meyer et al., 1998). Moreover, 
Taherian et al. found that normal cells express low levels of β3, β5, αvβ5 and 
αvβ6, whereas the cancer cell lines expressed high levels of β1, β5 and αvβ5. 
Interestingly, they found that only MDA-MB-435 expressed high levels of β3 and 
αvβ3 (Taherian et al., 2011) which is consistent with its possible origin from the 
M14 melanoma cell line. These studies may indicate that αvβ5 is the dominant 
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vitronectin receptor in cells of epithelial lineage. It has been shown that αvβ5 
integrin is implicated in breast cancer progression as its expression regulates 
breast cancer motility (Zhang et al., 2002, Doerr and Jones, 1996), apoptosis 
(Lin et al., 2004),(Jandova et al., 2012) and metastasis (Bianchi et al., 2010a).  
The expression of αv is well documented in human breast tissue. Pignatelli 
showed  weak to moderate expression of αv subunit on non-neoplastic 
epithelium and in 13/19 invasive ductal carcinomas and 15/17 invasive lobular 
carcinomas (Pignatelli et al., 1992). Coene et al. found that 64% of invasive 
ductal adenocarcinoma tissues express high level of αvβ5 integrin (Coene et 
al., 1997). More recently, Goodman et al. evaluated the presence of αvβ5 and 
αvβ3 integrins on invasive ductal breast carcinoma tissues and they found that 
αvβ3 integrin was only present on vasculature, whereas αvβ5 integrin was 
restricted to interstices and vasculature (Goodman et al., 2012). 
For the prostate cancer cell lines, the immunofluorescence and western blot 
results show αv integrin subunit expression to be very low and low in PC-3 and 
DU145 cell lines respectively. These results slightly differ from those of Zheng 
et al. and Goodman et al., who each found moderate expression of the αv 
integrin subunit in PC-3 cells using flow cytometry (Zheng et al., 2000), 
(Goodman et al., 2012). There are a number of possible reasons for the 
differences in integrin expression detected between studies, including different 
integrin detection methods, different specificity of antibody, different cell culture 
conditions, PC-3 cell heterogeneity, and the heterogeneity of cell 
subpopulations after long-term culture (Stachurska et al., 2012). 
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Furthermore, I found PC-3 and DU145 cells to express the β5 integrin subunit, 
with good correlation between immunofluorescence and the western blot results 
in this regard (Table 19). Goodman et al. and Bauer et al. reported little 
expression of β5 integrin subunits in PC-3 and DU145 cells (Goodman et al., 
2012, Bauer et al., 2007). However, Bisanz et al. showed that αvβ1 and αvβ5 
integrins mediate PC-3 cell adhesion to and migration on vitronectin.  Knocking 
down αv integrin expression in PC-3 cells inhibited the growth of PC-3 tumours 
in bone due to enhanced tumour-cell apoptosis in bone (Bisanz et al., 2005).  
 
With the colon cancer cell lines, the αv integrin subunit was moderately 
expressed and the β5 integrin subunit was moderately and highly expressed in 
HT-29 and DLD-1 cells respectively. Haier et al., also demonstrated low 
expression of αv and β5 integrin subunits in HT-29 using immunocytochemistry 
and western blot (Haier et al., 1999), whereas Goodman, found high expression 
of αv subunit in HT-29 cells by flow cytometry (Goodman et al., 2012). Studies 
showed that the expression of  αvβ5 plays an important role in the adhesion of 
HT-29 within the hepatic microvasculature (Enns et al., 2005b). Yoshioka et al. 
found that αvβ5 requires hepatocyte-derived heregulin to mediate cell migration 
on VN (Yoshioka et al., 2010). αvβ5 has been shown to suppress the apoptosis 
of colon carcinoma cells induced by serum deprivation (O'Brien et al., 1996). 
 
For the head and neck cancer OSC-19 cells, our results show that these cells 
over-express αv and β5 integrin subunits. Supporting these results are the 
immunofluorescence results conducted by Kawahara et al. (Kawahara et al., 
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1995). In addition, it has been shown that αvβ5 integrin is highly expressed in 
larynx and tongue cancers, and its expression is associated with lymphatic 
metastasis and angiogenesis (Li et al., 2013, Kurokawa et al., 2008).  
 
With regard to melanoma, I assessed the expression of αv and β5 integrin 
subunits in M14 cells using western blot only and the results showed that M14 
cells moderately and highly expresses αv and β5 integrin subunits respectively. 
These results are slightly different from the flow cytometry results of Goodman 
et al. who found high and moderate expression of αv and β5 integrin subunits 
respectively (Goodman et al., 2012). 
The immunofluorescence and western blot results show that HUVEC cells 
express high and moderate levels of the αv integrin subunit respectively. Both 
immunofluorescence and western blot results show that HUVEC cells express 
moderate levels of the β5 integrin subunit. These results are in agreement with 
what has been reported in the literature (Goodman et al., 2012, Dormond et al., 
2001). Dormond et al. investigated the role of αvβ5 and αvβ3 integrins in the 
adhesion, spreading, and migration of HUVEC cells on vitronectin using 
monoclonal antibodies that block the function of αvβ3 (LM609) and αvβ5 (P1F6) 
and found that, while LM609 completely blocked HUVEC adhesion, P1F6 had 
no effect (Dormond et al., 2001). However, Hood et al. found that αvβ5 integrin 
uses FAK/Src signalling pathway to stimulate endothelial cell proliferation, 
differentiation and migration (Hood et al., 2003). Also αvβ5 protect the cells 
from intrinsic-mediated apoptosis by activating Raf and MEK1-dependent (Alavi 
et al., 2003). 
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3.5.1.2 The expression of the α5 integrin subunit 
In this study, I used three antibodies to evaluate the α5 integrin subunit: 
ab93943, ab130968, and C-9 antibodies. The ab93943 antibody gave very clear 
membranous staining in immunocytochemistry, whereas western blot detected 
a single band with a molecular weight of roughly 20 kDa, which was smaller 
than the expected molecular weight of 115 kDa, and was expressed only in 
prostate cancer cell lines. This called into question the identity or specificity of 
the antibody supplied. The second anti-α5 (ab130968) antibody also gave us 
unsatisfactory results, detecting two bands, a faint one of the correct molecular 
weight, and a very strong one of very small molecular weight. A possible 
explanation for this is that the α5 subunit contains disulfide bonds between 
heavy and light chains, and due to the use of β-mercaptoethanol, the disulfide 
bonds were broken, producing a heavy chain (135 kDa) and a light chain (20 
kDa). However, although I avoided reducing agents, anti-α5 (ab130968) failed 
to detect α5. Finally, the C-9 antibody gave good results, recognizing a protein 
with a molecular weight of roughly 150 kDa, and gave membranous and 
cytoplasmic staining in immunofluorescence.  
 
α5 was not expressed by MCF-7 cells but was high frequency expressed  by 
MCF-7ADR. Nista et al., who found that Adriamycin-resistant breast cancer 
cells express high levels of α5β1. They provided evidence of the presence of 
FN receptors α5β1 and α4β1 on the surface of adriamycin resistant ADR MCF-7 
human mammary carcinoma cells but not on the parent adriamycin-sensitive 
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type (WT) by using cytofluorimetry and confirming the results by reverse 
transcription polymerase chain reaction (RT-PCR). From adhesion assay 
results, they found that the α5β1 receptor is responsible for ADR MCF7 cells 
adhering to FN which delivers a mitogenic signal to quiescent ADR MCF-7 cells  
and re-enters MCF-7 ADR into the S-phase and prevents apoptosis in serum 
free conditions (Nista et al., 1997). Moreover, Morozevich reported that MCF-7 
DOX expresses much more α5β1 integrin compared to MCF-7 (Morozevich et 
al., 2006). Also, they showed that MCF-7 DOX cells have a stronger ability to 
migrate through matrigel (in vitro invasiveness). This is due to the over 
expression of the α5β1 integrin which has the ability to regulate the expression 
of metalloproteinases 2 (MMP-2) through signalling pathways including PI-3K, 
Akt and Erk protein kinases or by direct recruitment of MMP-2 to the cell surface 
(Morozevich et al., 2006). Therefore, the α5β1 integrin becomes a target for 
therapeutic intervention to counter the survival and invasiveness of tumour cells 
(Morozevich et al., 2006). 
In addition, Ghiso et al. found that the α5β1 integrin function is associated with 
the urokinase plasminogen activator receptor (uPAR) and epidermal growth 
factor receptor (EGFR). In tumour cells uPAR interacts with and activates α5β1 
integrin, and this leads to increased FAK and ERK activities which, in turn, 
promote cancer cell migration, invasion, proliferation and leads to metastasis 
(Aguirre Ghiso et al., 1999). Another study confirmed the importance of the 
uPAR/α5β1 integrin interaction in cancer recurrence using small molecules that 
interact with integrin binding sites on uPAR. These molecules inhibit ERK 
activity and tumour growth and block metastases (Chaurasia et al., 2009) 
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The expression of α5β1 integrin is well documented as immunohistochemistry 
analysis showed that breast cancer tissues express high level of α5β1 integrin 
(Koukoulis et al., 1991). Moreover, the analysis of gene expression array data 
from breast cancer patients showed high level of α5 integrin which is associated 
with decreased survival (Nam et al., 2010).  
For prostate cancer, the α5 integrin subunit was over-expressed in DU145 cells 
and moderately expressed in PC-3 cells. These results are similar to flow 
cytometry results reported by Witkowski et al., who found that PC-3, DU145, 
and 431P cells expressed α5, α3, and α6 (Witkowski et al., 1993). Recently, 
Stachurska et al. demonstrated high levels of α5β1 on the surface of PC-3 via 
flow cytometry. Inhibition of α5β1 decreased the adhesion and spreading of 
tumour cells (Stachurska et al., 2012). 
For colon cancer, the α5 integrin subunit was not expressed by HT-29 cells and 
moderately expressed by DLD-1 cells. Schreiner et al. reported that the HT-29 
cell line does not express the α5β1 integrin (Shinohara et al., 1999). Moreover, 
Haier et al. found the α5 integrin subunit was absent in colon cancer cell lines 
regardless of metastatic ability (Haier et al., 1999). α5β1 integrin has been 
implicated in the inhibition of colon cancer cells growth in vitro by reducing DNA 
synthesis and cellular proliferation and decreases tumorigenicity in vivo (Varner 
et al., 1995). 
 
For head and neck cancer, OSC-19 cells expressed high levels of the α5 
integrin subunit in contrast to the results of Kawahara et al., who reported that 
OSC-19 cells lacked the α5 integrin subunit (Kawahara et al., 1995). Studies 
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have shown that the expression of the α5β1 integrin in head and neck 
squamous cell carcinoma is associated with tumour metastasis, poor prognosis, 
and resistance to therapy (Eke et al., 2012, Shinohara et al., 1999). 
For melanoma, the western blot results indicated that M14 cells express high 
levels of the α5 integrin subunit. The over-expression of the α5 integrin subunit 
in M14 was also seen by Del Bufalo et al., who assessed the expression of 
integrins by flow cytometry (Del Bufalo et al., 1998). Our results show that 
HUVEC cells express the α5 integrin subunit on their surface. This is the first 
study to investigate the expression of the α5 integrin subunit in the HUVEC cell 
line using immunofluorescence and western blot techniques. Many studies 
confirm the role of the α5β1 integrin in angiogenesis, finding α5β1 antagonists 
such as SJ749 and ATN-161 to inhibit angiogenesis and thus reduce tumour 
growth in vivo (Kim et al., 2002, Stoeltzing et al., 2003). 
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αv     
Cell line IF WB In literature References 
MCF-7 + + +++; FC (Taherian et al., 2011) 
MCF-7 ADR + +   
PC-3 +/- +/- ++; FC 
(Zheng et al., 2000) (Goodman et al., 
2012) 
   +/-; FC (Witkowski et al., 1993) 
DU145 + + ++; FC (Goodman et al., 2012) 
HT-29 +++ ++ +; WB and IF (Haier et al., 1999) 
   +++; FC (Goodman et al., 2012) 
DLD-1 +++ ++ +++; RT-PCR. (Bauer et al., 2007) 
HUVEC +++ ++ +++; FC 
(Goodman et al., 2012, Dormond et al., 
2001) 
M14  ++ +++; FC (Goodman et al., 2012) 
OSC-19 +++ ++ +++; IF (Kawahara et al., 1995) 
β5     
Cell line IF WB In literature References 
MCF-7 +++ +++ +++; FC (Taherian et al., 2011) 
MCF-7 ADR +++ ++   
PC-3 +++ + +; FC (Goodman et al., 2012) 
DU145 + +++ +; Fc (Goodman et al., 2012) 
HT-29 ++ ++ +; WB and IF 
++; FC 
(Haier et al., 1999) 
(Goodman et al., 2012) 
DLD-1 +++ +++   
HUVEC ++ ++ +++; FC 
+/-; FC 
(Goodman et al., 2012) 
(Dormond et al., 2001) 
 
 144 
 
M14  +++ ++; FC (Goodman et al., 2012) 
OSC-19 +++ +++ +++; IF (Kawahara et al., 1995) 
α5     
Cell line IF WB In literature References 
MCF-7 - - +; FC (Morozevich et al., 2006) 
MCF-7 ADR +++ +++ +++; FC and 
RT-PCR 
(Nista et al., 1997) 
PC-3 ++ ++ +++; FC 
(Stachurska et al., 2012) 
(Witkowski et al., 1993) 
 
DU145 +++ +++ +++; WB, IF 
and FC 
(Witkowski et al., 1993) 
 
HT-29 - - -; WB and IF (Haier et al., 1999)   
   -; FC (Varner et al., 1995) 
DLD-1 ++ +++ ++; FC (Petersen et al., 2013) 
HUVEC +++ +++   
M14  +++ +++: FC (Del Bufalo et al., 1998) 
OSC-19 +++ +++ -; IF (Kawahara et al., 1995) 
 
Table 19 Analysis of integrin (αv, α5 and β5) distribution on a panel of human cell lines 
obtained from immunofluorescence (IF) and Western blot (WB) results.  
 (−): no expression, (+/-) very low, (+): low expression, (++): moderate expression, (+++): high 
expression, blank: not tested. FC; Flow cytometry , WB; Western blot, IF; 
Immunofluorescence, RT-PCR; Reverse transcription polymerase chain reaction.  
 
 
 
 
 
 145 
 
3.5.2 Protein expression on xenograft tissues 
3.5.2.1 Immunohistochemistry on xenograft tissues 
In this study, the distribution of αv, β3, α5, and β5 integrin subunits in human 
tumour xenograft tissue in mice was characterized using immunohistochemistry 
and Western blot to compare the expression of integrins in xenograft tissues 
with the same tumour model in vitro because it is known that tumour 
microenvironments affect the expression pattern (Koshida et al., 2004, Taylor et 
al., 2012). This also allowed selection of an in vivo model that can be used in 
the future to evaluate the efficacy of novel integrin antagonists. The expression 
of integrins has been extensively studied in fresh frozen tissues, yet very rarely 
in FFPE tissues due to the lack of monoclonal antibodies that specifically stain 
integrins in FFPE tissues, and the fact that FFPE processes such as fixation 
and heating may mask epitopes and make antibody-antigen binding difficult 
(Goodman et al., 2012).  
In this study, FFPE xenograft tissues were used to evaluate the expression of 
αv, β3, α5, and β5 integrin subunits because histomorphology is not optimally 
maintained with frozen tissue making the evaluation of integrin distribution a 
challenge with frozen tissue.  Unfortunately, the immunohistochemistry 
performed on the FFPE tissues was unsuccessful in this study, even when 
using different antigen retrieval methods. Consistent with this,  the literature 
shows that detection of integrin in FFPE tissue is challenging. Goodman and his 
group produced rabbit monoclonal antibodies against the extracellular domains 
of αv integrins that would react with integrins within FFPE tissues,  however 
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although these antibodies have been used in several studies (Boger et al., 2013, 
Fabricius et al., 2011, Goodman et al., 2012) they have not been made 
available commercially.  
The expression of αv and β5 integrin subunits was evaluated via 
immunohistochemistry in fresh-frozen xenograft tissue using rabbit polyclonal 
antibodies Q20 (anti-αv) and ab15459 (anti-β5), each of which showed 
cytoplasmic immunolabelling in the xenograft tissues. Through the 
immunohistochemical analysis of the expression of αv and β5 integrin subunits, 
it was determined that colon, breast, head and neck, and prostate xenograft 
tissues expressed αv and β5 integrin subunits. The αv integrin subunit was 
highly expressed in the tumour cells of HT-29, OSC-19, and MCF-7 xenografts, 
and moderately expressed in the tumour and stromal cells of PC-3 xenografts. 
Furthermore, the β5 integrin subunit was strongly expressed in the stroma of 
OSC-19, and moderately expressed in the tumour cells MCF-7 and HT-29, as 
well as both the tumour and stromal cells of the PC-3 xenograft tissue. The 
immunohistochemical tumour and stroma results concerning αv and β3 integrin 
subunit expression within OSC-19, PC-3, HT-29 and MCF-7 xenografts are 
summarized in Table 20. 
3.5.2.2  Western blot on xenograft tissues 
The evaluation of the expression of α5 and β3 integrin subunits in human 
tumour xenograft tissue from mice by immunohistochemistry was difficult 
because non-specific binding was observed with the mouse antibodies B7 (anti-
β3) and C-9 (anti-α5). Even using the M.O.M. kit, non-specific binding of these 
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antibodies could not be suppressed. Therefore, fresh frozen xenograft tissues 
were used in Western blotting to evaluate the expression of α5 and β3 integrin 
subunits and to confirm their expression. With Western blot, B7 (anti-β3) and C-
9 (anti-α5) gave two bands: one band located at molecular weights consistent 
with α5 and β3 integrin subunits (150 kDa and 120 kDa, respectively), and 
another intense band between 70 and 55 kDa. In order to prove that non-
specific binding was a property of the mouse antibodies rather than non-
specificity for the human integrins, membranes were incubated with secondary 
antibodies only. Normal mouse tissue and human xenograft mouse tissue 
demonstrated non-specific binding due to the reaction of anti-mouse antibodies 
on mouse tissue. Excluding the non-specific band, the expression of integrin 
can be estimated by measuring bands consistent with the integrin molecular 
weight. The expression of αv, β3, α5, and β5 integrin subunits in Western blot 
were consistent with the immunohistochemistry results.  
This study represents the first evaluation of the expression of αv, β3, α5, and β5 
integrin subunits in OSC-19 head and neck cancer xenografted tissue. OSC-19 
expressed a high level of the αv integrin subunit, a moderate level of both the 
α5 and β3 integrin subunits, and a relatively low level of the β5 integrin subunit. 
Recently, Terry et al. evaluated the expression of αv and β3 integrin subunits in 
fresh frozen head and neck tumour xenografts (FaDu, SCCNij3, and SCCNij202) 
using immunohistochemistry and they found that tumour cells within these three 
tumour xenografts did not express αvβ3 integrin (Terry et al., 2014). 
With the PC-3 xenograft, β5 and β3 integrin subunits were strongly expressed, 
whereas α5 and αv integrin subunits were moderately expressed. Bisanz et al. 
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detected the expression of αv, β3, and β5 integrin subunits in PC-3 cells via 
flow cytometry in vitro and by immunohistochemistry and PCR ex vivo. They 
found that the PC-3 xenograft expressed moderate levels of the αv integrin 
subunit (Bisanz et al., 2005).  Taylor found that integrin β3 mRNA was elevated 
in PC-3 xenografts compared with corresponding cultured cells (Taylor et al., 
2012).  Our results are different from Zhou et al., who demonstrated, via 
immunohistochemistry, that HT-29 and PC-3 xenograft tissues express low and 
very low levels of the αvβ3 integrin, respectively (Zhou et al., 2011). 
In this study the expression of integrin subunits αv, β5, β3, and α5 in the HT-29 
xenograft tissue to range from high to none. Our results concerning αvβ3 
integrin expression are similar to Zhou et al.’s, yet slightly different from 
Goodman et al., who found no expression the αvβ3 integrin in HT-29 xenograft 
tissue (Zhou et al., 2011). Goodman et al. found a high expression of αvβ5 in 
HT-29 xenograft tissue (Goodman et al., 2012).  
This study demonstrated that MCF-7 xenografts express high levels of the α5 
and β5 integrin subunits and moderate levels of αv and β3 integrin subunits. In 
support of these results is a study by Goodman et al. who reported a high 
expression of the αvβ5 integrin in MDA-MB468 xenograft tissue (Goodman et 
al., 2012). The role of αvβ5 and α5β1 integrins in breast cancer was discussed 
earlier. αvβ3 has been shown to promote breast cancer invasion in vitro and in 
vivo by binding to matrix metalloproteinase MMP-2 (Deryugina et al., 2001). In 
in vitro studies, αvβ3 integrin was proved to mediate adhesion for breast cancer 
within the lung (Felding-Habermann et al., 2001). In vivo, over expression of this 
integrin increased breast cancer bone metastasis (Zhao et al., 2007). Integrin 
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distribution in a panel of xenografts obtained via immunohistochemistry and 
Western blot are summarized in Table 20. The expression of αv, β3, β5 and α5 
integrin subunits was increased in most xenograft tissue compared with the 
corresponding cultured cells except the expression of β5 and α5 integrin 
subunits was elevated in OSC-19 cultured cells. The difference between the 
expression of αv integrin subunit in HT-29, PC-3 and MCF-7 xenograft tissue 
and corresponding cultured cells and β5 integrin subunit in OSC-19 cultured 
cells and corresponding xenograft tissue  was statistically significant (P= 0.04, 
0.03, 0.01 and 0.03 respectively). 
The difference between the expression of integrins in vitro and in vivo is 
because the expression of integrins depend on stimuli produced by the 
microenvironment such as fibroblasts and immune cells including macrophages, 
their secreted factors, such as vascular endothelial growth factor, transforming 
growth factor β, and various chemokines (Alphonso and Alahari, 2009). Studies 
showed that when tumour cells proliferate, the local blood supply becomes 
inadequate, leading to a hypoxic, nutrient-deprived tumour environment. The 
local hypoxic condition activates hypoxia-inducible factor-1 (HIF-1), resulting in 
the release of vascular endothelial growth factor (VEGF), fibroblast growth 
factor-2 (FGF2) and tumour necrosis factor alpha (TNF-α) from proliferating 
tumour cells. These factors stimulate the expression of αvβ5, αvβ3 and α5β1 
integrins (Friedlander et al., 1995, Brooks et al., 1994a, Kim et al., 2000b). Also 
studies showed that chemokines, which are present in vivo, but not added to 
standard cell cultures, can regulate the expression and activity of integrins 
(Dehghani et al., 2014). 
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           IHC          WB   
 αv in 
tumour 
cells  
αv in 
stroma 
β5 in 
tumour 
cells 
β5 in 
stroma 
αv α5 β5 β3 
MCF-7 +++ - ++ - ++ +++ +++ ++ 
PC-3 ++ ++ ++ ++ ++ ++ +++ +++ 
HT-29 +++ - ++ - +++ - +++ + 
OSC-9 +++ - - +++ +++ ++ + ++ 
Normal     - - +/- - 
 
Table 20 Analysis of integrin (αv, α5 and β5) distribution on a panel of xenografts 
obtained from immunohistochemistry (IHC) and Western blot (WB) results. 
(−): no expression, (-/+) very low expression, (+): low expression, (++): moderate 
expression, (+++): high expression, blank: not tested. 
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3.6 Conclusion 
This study demonstrated: that all cell lines (MCF-7, MCF-7 ADR, PC-3, DU145, 
DLD-1, HT-29, HUVEC, OSC-19 and M14) express the αv, and β5 integrin 
subunits on their surfaces but with different levels of expression. The α5 integrin 
subunit is expressed by all cell lines except HT-29 and MCF-7. The expression 
of αv, α5, β5 and β3 integrin subunits was generally upregulated in vivo 
compared to cell lines in vitro, most likely due to the influence of the 
microenvironment on outside-in cell signalling. Based on the results obtained 
from these evaluations, six cell lines were selected as models to be used to 
further evaluate the potential of novel small molecule integrin antagonists to 
inhibit single or multiple integrins in vitro: DLD-1 and DU145 cells express 
multiple RGD-integrins so will be used as a model to investigate combined 
inhibition of these integrins, PC-3 and OSC-19 as models to investigate dual 
integrin antagonists, and MCF-7 and HT-29 as αvβ5-expressing models. MCF-7, 
OSC-19 and PC-3 xenografts could be used as in vivo model to evaluate the 
effect of multiple integrin antagonism and HT-29 as model for αvβ5 integrin 
antagonists. 
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4 CHAPTER 4: Evaluation of the effect of small molecule 
integrin antagonists on tumour cell migration 
 
4.1 INTRODUCTION 
The most frequent cause of death for patients with cancer is the metastasis of 
cancer cells from a primary tumour to a distant organ. The metastatic process 
consists of multiple steps, including the detachment of tumour cells from a 
primary tumor, invasion through connective tissue, intravasation into blood or 
lymph vessels, migration and extravasation, further tissue invasion, adhesion, 
proliferation, and survival in another site of the body.  
In cell migration, cells move on 2D surfaces, such as a basal membrane or 
ECM fibres. Invasion is movement of cells through a 3D matrix and this process 
requires adhesion and proteolysis of the ECM components. Tumour cells can 
migrate without invasion, but cannot invade without migration (Kramer et al., 
2013). 
 
Tumour cells migrate as single cells or expand in sheets, files, or clusters 
(collective migration). Single cell migration can be subdivided into amoeboid 
and mesenchymal movement. Mesenchymal migration is characterized by the 
movement of elongated, spindle-like cell bodies involved in focal adhesion and 
cytoskeletal contractility (Thiery, 2002). Alternatively, in amoeboid migration, 
cells move as rounded ellipsoids without need of focal attachment to the 
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extracellular matrix (Fackler and Grosse, 2008). In collective migration, cells 
move through the extracellular matrix while preserving functional cell-cell 
junctions (Vaughan and Trinkaus, 1966). The expression of genes involved in 
cell motility such as integrins is altered in cancer cells, and this enables cancer 
cells to respond to signals in microenvironments that stimulate tumour invasion.  
Studies have shown that integrins play a crucial role in tumour cell metastasis 
by mediating outside-in and inside-out signaling, and cross-talk mechanisms 
(Huttenlocher and Horwitz, 2011, Hood and Cheresh, 2002). Certain integrins, 
such as αvβ3 and αvβ5, enhance tumor metastasis (Vogetseder et al., 2013, 
Bianchi et al., 2010a), while other integrins, such as the β1 integrin subunit, 
sometimes decrease tumour dissemination (Yao et al., 2007). α5β1 integrin has 
shown both positive (Stachurska et al., 2012, McKenzie et al., 2013, Mierke et 
al., 2011) and negative correlations with metastasis (Schirner et al., 1998, 
Seftor et al., 1998). Therefore, the appropriate evaluation of α5β1 integrin 
expression and its role in cancer is crucial before targeting this integrin.  
A comprehensive overview on the role of integrin in cancer metastasis and the 
potential of targeting integrin to prevent cancer progression have been provided 
in many reviews (Suyin et al., 2013, Seguin et al., 2015, Ganguly et al., 2013, 
Goswami, 2013, Sutherland et al., 2012). A strong interest has therefore 
developed to greater understand and potentially target integrin-mediated 
migration in cancer progression. A summary of the features of in vitro assays 
that have been used to study cell migration and invasion is given in Figure 35.  
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Figure 35. I Schemes of the most common migration assays.  
(A) Transwell migration assay (Boyden chamber assay). Cells migrate through the 
pores within the membrane toward the chemoattractant in the well. (B) Wound healing 
assay. The cells migrate toward the cell-free area, which is created by scratching the 
cell monolayer with a P200 pipette tip. (C) Cell exclusion zone assay The cells migrate 
toward the cell-free area, which is created by utilising cell stoppers. (D) Fence assay. 
Cells are seeded inside a ring-shaped plastic device, which is removed after cell 
attachment. The cells migrate from the circular area to cell-free area. (E) Microcarrier 
bead assay. Cells are attached to the microcarrier beads surface and then beads 
coated with cells are placed onto cell culture dishes and incubated. Cells migrate to the 
plate surface and perform radial movement (Kramer et al., 2013).  
I 
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 Figure 35. II Schemes of the most common migration assays (continued). 
 
(F) Spheroid migration assay. Certain tumour cells have the ability to form multicellular 
spheroids. In this assay, the spheroid is placed in tissue culture dishes and the cells 
migrate concentrically outward. (G) Horizontal capillary assay. The cells migrate toward 
a chemoattractant within a capillary. (H) Capillary tube migration assay. Cells migrate 
into serum. (I) cells migration agarose technique assay. Cells migrate under the 
agarose layer toward the complete medium alone (control) or toward a 
chemoattractant. (J) Single cell motility assay. The plates are coated with colloidal gold 
particles and the cells are then added. During cell migration, the cells clear the gold 
particles, leaving bright tracks behind that can be measured.This method is now 
replaced by camera technology  that films the cells in motion (Kramer et al., 2013). 
II 
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In this study, a  2D wound-healing assay (scratch assay) was selected to 
evaluate the effect of integrin inhibition by neutralizing antibodies [LM609 (anti 
αvβ3 integrin), P1F6 (anti αvβ5 integrin), JBS5 (anti α5β1 integrin), and 10D5 
(anti αvβ6 integrin)] and novel small molecule integrin antagonists on tumour 
cell migration. 
The novel small molecule integrin antagonists synthesised in-house were 
designed to mimic the Arginine-Glycine-Aspartic acid (RGD) sequence of 
extracellular matrix proteins. They were designed by molecular modelling based 
on a novel scaffold between the Arginine and Aspartic acid mimetics as inspired 
by literature compounds. 
While the scratch assay is simple, rapid, inexpensive, allows for easy readout, 
and analysis, it also has certain disadvantages, such as variable wound size 
and some cells still attach to the scratch edges after wounding and these cells 
reattach and move into the wound area. The scratch assay has been used 
extensively to evaluate the effect of integrin inhibitors on tumour cell migration. 
For example, Ray et al. demonstrated that blocking α5β1 or αvβ3/β5 integrins 
by small molecule antagonists inhibits U87MG cell migration (Ray et al., 2014). 
Janik et al. used scratch assays to evaluate the role of α3β1 and αvβ3 integrins 
in the migration of melanoma cells (Janik et al., 2010). 
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4.2 AIMS AND OBJECTIVES 
The aim of the research described in this chapter was to evaluate the effect of 
novel small molecule integrin antagonists and the effect of antagonism of 
combinations of integrins on tumour cell migration in vitro. This was achieved by:  
 Optimization of the migration assay using the cell line models characterised 
in Chapter 3. 
 Determination which of four integrins (αvβ3, αvβ5, α5β1 and αvβ6) are 
primarily responsible for tumour cell migration by measuring cell migration 
under the influence of integrin-blocking antibodies LM609 (anti αvβ3 
integrin), P1F6 (anti αvβ5 integrin), JBS5 (anti α5β1 integrin), and 10D5 (anti 
αvβ6 integrin). 
 Evaluation of  the cytotoxicity of the novel small molecule integrin 
antagonists by the MTT assay, in order to select a non-cytotoxic dose of 
each compound for each cell line model. 
 Assessment of the effect of non-toxic doses of small molecule integrin 
antagonists on cell migration. 
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4.3 MATERIALS AND METHODS 
4.3.1 Materials 
The cell line models were maintained as described in Chapter 3. All cell culture 
reagents were obtained from Sigma-Aldrich unless indicated. 10 small molecule 
integrin antagonists that were synthesised by the Sheldrake group in the ICT 
were used. Compound stocks were prepared by dissolving compounds in 0.1% 
DMSO and then stored at −20 °C. Compound identification number and 
respective molecular weight is summarized in Table 21. The αIIbβ3 integrin 
antagonist GR144053 trihydrochloride (Tocris Bioscience) were stored at 
−20 °C. The antibodies and their applications are summarizedin Table 22. 
 
Compound number Molecular  weight  
ICT9019 503 
ICT9023 475 
ICT9024 503 
ICT9026 475 
ICT9055 542 
ICT9072 474 
ICT9073 516 
ICT9085 500 
ICT9087 542 
ICT9088 468 
ICT9094 557 
 
Table 21 Compounds and their molecular weights 
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Applications Primary 
antibody 
Company Secondary 
antibody 
Company 
Immunofluorescence Rabbit 
polyclonal anti 
Ki-67 antibody 
Millipore Alexa Fluor 546 
donkey anti rabbit 
IgG 
Millipore 
Western blot C-20: goat 
polyclonal anti 
αIIb integrin 
subunit 
Santa 
Cruz 
Polyclonal rabbit 
anti goat linked to 
horseradish 
peroxidise 
Dako 
Western blot ab15459: rabbit 
polyclonal anti 
β5. 
Abcam Polyclonal goat anti 
rabbit linked to 
horseradish 
peroxidise 
Dako 
Western blot Q-20: rabbit 
polyclonal 
antibody 
directed to αv. 
Santa 
Cruz 
Polyclonal goat anti 
rabbit linked to 
horseradish 
peroxidise 
Dako 
Scratch assay LM609: mouse 
monoclonal anti 
αvβ3 integrin 
Millipore n/a  
Scratch assay P1F6: mouse 
monoclonal anti 
αvβ5 integrin 
Millipore n/a  
Scratch assay JBS5: mouse 
monoclonal anti 
α5β1 integrin 
Millipore n/a  
Scratch assay 10D5: mouse 
monoclonal anti 
αvβ6 integrin 
Millipore n/a  
Table 22 Antibodies used in this chapter 
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4.3.2 Methods 
4.3.2.1 MTT assay 
1×104/ml of cells were seeded in 96-well plates in a final volume of 180 μl of 
medium and incubated for 24 hours at 37 °C in a 5% CO2 humidified 
atmosphere. In addition to the test wells, one set included wells of culture 
medium containing no cells (blank), and one set included cells that were not 
exposed to compound (control). 20 μl of the compounds with different 
concentrations were added to all wells except the control and incubated for 72 
hours at 37 °C in a 5% CO2 humidified atmosphere. 200 μl of MTT solution was 
added to each and the plate was incubated for 4 hours at 37 °C in a 5% CO2 
humidified atmosphere. The liquid was then removed and 150 μl of DMSO was 
added and mixed in to dissolve the formazan crystals. The absorbance at 550 
nm was measured using a Multiscan Plus spectrophotometer (Lab-systems 
Group, UK). The cell survival percentage was calculated as shown in the 
following equation. The IC50 values for each compound in each cell line were 
obtained from dose response curves. 
 
 
4.3.2.2 Scratch assay 
The desired cell concentrations in 350 µl of RPMI 1640 medium were seeded 
into a 24-well plate and set overnight at 37 °C in a 5% CO2 humidified 
The absorbance of the test wells – The absorbance of blank 
The absorbance of control – The absorbance of blank 
Cell survival % = 
×100 
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atmosphere to attach, spread, and form a confluent monolayer. A sterile P200 
pipette tip was then used to scratch the confluent monolayer to form a cell-free 
zone (approximately 650 μm in width) into which the cells at the edges of the 
wound could migrate. The old medium was gently removed, and the cells were 
washed twice with PBS. After scratching the monolayer, one well was incubated 
with medium (control) and the other wells were incubated with different 
concentrations of antibody or antagonist The width of the initial scratch (time 
zero) was measured at three points throughout the scratch area in each well 
using a calibrated graticule fixed to a phase-contrast microscope (Olympus, 
model CK2) within a 10x objective lens. The cells were then incubated at 37 °C 
in a 5% CO2 humidified atmosphere until the wound in the control well was 90% 
healed. The cells were then washed with PBS and left to dry. Following this, the 
cells were fixed with 70% ethanol for one minute, washed twice with PBS, and 
then placed in Harris’s haematoxylin solution for one minute. The cells were 
then washed in tap water for one minute and left to dry at room temperature. 
The stained cells were assessed by inverted microscope and images were 
taken by camera (Nikon camera, model: C-D 55230, Japan) connected to an 
inverted microscope (Nikon model SMZ1500, Japan) at three points throughout 
the scratch area. The degree of wound closure or cell migration expressed as 
area occupied by cells (free area before migration minus free area after 
migration) was determined using ImageJ analysis to measure cell migration 
percentage within the captured images. Cell migration percentage was 
calculated in two ways: for cells that migrated as single cells: 
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And for cells that migrated as a group: 
 
 
 
 
Alternatively, images of the initial scratch (time zero) and the time point at which 
the wound in the control was 90% healed were taken at three points along the 
scratch field using a lumascope (Etaluma, model 488, USA). The degree of 
wound closure or cell migration expressed as area occupied by cells (free area 
before migration minus free area after migration) was determined using ImageJ 
analysis to measure cell migration percentage within the captured images. The 
cell migration percentage was then calculated as in the previous equation. 
Statistical analysis of the difference from control was determined using a 
student’s t-test. If the calculated P-value was below 0.05 or 0.01, the results 
were considered statistically significant or highly significant, respectively.  
Migrated cell count × width at initial scratch 
100 Cell migration 
percentage = 
  
×100 
Control 
  
Free area before migration-free area after migration 
Free area before migration Cell migration 
percentage = 
  
×100 
Control 
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 Distinguishing cell proliferation from cell migration in the 4.3.2.2.1
scratch-wound assay  
4.3.2.2.1.1 Evaluating the effect of different serum concentrations on cell 
migration 
Cells were seeded in 24-well plates and incubated overnight to obtain a 
confluent cell monolayer. The scratch assay was carried out as described in 
section 4.3.2.2. After making the scratch, the cells were incubated with 
complete medium containing two different concentrations of fetal bovine serum 
(3 and 10%) at 37 °C in a 5% CO2 humidified atmosphere until the wound in the 
control well was 90% healed. 
4.3.2.2.1.2 Evaluating the proliferation marker Ki-67 by 
immunofluorescence 
The desired cell concentrations were seeded on autoclaved coverslips in six-
well plates and incubated overnight at 37 °C in a 5% CO2 humidified 
atmosphere to attach, spread, and form a confluent monolayer. The monolayer 
was scratched and left to heal for the appropriate time for each cell line. In each 
experiment, two cover slips were used, one for the initial scratch (time zero), 
and the other for the last time point of wound healing. The immunofluorescence 
technique was carried out as described in Chapter 3. To evaluate cell 
proliferation, cells were fixed with 4% PFA and blocked with 5% BSA for one 
hour at room temperature. These cells were incubated with anti-Ki-67 antibody, 
1:50 at 4 °C overnight, and then with the secondary antibody (Alexa Fluor 546 
donkey anti rabbit IgG) 1:200 for one hour at room temperature. 
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  Evaluation of integrin expression by Western blot 4.3.2.2.2
The scratch assay was set up as previously described but when the old medium 
was removed following the scratch, the cells were then washed twice with PBS 
and then cells in three wells were incubated with complete medium and other 
cells in three wells were incubated with 2.5 µg/ml of the JBS5 antibody (anti 
α5β1 integrin). The cells were incubated for 18 hours at 37 °C in a 5% CO2 
humidified atmosphere. The following day, the cells were washed twice with 
PBS prior to the addition of trypsin-EDTA, and the mixture was incubated for 
three minutes at 37 °C until the cells were completely detached. 3 ml of 
complete media was then added, and the cell suspension was centrifuged at 
room temperature for five minutes at a speed of 1000 RPM. The supernatant 
was then discarded and the cell pellets were re-suspended in 1 ml of PBS. The 
cell suspension was centrifuged again as per the prior step, the supernatant 
was discarded, and the cell pellets were stored at −20 °C. The Western blot 
procedure was carried out as described in Chapter 3.  
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4.4 RESULTS 
4.4.1 Wound assay 
4.4.1.1 Optimization of the scratch assay 
In order to understand the wound healing process and study cell-cell and cell-
extracellular matrix (ECM) interactions that mediate this response, the 2D 
scratch assay was used. 
MCF-7 and HT-29 cell lines (models for high αvβ5 integrin expression and 
negative for α5β1 integrin) were found to be unsuitable for use in the scratch 
assay because MCF-7 cells did not form a monolayer and HT-29 cells did not 
migrate on the plastic surfaces investigated. 
 8.5 × 105 cells/ml was found to be the optimum cell seeding concentration for 
OSC-19, DLD-1, DU145, PC-3, M14 and HT-29 cell lines to form a monolayer 
after overnight incubation. After formation of the scratch wound, the OSC-19 
cell line needed 18 hours to reach 90% healing, the DU145, PC-3 and M14 cell 
lines needed 24 hours and the DLD-1 cell line needed 41 hours. The HT-29 
scratch did not heal even after 72 hours (Figure 36). 
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Figure 36 Evaluating the time required for wound closure in tumour cell line 
models.  
The scratched monolayers were incubated with complete medium until the wound in 
the control was 90% healed. Images of cells stained with Harris’s Haematoxylin 
solution. Scale bar = 200 µm. 
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 Confirmation that the scratch-wound assay measures cell 4.4.1.1.1
migration 
In long term wound healing, it is difficult to differentiate between cell proliferation 
and migration.  I used two methods to determine whether wound closure in the 
scratch assay was by migration or proliferation into the wound. 
4.4.1.1.1.1 Evaluation of the proliferation marker Ki-67 and cell 
morphology by immunofluorescence  
Immunostaining was carried out on scratched cells to detect Ki-67, which is a 
nuclear protein expressed by proliferating cells in all phases of the active cell 
cycle. The absence of Ki-67 in cells at the scratch edges confirmed that cells 
moving into the wound area were not proliferating and hence supported 
migration as the method of wound healing. The Ki-67 expression was higher at 
the area immediately behind the scratch edges in DLD-1 and DU145 cells. 
However, it is the cells at the scratch edge that are important because they are 
most migratory and the rate of their migration reflects the overall rate of wound 
closure of the migrating monolayer of cells (Rodriguez et al., 2005)  (Figure 37).  
4.4.1.1.1.2 Evaluation of the effect of serum concentration on cell 
migration 
It is known that serum contains growth factors, cytokines and soluble ligands 
that may affect the rate of cell migration. Therefore, the effect of different serum 
concentrations on the migration rate was evaluated. In this experiment, OSC-19, 
DU145 and DLD-1 cell migration was monitored in a medium containing two 
different concentrations of FBS (low serum of 3% and the standard 10%). No 
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significant differences in migration promoted by the two concentrations were 
observed (P > 0.05) (Figure 38).  
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Figure 37 Immunofluorescence with anti-Ki-67 antibody.  
OSC-19, DU145 and DLD-1 cells were scratched and incubated at 37 °C in 5% CO2 
humidified atmosphere for 18, 24 and 41 hours respectively. The cells were fixed with 4% 
PFA, and blocked with 5% BSA. Cells were incubated with Ki-67, 1:50 at 4 °C overnight. 
The expression of Ki-67 (red) was absent in OSC-19 and low on DU145 and DLD-1 cells 
located at the scratch edges. The cells located at area behind the scratch express moderate 
level of Ki-67. Scale bar = 100 µm. 
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Figure 38 Effect of fetal bovine serum (3 and 10 %) on the wound assay 
Scratched cells were incubated with two different concentrations (3 and 10 %) of fetal 
bovine serum (FBS). Images of OSC-19, DU145 and DLD-1 cells were taken by 
Lumascope after 18, 24 and 41 hours respectively. Scale bar = 200 µm. Results shown are 
average ± SD of three independent experiments. No significant difference between 
migration rates was observed (P > 0.05). 
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 Determination of which integrins control migration in OSC-19 4.4.1.1.2
cells 
To address which integrin is primarily responsible for OSC-19 cell migration, 
three integrin-blocking antibodies were used: LM609 (anti αvβ3 integrin), P1F6 
(anti αvβ5 integrin) and JBS5 (anti α5β1 integrin). Based on the literature, the 
non-cytotoxic concentrations of these antibodies were used without first 
evaluating the cytotoxicity of these antibodies on this cell line. 
OSC-19 cell migration was 25% and 30% inhibited by integrin receptor blocking 
with LM609 (anti-αvβ3) 2.5 μg/ml and PIF6 (anti-αvβ5) 2.5 μg/ml respectively, 
whereas JBS5 (anti-α5β1) 2.5 μg/ml gave an agonist effect, increasing 
migration by 80% (Figure 39).   
To investigate the reason for this agonist effect, the impact of treatment with 
JBS5 on the expression of β3 and β5 integrins was determined. I found that 
blocking α5β1 integrin increased the expression of β3 and induced ectopic 
expression of αIIb. The expression of β3 and αIIb integrin subunits in stimulated 
cells was 42 and 13 fold higher than control respectively (Figure 40). The 
expression of αvβ5 integrin was not changed. 
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Figure 39 The effects of integrin-receptor blocking with neutralizing antibodies on OSC-19 cell 
migration using the scratch assay. 
OSC-19 cells were treated with different antibody concentration for 18 hours. The cell migration was 
inhibited by LM609 and PIF6 antibodies but JBS5 antibody increased OSC-19 cell migration. Results 
shown are representative of three independent experiments. Bar length = 250 μm. Results shown 
are average ± SD of three independent experiments.  * indicates P < 0.05, ** indicates P < 0.01, and 
*** indicates P < 0.001. 
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Figure 40 Alteration in integrin expression with JBS5 treatment. 
OSC-19 and M14 cells were stimulated with JBS5 (anti-α5β1) 2.5 μg/ml for 18 hours 
prior to Western blotting for integrin expression. (A) Lanes 1 + 2 antibody treated cells 
(T), Lanes 3 + 4 untreated controls. Membranes were blotted with anti β3 (B-7), anti αIIb 
(C-20) and anti β-actin antibodies, which recognize proteins with band size 125, 136 and 
42 kDa respectively. (B) Integrin expression levels normalised to β-actin calculated from 
three independent experiments. 
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 The effect of combination treatment on OSC-19 cell migration 4.4.1.1.3
These findings demonstrate that blocking of integrin α5β1 increases β3 
integrins expression, and notably induces αIIb expression, which is likely to 
result in αIIbβ3 surface expression and increased cell migration via αIIbβ3 and 
αvβ3. Therefore, the small molecule αIIbβ3 integrin antagonist GR144053 was 
used to evaluate the effect of blocking αIIbβ3 on OSC-19 cell migration in JBS5 
treated cells. I found that GR144053 gave dose-dependent inhibition of cell 
migration; 200 μM inhibited the cell migration by 30% (Figure 41).  
I then evaluated the effect of a multi-integrin inhibitor combination on OSC-19 
cell migration using the scratch assay; a significant reduction in migration (50%) 
was observed using a multi-integrin inhibitor combination that blocks α5β1, 
αvβ3, αvβ5 and αIIbβ3 integrins (Figure 42).  
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Figure 41 A dose-response curve 
OSC-19 treated with 2.5 μg/ml of JBS5 (anti-α5β1) antibody with different 
concentrations of αIIbβ3 antagonist GR144035. There is a significant reduction in cell 
migration with 200 μM GR144035. Scale bar = 250 µm. Results in the graph calculated 
from three independent experiments. * indicated P < 0.05. 
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Figure 42 Effects of multi-integrin inhibitor combinations on OSC-19 cell migration. 
OSC-19 treated with one or more antagonists: 0.5 μg/ml of JBS5 (anti-α5β1), 2.5 μg/ml of 
LM609 (anti-αvβ3), 2.5 μg/ml of PIF6 (anti-αvβ5), 200 μM GR144035 (anti-αIIbβ3) for 18 hours. 
Scale bar = 200 µm. Results in the graph calculated from three independent experiments.  The 
asterisk * indicates P < 0.05, ** indicates P < 0.01 and*** indicates P < 0.001. 
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 Determination of which integrins control migration in DLD-1 cells 4.4.1.1.4
To address which integrin is primarily responsible for DLD-1 cell migration, four 
integrin-blocking antibodies were used LM609 (anti αvβ3 integrin), P1F6 (anti 
αvβ5 integrin), JBS5 (anti α5β1 integrin) and 10D5 (anti αvβ6 integrin). The 
results suggest that JBS5 antibody had negligible effect on DLD-1 cell migration. 
DLD-1 showed a dose dependent response to PIF6 antibody (Figure 43 and 
Figure 44).  
Antagonists of αvβ3 and αvβ6 showed dose-dependent effects on DLD-1 
migration but the patterns were the inverse of one another. LM609 at 5 and 2.5 
μg/ml inhibited DLD-1 cell migration by 45%, but the lowest concentration, 1 
µg/ml, had little effect on cell migration. 5 and 2.5 μg/ml concentrations of 10D5 
antibody had a negligible effect on the migration of cells.  However, a significant 
reduction was observed using the lowest concentration of 10D5 antibody (1 
µg/ml) (Figure 43 and Figure 44). 
Moreover, I evaluated the effect of a multi-integrin inhibitor combination on 
DLD-1 cell migration using the scratch assay and found that blocking both αvβ3 
and αvβ5 integrins simultaneously caused a significant decrease in cell 
migration. However, no further reduction was observed when anti-α5β1 was 
added to the combination (Figure 45).  
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Figure 43 The effects of integrin receptor blocking with neutralizing antibodies on 
DLD-1 cell migration.  
DLD-1 cells were treated with different concentration of LM609 (anti-αvβ3), PIF6 
(anti-αvβ5), JBS5 (anti-α5β1) and 10D5 (anti-αvβ6). PIF6 and LM609 antibodies 
were the most effective in inhibiting cell migration. Bar length = 200 μm.  
 
 178 
 
 
   
   
Figure 44 The effect of integrin receptor blocking with neutralizing antibodies on 
DLD-1 cell migration.  
Results shown average ± SD of three independent experiments.  The asterisk * indicates P 
< 0.05 and ** indicates P < 0.01. 
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Figure 45 The effect of combination anti-integrin treatment on DLD-1 cell migration. 
DLD-1 cells were treated with two or more antibodies. Scale bar = 200 µm. Results shown are 
representative/averages of three independent experiments.  The asterisk * indicates P < 0.05, 
** indicates P < 0.01, and *** indicates P < 0.001. 
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 Effect of novel small molecule antagonists on DLD-1 cell 4.4.1.1.5
migration. 
The non-cytotoxic concentrations of integrin antagonists were evaluated by 
MTT assay. The MTT assay is a colourimetric method where viable cells with 
dehydrogenase activity metabolise MTT (a yellow water-soluble tetrazolium salt; 
3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyl tetrazolium bromide) into a purple 
coloured formazan product.  Mitochondrial succinate dehydrogenase is the 
principle reductase involved. Dead cells are unable to convert MTT into 
formazan thus colour formation is proportional to the number of viable cells. 
DMSO is used to dissolve the formazan product formed and the absorbance of 
the resulting solution is measured by vis-spectrophotometry. The intensity of the 
product colour is measured at 550 nm, and the optical density is directly 
proportional to the number of living cells in the culture. 
The MTT assay was used to evaluate the cytotoxicity of 7 novel small molecule 
integrin antagonists which were synthesised at the ICT (ICT9055, ICT9072, 
ICT9073, ICT9085, ICT9087, ICT9088 and ICT9094) against the DLD-1 cell line 
(expresses high level of αvβ5). The cytotoxicity of ICT9019, ICT9023, ICT9024 
and ICT9026 compounds had previously been established in the DLD-1 and 
DU145 cell lines (Unpublished results, M Sutherland). Non-cytotoxic 
concentrations of each compound (IC20) defined as a dose that kills less than 20% 
of cells was obtained from MTT dose-response curves (Figure 46).   
Non-cytotoxic concentrations IC20 (summarized in Table 23) were used in 
scratch assay to evaluate the effect of these compounds on DLD-1 cell 
migration. ICT9055 and ICT9072 inhibited the cell migration by 70% and 60% 
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respectively. Other compounds had a negligible effect on the migration of cells 
(Figure 47).  
ICT9055 and ICT9072 are known to have high activity against αvβ3 integrin 
(Alshammari, 2013) but in this study, these two compounds significantly 
inhibited the migration of DLD-1 cells. As shown in Figure 47, both αvβ3 and 
αvβ5 contributed significantly to DLD-1 migration, and contribution of αvβ5 may 
be slightly higher than αvβ3. To investigate the specificity of ICT9055 and 
ICT9072, the scratch assay cells were incubated with LM609 antibody to block 
αvβ3 whilst allowing binding to αvβ5. Cells were then incubated with ICT9055 
and ICT9072. I found that blocking of αvβ3 integrin increased the effect of these 
compounds. ICT9055 with or without LM609 inhibited the cell migration by 80% 
and 70% respectively.  Also ICT9072 with or without LM609 inhibited the cell 
migration by 85% and 45% respectively (Figure 48). Incubating the cells with 
LM609 and compound together was significantly more effective than sequential 
treatments with 2 separate agents. Taken together with previous results, these 
data could indicate that ICT9072 and ICT9055 are inhibitors of both αvβ5 and 
αvβ3 integrins or that LM609/compound alone incompletely inhibits αvβ3 at the 
concentration tested whereas the combination improves receptor occupancy. 
LM609 and the compounds could displace one another from integrins.  
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Figure 46 Dose response curves of the cytotoxicity of small molecule integrin 
antagonists in DLD-1 cells. 
The curve profiles were obtained by three in vitro experiments. Mean ± SD of triplicate 
determination is given. 
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Compound  Non-cytotoxic concentrations 
used on DLD-1 IC20 (µM) 
IC50 (µM) 
ICT9019 5 > 5 
ICT9023 100 > 100 
ICT9024 5 100 
ICT9026 100 > 100 
ICT9055 5 > 10  
ICT9072 10 100 
ICT9073 1 25 
ICT9085 10 > 100 
ICT9087 1 18 
ICT9088 10 > 100 
ICT9094 1 18 
Table 23 Non-cytotoxic concentrations of novel small molecule integrin 
antagonists which were synthesised at the ICT 
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Figure 47 The effect of novel small molecule integrin antagonists on DLD-1 cell 
migration. 
DLD-1 cells were incubated with small molecule integrin antagonists for 41 hours. Bar length 
= 200 μm. Results shown are representative/average of three independent experiments. The 
asterisk * indicates P < 0.05 and ** indicates P < 0.01. 
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Figure 48 Evaluation of the specificity of ICT9055 and ICT9072.  
DLD-1 cells were incubated with LM609 or PIF6 or with a mixture of LM609 and ICT9055 or ICT9072, 
or preincubated with LM609 for 2 hours before compounds were added. Results shown are 
representative of three independent experiments.  Scale bar = 200 µm. The asterisk * indicates P < 
0.05, ** indicates P < 0.01 and *** indicates P < 0.001. 
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 Determination of which integrins control migration in DU145 cells 4.4.1.1.6
The DU145 cell line (which expresses αvβ3 and αvβ5 integrins) was used as a 
model to evaluate dual antagonists on cell migration. The same antibodies used 
in DLD-1 except 10D5 (anti-αvβ6) were used to characterise the DU145 cell line 
in the scratch assay to determine which integrins have significant role in DU145 
cell migration.  
The results show that both αvβ3 and αvβ5 integrins had a significant role in 
DU145 cell migration; PIF6 and LM609 antibodies both inhibited the cell 
migration by 45 % and this is less effective than in DLD-1, and the dose 
response curves are flat. JBS5 antibody had a reverse dose-response 
compared to PIF6 and LM609 antibodies effect on cell migration where the 
lowest concentration inhibited the cell migration by 30% but the highest 
concentration had no effect (Figure 49 and Figure 50). 
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Figure 49 The effect of integrin receptor blocking with inhibitory antibodies on DU145 cell 
migration. 
DU145 cells were treated with different concentration of LM609 (anti-αvβ3), PIF6 (anti-αvβ5) and 
JBS5 (anti-α5β1). PIF6 and LM609 antibodies were the most effective to inhibit cell migration. 
Bar length = 200 μm. 
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Figure 50 The effect of integrin receptor blocking with neutralizing antibodies on 
DU145 cell migration. 
DU145 were scratched and treated with different concentrations of each antibody 
(LM609 (anti-αvβ3), PIF6 (anti-αvβ5) and JBS5 (anti-α5β1)). Results shown are 
average ± SD of three independent experiments.  * indicates P < 0.05. 
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 The effect of novel small molecule antagonists on DU145 cell 4.4.1.1.7
migration. 
The non-cytotoxic concentration IC20 and IC50 of each compound was obtained 
from the respective MTT curve (Figure 51) and summarized in Table 24. The 
non-cytotoxic concentrations IC20 were used in the scratch assay to evaluate 
the effect of these compounds on cell migration.    
ICT9024, ICT9026 and ICT9023 (50 µM) and ICT9087 (1 µM), significantly 
decreased cell migration by 60%, 60%, 50% and 20% respectively. ICT9085 
and ICT9094 (10 µM) and ICT9073 (0.1 µM) inhibited cell migration by 30%. At 
the lowest concentration (0.01 µM), ICT9055 inhibited cell migration by 25%. 
Other compounds had a negligible effect on the migration of cells (Figure 52). 
This suggests that ICT9024, ICT9026, ICT9023 and ICT9087 can block either 
or both αvβ3 and αvβ5 integrins thus inhibiting DU145 cell migration. 
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Figure 51 Dose response curves of the cytotoxicity of small molecule integrin 
antagonists in DU145 cells. 
Mean ± SE of triplicate determination is given. 
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Compound  Non-cytotoxic concentrations 
used on DU145 IC20 (µM) 
IC50 (µM) 
ICT 9019 5 100 
ICT9023 50 > 100 
ICT9024 50 > 100 
ICT9026 50 > 100 
ICT9055 0.01 1 
ICT9072 0.1 17 
ICT9073 0.1 8 
ICT9085 10 > 100 
ICT9087 1 50 
ICT9088 1 100 
ICT9094 10 70 
Table 24 Non-cytotoxic concentrations of novel small molecule integrin 
antagonists which were synthesised at the ICT 
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Figure 52 The effect of novel small molecule integrin antagonists on DU145 cell 
migration. 
DU145 cells were wounded and then incubated with different concentrations of integrin 
antagonists for 24 hours. Bar length = 200 μm. Results shown are representative/average of 
three independent experiments. * indicates P < 0.05. 
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 Determination of which integrins control migration in M14 cells 4.4.1.1.8
Previous results in our group showed that blocking αvβ3 integrin by LM609 
(2.5 µg/ml) resulted in 55% inhibition of M14 cell migration. In this study the 
participation of αvβ5 and α5β1 integrins in M14 cell migration was evaluated 
also by scratch assay. M14 cell migration was 50% inhibited by integrin 
receptor blocking with PIF6 (2.5 μg/ml). JBS5 antibody (2.5 µg/ml) increased 
migration by 40 % (Figure 53). The integrin expression profile showed that 
JBS5 antibody increased the expression of αvβ3 and induced ectopic 
expression of αIIbβ3 (Figure 40). 
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Figure 53 The effect of integrin receptor blocking on M14 cell migration. 
Results are shown as representative/average of three independent experiments. * 
indicates P < 0.05. Bar length = 200 μm.  
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4.5 DISCUSSION 
The objective of this study was to develop models that can be used to 
evaluate the potential of new integrin antagonists on inhibiting cancer cell 
migration. In order to test this, the blockade of one or multiple integrins by 
neutralizing antibodies or small molecule antagonists was performed in a 2D 
wound-healing assay (scratch assay).  
In a wound-healing assay, the cells used should have certain 
characteristics, such as the ability to form a monolayer, the ability to be motile, 
and prolonged doubling times. These characteristics were studied among the 
cell line models selected in Chapter 3. I found that MCF-7 (expressing a high 
level of the αvβ5 integrin and a lack of the α5β1 integrin) and MCF-7ADR were 
unable to form monolayers because they grow as clumps. Furthermore, the HT-
29 cell line was found to be unsuitable for use in a wound-healing assay 
because it does not have the ability to be motile and migrate on a plastic 
surface. In support of this finding, Herrera found that HT-29 cells do not spread 
on plastic surfaces unless a hepatocyte growth factor is added (Herrera, 1998). 
Other cell line models, such as DLD-1, OSC-19, PC-3, M14, and DU145, 
were found to form a monolayer and migrate. The DLD-1, OSC-19, and DU145 
cell lines showed sheet-like epithelial migration behaviour (collective migration), 
whereas, the M14 and PC-3 cell lines migrated as single cells. These cell line 
models were screened in terms of wound healing time in order to select the best 
model. The OSC-19 cells showed rapid wound healing (with a scratch nearly 90% 
healed after 18 hours). The PC-3, M14, and DU145 cells exhibited moderate 
wound healing after 24 hours, whereas DLD-1 showed slow wound healing 
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(with a scratch nearly 90% healed after 41 hours). In prolonged wound healing, 
cells with short doubling time make distinguishing between cell proliferation and 
migration is difficult. Therefore, the expression of proliferation marker Ki67 was 
evaluated by immunofluorescence. In the DU145 and DLD-1 cells, the cells at 
the scratch edges expressed low levels of Ki67, which meant that cells moving 
into the wound area had migrated.  
Moreover, this study confirms that different concentrations of serum have 
no effect on the rate of cell migration, although they could have an effect on cell 
proliferation. This observation is in agreement with the results of Kim et al. 
(2012), who observed the same cell migration rates in mediums with 5% and 10 
% FBS solutions (Kim et al., 2012). 
The OSC-19 cell line expresses high levels of αv, β5 and α5 integrin 
subunits and this is in agreement with the expression profile of integrins in 
clinical samples where the tumour cells express high and moderate level of β5 
and α5β1 integrins respectively. The exploration of integrin antagonist 
properties in this cellular model may reflect what could happen when blocking 
several integrins in cell migration. The contribution of α5β1, αvβ3, and αvβ5 to 
cell migration was studied in specific antibody-blocking experiments. As 
expected, αvβ5 proved to be essential for the ability of the cells to migrate. 
Bianchi et al. demonstrated that β5 plays a crucial role in the TGFβ-induced 
epithelia mesenchymal transition. Further they found that depletion of β5 
integrin significantly inhibited breast cancer cells invasion (Bianchi et al., 2010a). 
αvβ5 integrin also enhances cell migration and liver metastasis of colon 
carcinoma mediated by hepatocyte-derived heregulin (Yoshioka et al., 2010).  
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 Blocking either αvβ3 or αvβ5 inhibited cell migration by 25% and 30%. 
Surprisingly, the combination of αvβ3 and αvβ5 anti-integrin antibodies did not 
increase the inhibitory effect, which might mean that blocking both αvβ3 and 
αvβ5 releases signalling effectors for use by another integrin (Parikka et al., 
2006). Crosstalk between integrins plays a role in many biological processes, 
such as tumour invasion, morphogenesis, and metastasis, and includes the 
combination or activation of integrins that stimulate or inhibit the function of 
other integrins in the same cell. Many studies have proven the crosstalk 
between integrins such as β1, β2, and β3 (Pijuan-Thompson and Gladson, 
1997) (Simon et al., 1997). For example, the activity of the α2β1 integrin 
receptor is stimulated by αvβ5/6 integrins in colon cancer (Defilles et al., 2009).  
My data showed that blocking α5β1 integrin enhances OSC-19 cell 
migration. This study showed that blocking the α5β1 integrin induces the 
alteration and switching of the expression of other integrins. Protein expression 
profiling revealed marked changes in αIIbβ3 integrin levels that may be 
implicated in OSC-19 cell migration. This result is similar to the work of Parvani 
et al. who showed that inactivation of β1 integrin by inhibitory antibodies leads 
to increased expression of β3 by activating p38 MAPK pathway, which in turn 
enhanced the metastasis of breast cancer (Parvani et al., 2013). Moreover, our 
data accords quite well with a study by Jeanes et al., who deleted the β1-
integrin gene in situ from primary cultures of mammary epithelial cells to study 
the cellular role of specific integrins in cell proliferation and migration. The study 
found that either the knockdown or artificial inhibition of β1-integrins in breast 
cancer enables β3 integrin subunits to promote migration or even metastases 
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(Jeanes et al., 2012). In further agreement with these results, a study by Vellon 
et al. found the blockage of α5β1 integrins induced the cell migration of hepatic 
progenitor cells by stimulating cell-signalling pathways involved in cell motility 
(Vellon et al., 2010).   
I found inhibition by the αvβ3 and αvβ5 integrin antibodies to be greater 
in the presence of the α5β1 antibody and αIIbβ3 small molecule antagonists, 
indicating that multiple integrins participate in OSC-19 cell migration, and 
complete blockade of both β3 integrins is required to reverse the pro-migratory 
effects of α5β1 inhibition. Our findings suggest that the selective deactivation of 
the α5β1 integrin may not be a safe therapy for head and neck cancer, whereas 
multi-integrin targeting may play a significant role in inhibiting head and neck 
cancer metastasis. This result provides a new interpretation of the results of the 
Phase II clinical trial of cilengitide in combination with cisplatin, 5-fluorouracil, 
and cetuximab did not improve progression-free survival in patients with 
recurrent and/or metastatic of head and neck squamous cell carcinomas 
(Vermorken et al., 2014);  cilengitide is a dual αvβ3 and αvβ5 inhibitor which 
also has some effects on α5β1 integrin. This anti-α5β1 activity may induce 
αIIbβ3 expression, providing a resistance mechanism since cilengitide does not 
inhibit αIIbβ3. Still this data needs confirmation by using other head and neck 
cancer cell lines and α5β1 integrin antibodies to exclude an idiosyncratic effect. 
 
In this study, the DLD-1 cell line was utilised because it expressed moderate 
levels of α5 and β5 and a low level of β3. The contribution of the α5β1, αvβ3, 
αvβ5, and αvβ6 integrins in DLD-1 cell migration was determined in specific 
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antibody blocking experiments. The data showed that DLD-1 cell migration was 
mediated primarily by the αvβ5 integrin and partially by αvβ3. This result is in 
agreement with Enns et al. who demonstrated that colon cancer cells attached 
to vitronectin mainly by the αvβ5 integrin and blocking the αvβ5 integrin by 
antibodies or small molecules inhibits cell adhesion to vitronectin, which 
enables the metastasis of cells (Enns et al., 2005a).  
Moreover, the data showed that α5β1 integrin was not essential in DLD-1 cell 
migration, and its blockage did not affect cell migration. Surprisingly, the lowest 
concentration of αvβ6 inhibited cell migration by 50%, whereas the highest 
concentration had no effect. It has been shown that αvβ6 integrin plays an 
important role in colon cancer progression where its expression lead to 
increased cell proliferation and enhanced cell migration and invasion (Cantor et 
al., 2013) mediates metastasis to the liver (Yang et al., 2008) and stimulation of 
MMP-9 (Gu et al., 2002). The unexpected results in our case could be due to 
the ability of αvβ6 integrin to release cell signalling effectors to interact with 
other integrins and enhance their function. A study by Defilles et al. provided 
evidence for the negative regulation of the α2β1 integrin by the αvβ5/β6 
integrins in two different adenocarcinoma cell lines. The blocking of αvβ5/β6 
integrins was found to enhance cell migration toward type I collagen, and α2β1 
engagement was found to enhance outside-in signalling by increasing the 
phosphorylation of FAK and ERK1/2 (Defilles et al., 2009). In addition, Cantor et 
al. showed that transfection of SW480 colon cancer cells with β6 repressed the 
expression of other integrins whose expression is known to have a role in 
cancer progression such as α2, α6, β1, β4 and β5. Therefore,  inhibition of β6 
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could lead to expression and enhanced cell migration dependent on other 
integrins (Cantor et al., 2013).  
After characterizing the assay and identifying which integrins were primarily 
responsible for DLD-1 cell migration, the effect of novel small molecule 
antagonists on DLD-1 cell migration was evaluated. Before using the 
antagonists on DLD-1 cells, the cytotoxicity of certain compounds was tested 
using the MTT assay. The cytotoxic effect was evaluated to confirm that the 
results obtained were due to blockade of integrin function (inhibition of cell 
migration in the scratch assay), not due to general toxicity. 
 ICT9023 and ICT9026 had no toxic effects on DLD-1 cells whereas, other 
compounds had variable toxic effects on DLD-1 cells and this may be due to the 
inhibition of αvβ5 or αvβ6 integrins which are known to be important in colon 
cancer survival. O'Brien et al. showed that αvβ5 suppress the apoptosis of 
colon carcinoma cells induced by serum deprivation and it could be that these 
compounds inhibit αvβ5 receptor and mediate apoptosis (O'Brien et al., 1996). 
Also it has been shown that αvβ6 integrin is involved in tumour growth and 
down regulation of this receptor inhibits tumour growth in vivo (Ahmed et al., 
2002).  Zhao et al. showed that blocking αvβ6 integrin caused apoptosis of 
colon cancer in vitro (Zhao-Yang et al., 2008).  
Among these compounds, the highest effect of inhibiting DLD-1 cell migration 
came from ICT9055 and ICT9072. According to previous unpublished ELISA 
and adhesion assay results (Fatemah Alshammar, Mark Sutherland, Andrew 
Gordon and Manar Zraikat), ICT9055 has shown high activity against the αvβ3 
integrin. However, DLD1 expressed several αv integrins. To determine whether 
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the effect on DLD1 was due to inhibition of αvβ3, αvβ5 or both, cells were 
preincubated with the LM609 antibody (5 µg/ml) to block the αvβ3 integrin 
before treatment with ICT9055 or ICT9072. I found blocking the αvβ3 integrin to 
increase the effect of ICT9055 and ICT9072. These data may indicate that 
these two compounds have affinity for the αvβ5 integrin as well as αvβ3, and 
further suggests that the two heterodimers cooperated in the regulation of DLD-
1 cell migration. Alternatively this result could indicate that blocking of integrin 
by either LM609 or compound incompletely inhibits αvβ3 whereas the 
combination improves receptor occupancy. LM609 and compound could 
displace one another from integrins, which further complicates interpretation. It 
is important to study the selectivity of the compounds on cells that express 
single integrins but in this study it was difficult to find cell lines that express one 
integrin. Therefore, it is worthy to do integrin knockdown or transfection studies 
in the future.  
In addition, due to its expression of high levels of the β5 and α5 integrin 
subunits, the DU145 prostate cancer cell line was used to evaluate the effect of 
novel small molecule antagonists in the scratch assay. Characterisation with 
blocking antibodies showed that the αvβ5 and αvβ3 integrin antibodies have the 
same effect on DU145 cell migration, significantly inhibiting cell migration by 
40%. Studies have shown that prostate cancer cells adhere to vitronectin by the 
αvβ3 integrin (Zheng et al., 1999) and migrate on vitronectin by αvβ5 (Bisanz et 
al., 2005). Also it has been shown that blocking integrins αvβ5, α5β1, and αvβ3 
by a disintegrin contortrostatin inhibits the migration of PC-3 prostate cancer 
cells (Lin et al., 2010). Furthermore, Witkowski et al. found DU145 to depend on 
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the α5β1 integrin to adhere to fibronectin (Witkowski et al., 1993), and 
Stachurska et al. have reported the α5β1 integrin to enhance the adhesion and 
migration of prostate cancer cells (PC-3) to fibronectin (Stachurska et al., 2012). 
In agreement with this, I found the α5β1 integrin to play a crucial role in DU145 
cell migration in that the α5β1 antibody showed a reverse dose response. The 
lowest concentration of α5β1 antibody significantly reduced cell migration, 
whereas the highest concentration did not affect cell migration. This could be 
due to the fact that the complete inhibition of the α5β1 integrin activates 
intracellular signalling to regulate cell functions by another integrins; if α5β1 is 
not able to signal, intracellular signalling effectors are redirected to other 
integrins, enhancing their signalling. Indeed, crosstalk between α5β1 and other 
integrins has been well documented. Kim et al. found the α5β1 integrin to 
regulate the αvβ3 integrin and mediate endothelial cell migration and 
angiogenesis (Kim et al., 2000b), and Lishko et al. demonstrated increasing 
levels of integrin αMβ2 to retard α5β1-mediated migration (Lishko et al., 2003).  
Among the tested compounds, ICT9023, ICT9024, ICT9026 and 
ICT9087 had a significant effect on inhibiting DU145 cell migration. These 
compounds appear to have effect on multiple integrins including αvβ3, αvβ5 
and especially α5β1 integrin which has been shown to participate in DU145 cell 
migration but not in DLD-1 cell migration. ICT9085, ICT9094, ICT9019, ICT9087, 
ICT9073, and ICT9055 had a moderate effect on cell migration (about 20%). 
ICT9072 showed no effect on DU145 cell migration and this is in contrast to its 
effect on DLD-1 cell migration. This could be due to an effect on αvβ6 integrin 
which is absent in DU145 (in house PCR data, Andrew Gordon). The 
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comparison of the effect of ICT compounds on DLD-1 and DU145 cells 
migration is summarized in Table 25. 
 DLD-1 DU145 
Protein expression 
profile 
αvβ3, αvβ5 and α5β1 αvβ3, αvβ5 and α5β1 
RNA expression profile αvβ6 Express neither αvβ6 
nor αvβ8 
Integrin which primarily 
responsible for tumour 
cell migration 
αvβ5, αvβ3 and αvβ6 αvβ5, αvβ3 and α5β1 
Compound number Inhibition percentage Inhibition percentage 
ICT9019 No effect 20% 
ICT9023 No effect 50% 
ICT9024 No effect 55% 
ICT9026 No effect 55% 
ICT9055 80% 20% 
ICT9072 60% No effect 
ICT9073 No effect 20% 
ICT9085 No effect 22% 
ICT9087 No effect 20% 
ICT9088 No effect No effect 
ICT9094 20% 20% 
Table 25 Comparison of the effect of ICT compounds on migration of DLD-1 and 
DU145 cells  
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In previous work (Alshammari, 2013), the melanoma cell line M14 was 
used as a αvβ3 integrin model to evaluate the effect of novel small molecule 
antagonists on cell migration. The results showed the αvβ3 integrin to play a 
crucial role in cell migration. In this study, the scratch assay was used to 
determine the involvement of αvβ5 and α5β1 integrin in M14 cell migration. The 
results showed that the αvβ5 integrin also participates in M14 cell migration. 
Ruffini et al. reported the ανβ5 and ανβ3 integrins to be involved in melanoma 
cell invasion, while the α5β1 integrin was not (Ruffini et al., 2014). However, my 
study showed that the high concentration of JBS5 antibody enhanced M14 cell 
migration. This study showed that treating M14 cells with 2.5 µg/ml of JBS5 
antibody stimulated the expression of αvβ3 and induced the ectopic expression 
of αIIbβ3 on stimulated M14 cells similar to my observations in OSC-19.  
4.6 Conclusion 
The scratch assay was characterized and then used to evaluate the effect of 
novel small molecule antagonists on cell migration. OSC-19 was used as a 
model for multi-integrin expression, DLD-1 was used as a model for αvβ5 
integrin, and DU145 and M14 were used as models for αvβ3 and αvβ5. Our 
findings suggest that the selective inactivation of the α5β1 integrin may not be a 
safe therapy for head and neck cancer or melanoma due to the activation of 
intracellular signalling that leads to the stimulation of other sets of integrins to 
maintain cell migration. Therefore, multi-integrin targeting may be important to 
inhibit cancer metastasis since it blocks integrins that may be upregulated by 
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selective α5β1 antagonism. Furthermore, among 10 novel small molecule 
antagonists, certain compounds were found to have significant antagonistic 
effects, such as ICT9055 and ICT9072, which were the most effective at 
reducing DLD-1 cell migration, and ICT9023, ICT9024, and ICT9026, which 
were the most effective at inhibiting DU145 cell migration. These compounds 
merit further investigation such as evaluating their effect on cancer cell invasion 
(using e.g  a 3D invasion assay) to assist identification of those compounds 
being selected for investigation in animal models of tumour invasion and 
metastasis. 
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5 CHAPTER 5: General discussion 
5.1 Discussion 
Integrins are heterodimeric glycoprotein receptors that mediate cell-cell and 
cell-extracellular matrix interactions. They are involved in several biological 
processes that are crucial to both body homeostasis and pathological 
conditions, such as cell proliferation, differentiation, adhesion, invasion, 
migration, apoptosis and angiogenesis. Moreover, it has been found that 
integrins are implicated in cancer progression (Goswami, 2013, Ganguly et al., 
2013, Seguin et al., 2015). In terms of cancer treatment, the main problems 
associated with chemotherapy are the long-term toxicities and drug resistance. 
It is therefore important to identify targets that are highly expressed in tumour 
tissue but not expressed (or only at low levels) in normal tissue. 
Immunohistochemistry studies have shown that integrins are overexpressed on 
tumour tissues when compared to normal tissues (Fabricius et al., 2011, Li et 
al., 2013, Ha et al., 2014). Further, studies have shown that activated 
endothelial cells that participate in tumour angiogenesis overexpress integrins 
αvβ3, αvβ5 and α5β1, whereas quiescent endothelial cells do not (Avraamides 
et al., 2008, Fabricius et al., 2011, Goodman et al., 2012, Kim et al., 2000a). All 
these facts have led drug companies to design inhibitors targeting specific 
integrin-ligand interactions in order to prevent cancer progression and 
angiogenesis. Many integrin inhibitors have been subject to clinical trials and, 
while there are 72 trials still active, 46 have been discontinued and only 4 drugs 
are commercially approved (Goswami, 2013). 
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Many potential novel small molecule integrin antagonists have been 
synthesised at the Institute of Cancer Therapeutics and thus need to be 
evaluated for their potential to block integrin ligation and, consequently, inhibit 
tumour cell invasion, migration and metastasis. As the tumour cells express 
several integrins on their surface, one hypothesis suggests the importance of 
multi-integrin antagonism in order to block entire families of integrins that are 
involved in cancer progression and angiogenesis. 
In this project, the aim was to evaluate the effect of potential novel small 
molecule integrin antagonists on the inhibition of human tumour cell migration 
using 2D wound healing assays (scratch assays). This was achieved by: 
 Evaluating the targets (αvβ3, αvβ5 and α5β1 integrins) in clinical tumour 
samples.  
 Detecting the expression of αvβ3, αvβ5 and α5β1 integrins in human 
xenograft tissue as well as in human tumour cell lines. 
  Developing models that can be used for both the in vitro and in vivo 
evaluation of novel small molecule integrin antagonists. 
5.1.1 The expression of αv, β5, αvβ3 and α5β1 integrins in clinical tumour 
samples  
It is very challenging and important when targeting integrins to select the 
appropriate integrin in a specific type of cancer because the failures of drug 
evaluation in the clinic could be attributed to incorrect target selection. Failure of 
cilengitide in head and neck cancer was suggested to be partially due to the 
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lack of the expression of αvβ3 on tumour cells (Fabricius et al., 2011, 
Vermorken et al., 2014).  
The role of αv, αvβ5, α5β1 and αvβ3 integrin in head and neck cancer has been 
provided in many reviews (Charalabopoulos et al., 2005, Thomas and Speight, 
2001, Ziober et al., 2001). The up regulation of αvβ5 integrin was reported in 
oral squamous cell carcinoma (Jones et al., 1997), in tongue (Kurokawa et al., 
2008) and in laryngeal squamous cell carcinoma (Li et al., 2013). The 
expression of αvβ5 integrin is associated with lymphatic metastasis and 
angiogenesis (Li et al., 2013). α5β1 integrin expression was associated with 
invasion and metastasis, and with a poor prognosis (Shinohara et al., 1999, 
Vitolo et al., 2000, Charalabopoulos et al., 2005).  
The role of αv, αvβ5, α5β1 and αvβ3 integrin in prostate cancer is well 
documented and was previously reviewed by Goel, Suyin and Sutherland (Goel 
et al., 2008, Suyin et al., 2013, Sutherland et al., 2012).  Studies showed that 
αvβ3 is implicated in prostate cancer proliferation (De et al., 2003), 
differentiation (Hurt et al., 2010), adhesion and migration to the bone 
microenvironment (Cooper et al., 2002). The expression of αvβ5 integrin in 
prostate cancer cells has been shown to correlate significantly with the Gleason 
pattern and patient survival (Hess et al., 2014). Moreover, it has been shown 
that αvβ5 has an important role in the invasion and survival of prostate cancer 
(Gordon et al., 2009) and in the growth of prostate cancer in bone (Bisanz et al., 
2005). In addition, studies have shown that α5β1 integrin is involved in the 
proliferation of prostate cancer cells (Goel et al., 2010) and adhesion and 
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spreading of prostate cancer cells interacting with FN (Stachurska et al., 2012). 
Based on these studies on head and neck and prostate cancer, the expression 
of αvβ3, αvβ5 and α5β1 was evaluated in clinical prostate and head and neck 
tumour tissue samples using immunohistochemistry. 
The problem faced in such immunohistochemistry studies is the lack of 
monoclonal antibodies that label integrins in formalin-fixed, paraffin-embedded 
(FFPE) tissues. Recently, matched rabbit monoclonal antibodies against 
integrins that are suitable to be used with native and FFPE human tissues have 
been produced (Goodman et al., 2012). However, these antibodies are not 
generally available to researchers and, therefore, fresh frozen human tissues 
were used. 
In head and neck cancer tissues, the results show that αvβ3, αvβ5 and α5β1 
integrins are extensively expressed in tumour cells but weakly expressed in 
normal squamous epithelium. Further, our data showed that αv, αvβ3, αvβ5 and 
α5β1 integrins are more highly expressed in tumour stroma than in the normal 
stroma, especially αvβ5. The difference between the expression of αv, αvβ3, 
αvβ5 and α5β1 integrins in tumour tissues and control normal tissues was 
statistically significant (P<0.2 in this very small study). These results are in 
agreement with the results of Fabricius et al., who found that the expression of 
αvβ5 and α5β1 integrins in tumour tissue was significantly higher than that of 
squamous epithelium in normal tissues and the expression of αvβ3, α5β1 and 
αvβ5 was higher in tumour stroma than in normal stroma in control tissue but 
slightly different regarding αvβ3 expression where they found a low expression 
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of αvβ3 integrin in the cells of head and neck tumour tissues (Fabricius et al., 
2011). In this study, I found a positive correlation between αvβ3, α5β1 and β5 
expression and lymph node metastasis.  
In the data presented here, among the three integrins, the expression of αvβ3 
integrins was very strong in endothelial cells within normal and tumour tissue, in 
line with a role in cancer angiogenesis as shown in previous studies (Max et al., 
1997, Beer et al., 2007). These results indicate that the targeting of αvβ3, αvβ5 
and α5β1 integrins affects mainly tumour cells and tumour stroma with little 
effect on normal tissues. This strategy is important in preventing unwanted 
inhibition of normal body functions and, consequently, reducing long-term 
toxicities. It will be necessary to identify an in vitro head and neck model which 
mimics tumour integrin expression to investigate the effect of a combination 
therapy that targets and blocks αvβ3, αvβ5 and α5β1 integrins in cancer 
metastasis.  
In prostate cancer tissues, the results show that the expression of integrins in 
tumour cells from high to low was αv, αvβ5, α5β1 and αvβ3, suggesting αvβ3 is 
not the major αv receptor in prostate tumour cells.  The expression of integrins 
in stroma from high to low was αvβ3, α5β1, αv and αvβ5. The endothelium 
expressed low level of αvβ3, αvβ5 and αv and did not expressed α5β1.  
The limitation associated with this part of the research is the small number of 
samples (number of head and neck sample = 10 and number of prostate 
samples = 9) which hampered our efforts to determine the correlation between 
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integrin expression and clinical outcome. With help from a statistician, Dr 
Andrew Scally, I was able to find potential correlation by using P value of < 0.2-
0.4 as a significant effect. These trends will require confirmation using a larger 
number of samples. 
The results of this study suggest appropriate combination of integrins to target. 
αvβ3/αvβ5/α5β1 antagonists will be more effective in both head and neck and 
prostate cancer than single integrin antagonists. In head and neck, αvβ5 and 
α5β1 antagonists will target tumour and tumour stroma, and to target 
angiogenesis it is more effective to include αvβ3 integrin in designing the 
antagonists. In prostate cancer, αvβ3, αvβ5 and α5β1 antagonists will affect 
tumour and tumour stroma. 
5.1.2 The expression of αv, β3, β5 and α5 integrin subunits in a panel of 
tumour cell lines 
Prostate cancer cells PC-3 and DU-145, tongue squamous carcinoma cells 
OSC-19, and a range of cell lines with either high or low expression of the αv, 
β5 and α5 integrin subunits; human breast carcinoma cells MCF-7, MCF-
7ADR/NCRI ADR-RES cells as a drug-resistant model, melanoma cells M14, 
colorectal adenocarcinoma cells DLD-1 and HT-29, and human umbilical vein 
endothelial cells HUVEC based on published results (Goodman et al., 2012, 
Hirakawa et al., 2006) were used. In order to select cell line models with either 
high or low expression of the αv, β5 and α5 integrin subunits to use in functional 
studies, the expression of these integrin subunits was evaluated by Western 
blot and immunofluorescence. Based on the results obtained from these 
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evaluations, six cell lines were selected as models to be used to further 
evaluate the potential of novel small molecule integrin antagonists to inhibit 
single or multi-integrins in vitro. DLD-1 and DU145 express αvβ3, αvβ5 and 
α5β1 so would be expected to respond best to multi-integrin antagonists, 
whereas PC-3 and OSC-19 express αvβ5 and α5β1, so would be expected to 
respond best to dual integrin antagonism of αvβ5 and α5β1. In order to evaluate 
anti-αvβ5 activity, the cells would need to have αvβ5 integrin as the only RGD-
binding integrin and our data showed that MCF-7 and HT-29 express αvβ5 but 
do not express α5β1, therefore these two cell lines could be used to for this 
porpose. 
5.1.3 The expression of αv, β3, β5 and α5 integrin subunits in a mouse 
xenograft model 
The cell lines identified above could be used to assess integrin functional 
inhibition in vitro. However, they may behave differently in vivo because, 
compared to cell culture, growing human tumour cells in vivo is known to alter 
the expression profile of integrins in response to the extracellular environment 
(Koshida et al., 2004, Taylor et al., 2012). Therefore, the αv, β3, β5 and α5 
integrin subunits expression profile in the corresponding xenografts was 
evaluated by immunohistochemistry and Western blot and compared to the 
expression in the corresponding cultured cells. In this study, two rabbit 
antibodies, Q20 (anti-αv) and ab15459 (anti-β5), were used, both of which 
showed cytoplasmic immunolabelling in the xenograft tissues. They did not 
develop any non-specific binding. The αv integrin subunit was expressed in the 
tumour cells of the HT-29, OSC-19, and MCF-7 xenografts, and in both the 
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tumour and stromal cells of the PC-3 xenografts. The β5 integrin subunit was 
expressed in the tumour cells of the HT-29 and MCF-7 xenografts, as well as in 
both the tumour and stromal cells of the PC-3 xenograft and the stromal cells of 
the OSC-19 xenograft.   
The detection of integrins by mouse antibodies was a challenge in the xenograft 
mouse tissue because of the development of non-specific bindings. Two mouse 
antibodies, B7 (anti-β3) and C-9 (anti-α5), were used but I was unfortunately 
unable to use them to detect the expression of β3 and α5 subunits by 
immunohistochemistry because of the development of non-specific binding. 
Western blot results confirmed what was seen in immunohistochemistry; the 
rabbit antibodies identified the integrin selectively (one band in a specific 
molecular weight) while the mouse antibodies B7 (anti-β3) and C-9 (anti-α5) 
gave two bands: one band located at the correct molecular weight (150 kDa and 
120 kDa, respectively) and one strong band between 70 and 55 kDa. The 
expression of the integrin was estimated by excluding the non-specific bands, 
which were located between 70 and 55 kDa. The Western blot results confirm 
that the αv, β3, α5, and β5 integrin subunits are expressed in all four xenograft 
tissues at a variable level, except for the HT-29 xenograft tissue that lacked the 
α5 integrin subunit.  
In general, the expression of αv, β3, β5 and α5 integrin subunits was increased 
in xenograft tissue compared with the corresponding cultured cells except the 
expression of β5 and α5 integrin subunits in OSC-19 cultured cells was 
elevated compared to xenografts. The difference between the expression of 
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integrins in xenograft tissue compared with the corresponding cultured cells is 
likely to be due to the contribution of the xenograft stroma in stimulating the 
expression of integrins. This data is a good starting point to select in vivo 
models to be used once novel antagonists eventually progress to in vivo 
screening. 
5.1.4 The effect of integrin antagonists on tumour cell migration 
One aim of this study was to evaluate the effect of integrin antagonists on 
tumour cell migration and the OSC-19 cell line was selected for this purpose 
because it expresses αv, β5 and α5 integrin subunits.  
After optimising the scratch assay conditions, the RGD-binding integrin that is 
primarily responsible for tumour cell migration was determined by measuring 
cell migration under the influence of integrin-blocking antibodies. In this study, 
blocking either the αvβ3 or αvβ5 integrins partially inhibited migration of OSC-
19 cells, but blocking the α5β1 integrin enhanced tumour cell migration. These 
results indicate that a single antagonist is unlikely to completely inhibit tumour 
migration; therefore, multi-integrin antagonists will be very important in 
preventing tumour migration (Sheldrake and Patterson, 2014). Antagonist 
combinations that block αvβ3 and αvβ5 as well as α5β1 and αIIbβ3 integrins 
significantly inhibited tumour cell migration, which indicates the importance of 
multi-integrin antagonists in preventing head and neck cancer migration.  
Multi-integrin antagonists are expected to have higher efficacy than specific 
antagonists because of the ability of the integrins to replace one another when 
one receptor is completely non-functional (Parikka et al., 2006) and by stopping 
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the crosstalk between integrins that plays a role in many biological processes 
including the combination or activation of integrins that stimulate or inhibit the 
function of other integrins in the same cell. Many studies have proven the 
crosstalk between integrins such as β1, β2, and β3 (Pijuan-Thompson and 
Gladson, 1997, Simon et al., 1997). For example, the activity of the α2β1 
integrin receptor is stimulated by αvβ5/6 integrins in colon cancer (Defilles et al., 
2009). Further, inhibition of the β1 integrins in breast cancer enhances the β3 
integrin subunits to promote migration or even metastases (Jeanes et al., 2012). 
Moreover, it has been reported that using antibodies to inhibit the β1 integrin 
leads to increased expression of β3 through activation of p38 MAPK pathway, 
which in turn may enhance the metastasis of breast cancer (Parvani et al., 
2013). In a future study, it may also be worthwhile to investigate the effects of 
blocking integrins on cell signalling pathways such as Src and MAPK pathways 
in order to understand the mechanism that mediates the migration. In the future, 
other other head and neck cell lines and another anti-α5β1 antibody should be 
used to confirm our data. 
5.1.5 The effect of novel small molecule antagonists on tumour cell 
migration 
The DLD-1 cell line was selected as model to evaluate the effect of multi-
integrin antagonism on cell migration due to its expression of αv, β3, β5 and α5 
integrin subunits. After the measurement of cell migration under the influence of 
integrin-blocking antibodies, the results showed that DLD-1 cell migration was 
mediated primarily by the αvβ5 integrin and partially by αvβ3 and αvβ6.  Using 
this cell line to evaluate the potential of novel small integrin antagonists, 
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ICT9055 and ICT9072 were identified as blocking cell migration at IC20 
concentrations. Other compounds did not show any effect at the concentrations 
used. ICT9055 and ICT9072 have been previously shown to be highly potent 
αvβ3 antagonists, and ICT9055 was very selective against other RGD-binding 
integrins in ELISA assays (unpublished results, Mark Sutherland). In order to 
determine whether the effect of these two compounds on DLD-1 was due to the 
inhibition of αvβ3 alone or the inhibition of both αvβ3 and αvβ5, the αvβ3 
integrin was blocked by preincubating the cells with what was assumed to be a 
saturation concentration (5 µg/ml) of LM609 antibody. I found that blocking the 
αvβ3 integrin increased the potential of ICT9055 and ICT9072 to inhibit DLD-1 
cell migration. This result suggests that these two compounds have affinity for 
the αvβ5 integrin as well as αvβ3, and further suggests that the two 
heterodimers cooperated in the regulation of DLD-1 cell migration. Alternatively 
this result could indicate that blocking of integrin by either LM609 or compound 
incompletely inhibits αvβ3 whereas the combination improves receptor 
occupan. 
The role of the αvβ5 integrin in colon cancer is well-documented. As Enns et al. 
(2005) demonstrated, blocking the αv or αvβ5 integrins significantly decreases 
tumour cell adhesion in vivo within the hepatic microvasculature. Yoshioka et al. 
(2010) found that the expression of αvβ5 in LS-LM6 (a highly liver-metastatic 
human colon cancer cell line) is higher than in the parental cell line (LS174T). 
Hepatocyte-derived heregulin (HRG) stimulates the αvβ5 integrin to mediate 
LS-LM6 migration in vitro. In vivo, they demonstrated that knockdown of αv by 
small-interfering RNAs (siRNAs) inhibited the liver metastasis of LS-LM6 
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(Yoshioka et al., 2010). αvβ5 integrin has been shown to suppress the 
apoptosis of colon carcinoma cells induced by serum deprivation (O'Brien et al., 
1996). Data from my study has demonstrated the involvement of the αvβ3 
integrin in DLD-1 cell migration, which is in agreement with previous findings 
concerning its role in colon cancer. For example, a recent study showed that β3 
integrin expression was significantly higher in patients with advanced stage, 
poorly differentiated tumours, and with lymph node invasion than in patients 
with early stage, well or moderately differentiated tumours, and without 
lymphatic metastasis (Ibrahim et al., 2013). Integrin antagonists, such as S247, 
which was described as an αvβ3 antagonist but actually has affinity for all αv 
integrins, inhibits colon cancer liver metastasis in vivo as well as cell 
proliferation, adhesion and migration, and also mediates apoptosis in vitro 
(Reinmuth et al., 2003). Reinmuth et al.’s (2003) study showed that integrins 
other than αvβ3 and αvβ5 participate in colon cancer metastasis. αvβ6 integrin 
expression is associated with the tumour’s progression and the poor prognosis 
of patients with colon cancer (Niu et al., 2014). Moreover, αvβ6 regulates colon 
cancer cell survival through ERK signalling, which results in tumour cell 
proliferation (Peng et al., 2009). Further, blocking αvβ6 increased the apoptosis 
of HT-29 cells through decreasing Bcl-2 and increasing Bax, caspase-3 and 
caspase-9 activity (Zhang et al., 2008). These studies indicate the importance 
of αvβ6 in colon cancer progression, although our own study showed that the 
expression of αvβ6 RNA on DLD-1 was low (in house PCR data, Andrew 
Gordon). Interestingly, in this study, the results of blocking the αvβ6 integrin 
showed that the lowest concentration of anti-αvβ6 reduced cell migration 
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whereas the highest concentration had no effect; this may indicate blocking the 
αvβ6 integrin stimulates the cells to express another integrin or switch on 
another pathway to mediate cell migration. This corresponds with the findings of 
Defilles et al. (2009) that decreasing the expression of the αv integrins by either 
siRNA or lysosomal targeting strategies or inhibiting their function using 
blocking antibodies or disintegrins resulted in enhanced α2β1 integrin-
dependent cell migration and increased outside-in signalling as demonstrated 
by the elevated phosphorylation of FAK and MAPK. This data suggests the 
importance of multi-integrin antagonists including αvβ3, αvβ5 and possibly αvβ6 
in preventing colon cancer metastasis whereas α5β1 had no effect on cell 
migration.  
In order to evaluate the potential of the novel small molecules on prostate 
cancer, the DU145 cell line was selected as a model to evaluate the effect of 
multiple integrin antagonism on cell migration since the expression profile 
showed that this cell line expressed αv, β5 and α5 integrin subunits. Also, our 
study showed that this cell line expresses αvβ3 but does not express αvβ6 or 
αvβ8 (in house PCR data, Andrew Gordon). This data is in agreement with the 
expression profile of RGD-binding integrins in formalin-fixed and paraffin-
embedded (FFPE) tissue samples from prostate cancer patients where the 
immunohistochemistry results showed that the αvβ6 and αvβ8 integrins were 
not expressed in tumour cells, and that αvβ3 was expressed in the blood 
vessels only. The αvβ5 integrin was almost always expressed in prostate 
cancer cells in correlation with the Gleason pattern (GP) (Hess et al., 2014, 
 218 
 
Goodman et al., 2012). Based on this data, the involvement of either the αvβ6 
or αvβ8 integrins in DU145 cell migration was thought unlikely. 
The measurement of cell migration under the influence of integrin-blocking 
antibodies indicated that both the αvβ5 and αvβ3 integrins play a major role in 
DU145 cell migration, whereas the α5β1 integrin has a reverse effect whereby 
the lowest concentration of α5β1 antibody significantly reduced cell migration 
while the highest concentration did not affect cell migration. Again, this could be 
because the complete inhibition of a particular integrin activates intracellular 
signalling to mediate cell functions by other integrins; if α5β1 is not able to 
signal, the intracellular signalling effectors are redirected to other integrins, thus 
enhancing their signalling. This was demonstrated by Kim who found the α5β1 
integrin to regulate the αvβ3 integrin and mediate endothelial cell migration and 
angiogenesis(Kim et al., 2000b). Similarly, Lishko et al. identified that increasing 
the levels of integrin αMβ2 retards α5β1-mediated migration (Lishko et al., 
2003). α5β1 integrin mediates the adhesion of prostate cancer cells to 
fibronectin (Witkowski et al., 1993). Stachurska et al. found that blocking only 
one of either α5β1 or αvβ3 did not completely inhibit the cell adhesion to 
fibronectin, indicating the importance of inhibiting all redundant integrins to 
affect cell functions (Stachurska et al., 2012). 
Evaluation of the impact of the novel compounds on DU145 cell migration 
showed that ICT9023, ICT9024, and ICT9026 had no cytotoxicity at 50 µM and 
had a high effect in inhibiting DU145 cell migration. ICT9085, ICT9094, 
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ICT9019, ICT9087, ICT9073, and ICT9055 had a moderate effect on cell 
migration (about 20%).  
These result encourages the investigation of the effects of ICT9023, ICT9024, 
ICT9026 ICT9055 and ICT9072,  compounds on other functional assays, such 
as the 3D Boyden Chamber transwell migration assay, to evaluate the effect of 
integrin inhibitors on tumour cell invasion. As part of the compound 
development process, it would be useful to identify the effects of these 
compounds on cell signalling pathways as potential biomarkers of efficacy. 
Moreover, the pharmacokinetic and pharmacodynamics of the most active 
compounds should be estimated before starting in vivo studies.  
5.2 Conclusion 
This study has evaluated the expression at the protein level of a panel of 
integrins in cell culture, xenografts and in clinical material for head and neck, 
prostate and colon cancers. The results support the potential  for the use of  
integrin inhibitors, particularly multi-integrin inhibitors, to prevent cancer cell 
migration, a prerequisite for tumour invasion and metastasis. By using an in 
vitro 2-D migration assay (scratch assay), novel small molecule integrin 
antagonists were shown to have significant antagonistic effects on tumour cell 
migration, at concentrations considerably lower than required to show 
cytotoxicity, suggesting that these compounds could be further developed for 
use in chronic inhibition of tumour invasion and metastasis. 
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5.2.1 Future work 
• Evaluate the expression of αv, β5, αvβ3 and α5β1 integrins in a larger 
clinical sample size to determine the correlation between integrin expression 
and cancer progression. 
• Confirm the role of α5β1 integrin in head and neck cell migration by using 
another α5β1 integrin antibody and other head and neck cancer cell lines. 
• Determine the effect of blocking α5β1 integrin on the signalling pathways, 
especially the P38 MAPK pathway. 
• Use proteomics to identify alterations in protein expression that could 
influence cell migration after blocking α5β1 integrin; this study will help to 
design selective compounds for these specific proteins.  
• Investigate the effect of novel small molecule integrin antagonists on 
tumour cell invasion by using a further 2D assay, such as the modified Boyden 
chamber assay. 
• Use of tumour spheroids as a 3D invasion model to study the effect of 
novel small molecule integrin antagonists. 
• Determine the effect of novel small molecule integrin antagonists on 
signalling pathways. 
• Estimate the pharmacokinetics and pharmacodynamics of the most 
active compounds in vivo. 
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